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Eczema is a common chronic skin condition. Probiotics have been proposed as an effective treatment for eczema; their use
is increasing, as numerous clinical trials are under way. This is an update of a Cochrane Review first published in 2008,
which suggested that probiotics may not be an effective treatment for eczema but identified areas in which evidence was
lacking.
Objectives
To assess the effects of probiotics for treating patients of all ages with eczema.
Search methods
We updated our searches of the following databases to January 2017: the Cochrane Skin Group Specialised Register, the
Cochrane Central Register of Controlled Trials (CENTRAL), in the Cochrane Library, the Global Resource of Eczema Trials
(GREAT) database, MEDLINE, Embase, PsycINFO, the Allied and Complementary Medicine Database (AMED), and Latin
American Caribbean Health Sciences Literature (LILACS). We searched five trials registers and checked the reference lists
of included studies and relevant reviews for further references to relevant randomised controlled trials (RCTs). We also
handsearched a number of conference proceedings. We updated the searches of the main databases in January 2018 and
of trials registries in March 2018, but we have not yet incorporated these results into the review.
Selection criteria
Randomised controlled trials of probiotics (live orally ingested micro-organisms) compared with no treatment, placebo, or
other active intervention with no probiotics for the treatment of eczema diagnosed by a doctor.
Data collection and analysis
We used standard methodological procedures as expected by Cochrane. We recorded adverse events from the included
studies and from a separate adverse events search conducted for the first review. We formally assessed reporting bias by
preparing funnel plots, and we performed trial sequential analysis for the first primary outcome - eczema symptoms at the
end of active treatment.
We used GRADE to assess the quality of the evidence for each outcome (in italic font).
Main results
We included 39 randomised controlled trials involving 2599 randomised participants. We included participants of either
gender, aged from the first year of life through to 55 years (only six studies assessed adults), who had mild to severe
eczema. Trials were undertaken in primary and secondary healthcare settings, mainly in Europe or Asia. Duration of
treatment ranged from four weeks to six months, and duration of follow-up after end of treatment ranged from zero to 36
months. We selected no standard dose: researchers used a variety of doses and concentrations of probiotics. The probiotics
used were bacteria of the Lactobacillus and Bifidobacteria species, which were taken alone or combined with other
probiotics, and were given with or without prebiotics. Comparators were no treatment, placebo, and other treatments with no
probiotics.
For all results described in this abstract, the comparator was no probiotics. Active treatment ranged from six weeks to three
months for all of the following results, apart from the investigator-rated eczema severity outcome, for which the upper limit of
active treatment was 16 weeks. With regard to score, the higher the score, the more severe were the symptoms. All key
results reported in this abstract were measured at the end of active treatment, except for adverse events, which were
measured during the active treatment period.
Probiotics probably make little or no difference in participant- or parent-rated symptoms of eczema (13 trials; 754
participants): symptom severity on a scale from 0 to 20 was 0.44 points lower after probiotic treatment (95% confidence
interval (CI) -1.22 to 0.33; moderate-quality evidence). Trial sequential analysis shows that target sample sizes of 258 and
456, which are necessary to demonstrate a minimum mean difference of -2 and -1.5, respectively, with 90% power, have
been exceeded, suggesting that further trials with similar probiotic strains for this outcome at the end of active treatment may
be futile.
We found no evidence suggesting that probiotics make a difference in QoL for patients with eczema (six studies; 552
participants; standardised mean difference (SMD) 0.03, 95% CI -0.36 to 0.42; low-quality evidence) when measured by the
participant or the parent using validated disease-specific QoL instruments.
Probiotics may slightly reduce investigator-rated eczema severity scores (24 trials; 1596 participants). On a scale of 0 to 103
for total Severity Scoring of Atopic Dermatitis (SCORAD), a score combining investigator-rated eczema severity score and
participant scoring for eczema symptoms of itch and sleep loss was 3.91 points lower after probiotic treatment than after no
probiotic treatment (95% CI -5.86 to -1.96; low-quality evidence). The minimum clinically important difference for SCORAD
has been estimated to be 8.7 points.
We noted significant to extreme levels of unexplainable heterogeneity between the results of individual studies. We judged
most studies to be at unclear risk of bias; six studies had high attrition bias, and nine were at low risk of bias overall.
We found no evidence to show that probiotics make a difference in the risk of adverse events during active treatment (risk
ratio (RR) 1.54, 95% CI 0.90 to 2.63; seven trials; 402 participants; low-quality evidence). Studies in our review that reported
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adverse effects described gastrointestinal symptoms.
Authors' conclusions
Evidence suggests that, compared with no probiotic, currently available probiotic strains probably make little or no difference
in improving patient-rated eczema symptoms. Probiotics may make little or no difference in QoL for people with eczema nor
in investigator-rated eczema severity score (combined with participant scoring for eczema symptoms of itch and sleep loss);
for the latter, the observed effect was small and of uncertain clinical significance. Therefore, use of probiotics for the
treatment of eczema is currently not evidence-based. This update found no evidence of increased adverse effects with
probiotic use during studies, but a separate adverse events search from the first review revealed that probiotic treatment
carries a small risk of adverse events.
Results show significant, unexplainable heterogeneity between individual trial results. Only a small number of studies
measured some outcomes.
Future studies should better measure QoL scores and adverse events, and should report on new probiotics. Researchers
should also consider studying subgroups of patients (e.g. patients with atopy or food allergies, adults) and standardising
doses/concentrations of probiotics given.
Plain language summary
Probiotics for treating eczema
Review question
This Cochrane Review aimed to find out, by analysing data from randomised controlled trials (RCTs), if probiotics (bacteria,
fungi, or yeasts) are effective in treating eczema of any severity in people of all ages when compared with placebo (an
identical but inactive treatment), no treatment, or another treatment that does not include probiotics. We wanted to find out if
treatment with probiotics improves the symptoms, quality of life, or severity of eczema in patients at the end of active
treatment and during follow-up after the active treatment has finished.
Background
Eczema is an itchy, non-contagious, inflamed skin condition that affects between 5% and 20% of people at some time in their
life. People with eczema have different bacteria in their gut compared to people without eczema, and sometimes they have
inflammation in their gut. It has been suggested that eczema symptoms may be treated by changing the mix of gut bacteria
or by reducing inflammation in the gut. Probiotics, which are live micro-organisms taken by mouth, such as the Lactobacillus
bacteria found in unpasteurised milk and yoghurt, might achieve this.
This is an update of a previous Cochrane Review published in 2008; this update is important because more trials have been
done since publication of the first review, and because use of probiotics is increasing and new treatments for eczema are
needed.
Study characteristics
We included 39 randomised controlled clinical trials (RCTs) with 2599 participants, which we identified in searches up to
January 2017.
These studies included people of either gender and of all ages, although most studies assessed children who had been told
by a healthcare professional that they had eczema. Participants had eczema ranging from mild to severe, and RCTs
compared treatment with live micro-organisms (probiotics) of varying dose and concentration, taken by mouth, versus no
treatment, placebo, or another treatment with no probiotics.
The probiotics included were bacteria of the Lactobacillus and Bifidobacteria species taken alone or in combination with
other probiotics for a period ranging from four weeks up to six months. We did not look at studies that were seeking to
prevent eczema. Most studies were done in Europe, and some were done in Asia, Australia, and New Zealand - all in a
medical setting. Most studies were conducted at a single centre. Reviewers applied no language restrictions on study
selection. Ten studies were funded by companies supplying the probiotics, and another four studies did not declare the
source of funding.
Key results
Please note that results in this summary are based on the following: a comparison of probiotic against no probiotic; treatment
over six weeks to three months, except for the investigator-rated eczema severity outcome, for which participants were
treated longer (16 weeks); and outcomes measured at the end of the treatment period, apart from adverse events, which
were assessed throughout treatment. Unless otherwise stated, outcomes were measured by participants or parents. The
included studies assessed a variety of probiotics of differing concentrations or doses. With regard to score, the higher the
score, the more severe were the symptoms.
We found that currently available probiotics probably make little or no difference in reducing eczema symptoms,
such as itching and sleep loss (moderate-quality evidence).
However, we did find that these probiotics may slightly reduce the severity of eczema scored by patients and their
healthcare professionals in combination (low-quality evidence), although it is uncertain if such a change is meaningful for
patients.
In terms of patient quality of life, we found no evidence that probiotics make a difference (low-quality evidence).
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We found no evidence of an increase in adverse events; those reported in included studies that were related to treatment
were tummy and gut upset with diarrhoea, constipation, vomiting, and colic pains (low-quality evidence).
Analysis suggests that further probiotic studies assessing the effects of eczema symptoms may not be worthwhile, as they
are unlikely to change the outcome at the end of active treatment.
Quality of the evidence
The quality of evidence supporting our key findings was low, apart from one moderate rating for participant-rated symptoms
of eczema. Reasons for this include variability between studies, which could not be explained, and not enough available
data.
Background 
Description of the condition
Disease definition
Eczema is a non-infective chronic inflammatory skin disease characterised by an itchy and usually red rash. The
terms 'eczema' and 'dermatitis' have been used synonymously, and eczema is associated with atopy. 'Atopy' is
defined as a genetic predisposition to become sensitised and produce immunoglobulin (Ig)E antibodies in
response to ordinary exposure to allergens (Johansson 2004). Despite the association between eczema and atopy,
up to 40% of children with eczema do not have atopy when defined according to allergy tests such as skin prick tests
(Bohme 2001; Flohr 2004). A revised nomenclature for allergy provided in Johansson 2001 has been updated by
the World Allergy Organization (Johansson 2004). The new nomenclature is based on the mechanisms that initiate and
mediate allergic reactions. The term 'eczema' is proposed to replace the previous term 'atopic eczema/dermatitis syndrome'.
What was termed atopic eczema dermatitis syndrome in 2001 is now thought to be not one single disease, but rather an
aggregation of several diseases with certain characteristics in common. The term 'atopy' cannot be used until IgE
sensitisation has been confirmed by IgE antibodies in the blood or by a positive skin prick test (SPT) to common
environmental or dietary allergens such as pollen, house dust mite, cow's milk, or egg. If this is done, the term 'eczema' can
be split into 'atopic eczema' and 'non-atopic eczema'.
For the purpose of this review, we will use the term 'eczema' and will include eczema when IgE sensitisation has been
confirmed, eczema when IgE sensitisation is absent, and eczema when IgE sensitisation has not been assessed.
Epidemiology and causes
Eczema is the most common inflammatory skin disease of childhood, affecting 5% to 20% of children at any one
time (Nankervis 2016; Williams 1999). The International Study of Asthma and Allergies in Childhood (ISAAC)
Phase III revealed the prevalence of current eczema for children six to seven years of age as ranging from 0.9% in
India to 22.5% in Equador, and for adolescents 13 to 14 years of age, from 0.2% in China to 24.6% in Columbia (Odhiambo
2009). The same study showed prevalence of symptoms of severe eczema ranging from 0.0% to 4.9% for children
aged six to seven years, and from 0.0% to 5.8% for adolescents aged 13 to 14 years. Around 2% of adults have
eczema, and many of them have a more chronic and severe form (Charman 2002). One-year prevalence of
eczema in adults in the United States was estimated to be 10.2% (Silverberg 2013). Eczema is often associated with
other atopic diseases such as asthma, allergic rhinitis, or food allergies (Beck 2000), and sufferers often have a
family history of allergic disease. Wide variation in the prevalence of eczema has been noted between different
countries, and studies suggest that prevalence is increasing in developing countries (Odhiambo 2009; Williams 2008).
The cause of eczema is not clearly understood. The finding that loss-of-function variants of the skin barrier protein
filaggrin are a predisposing factor for atopic dermatitis in Western Europeans was an important one in research on the
etiopathogenesis of atopic dermatitis (Palmer 2006). The same or other variants were found in other populations such as
Japanese - reported in Enomoto 2008 and Nemoto-Hasebe 2009 - and Han Chinese - reported in Zhang 2011. The
pathogenesis of eczema is complex and involves a combination of factors: skin barrier defects, innate and adaptive
immunity, and exposure to environmental allergens and microbes (Bieber 2008). The innate and adaptive immune
system products have an effect on major proteins of the epidermal barrier function and on defence against pathogens (
Malik 2017). Research has also pointed to the possible role of gut microbes (Abrahamsson 2012; Bjorksten 2001; Ismail
2012; Song 2016; Watanabe 2003).
Clinical features
Eczema is an itchy, chronic, non-contagious, and relapsing condition. In infancy, it is predominantly localised on the
face, in the nappy area, and on extensor surfaces of the knees and elbows; in childhood, it involves mainly the flexures,
the face, and the neck and continues similarly in adulthood. It can be generalised. Involvement of the hands and feet is
more common in adulthood. In infancy, the rash of eczema consists of red, edematous papules and vesicles, and it
later shows erythematous patches with papules, vesicles, exudate, crusting, lichenification, and hyperpigmentation or
hypopigmentation depending on the skin type. It can be complicated by bacterial and viral infections and
lymphadenopathy. The severity of eczema is variable, ranging from localised mild dryness and redness with little impact
on quality of life to generalised involvement with severe limitation of everyday activity and sleep loss. Itch is the
predominant symptom; it can be exacerbated by warmth, sweating, bathing, exercise, woollen clothes, and emotional
upset (Rook 2016).
Natural history
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For 45% of patients, eczema starts within the first six months of life, and by one and five years, 60% and 85%,
respectively, of those likely to develop it will have done so. Up to 70% of these cases will have spontaneous remission
before adolescence (Bieber 2008). Emerging evidence suggests that eczema may have similar prevalence in
adolescence and early adulthood as in childhood (Abuabara 2018).
Impact
Eczema varies in severity, which can be measured in several ways. A systematic review of instruments measuring
signs of eczema included 16 different scales used in validation studies. Two of them - the Eczema Area and Severity
Index (EASI) and the Severity Scoring of Atopic Dermatitis (SCORAD) - are considered the best for assessing
severity of signs of atopic dermatitis based on validity, responsiveness, internal consistency, interobserver and
intraobserver reliability, interpretability, and feasibility (Schmitt 2013). The HOME initiative
(Harmonizing Outcome Measures for Eczema) comprises an international group that is working to
reach agreement on core outcome measures that should be reported in all clinical trials for
eczema. Its goal is to enable comparison of data across trials for eczema (www.homeforeczema.org).
The intense itch and scratching can lead to severe sleep disturbance in children and adults with eczema, resulting
in tiredness and lack of concentration. Sleep loss, as well as systemic inflammation and impaired quality of life,
may contribute to mental health disorders associated with eczema, such as depression and attention
deficit/hyperactivity disorder (Silverberg 2017). A study comparing the effect on quality of life of children with chronic
skin disease shows that for children and parents, atopic dermatitis caused the greatest impairment, scoring worse
than chronic diseases such as epilepsy, enuresis, and diabetes (Beattie 2006). Eczema has a significant impact on the
quality of life of family or parents of the patient. Sleep loss, time spent caring for the patient, and time taken off work to
look after the affected child have a significant impact on the quality of life and finances of the parents and family of the
patient with eczema (Lewis-Jones 2006).
Eczema also brings considerable costs to the community as a whole. For example, the cost of childhood eczema to the
Australian community was estimated at AUD316.7 million (USD239.3 million; Euro195.9 million) per year in 1999 (Kemp
1999). In the United States, the estimated national cost of atopic dermatitis ranged between USD364 million and
USD3.8 billion (Mancini 2008). The healthcare costs of eczema in adults are comparable to those of epilepsy,
emphysema, and other chronic diseases (Ellis 2002). Direct costs to the family are incurred for purchasing treatments,
special clothing, and bedding, and for extra laundry expenses; indirect costs are associated with lost working days when
parents are looking after an unwell child. The wider economic implications are seen in the costs of healthcare professionals;
the lost opportunities for parents of sick children who do not have the option of seeking employment; and employment
limitations faced by the child as a result of missed schooling.
Description of the intervention
No cure is currently known for eczema; however, a wide range of treatments are available to control and reduce
the symptoms (Fennessy 2000; Lamb 2002; Nankervis 2016). Health professionals assist people in management of
their disease through a variety of treatment methods, including emollients, topical steroids, topical tars, and topical
tacrolimus and pimecrolimus. Other treatments such as wet wrap dressings, phototherapy, avoidance of triggers such
as food allergens, and complementary therapies are also used (Ernst 2000). Many treatments are of unknown
effectiveness (Nankervis 2016). Emollients, topical corticosteroids, and topical calcineurin inhibitors are universally
recommended (Nankervis 2016; Smethurst 2002). With deeper knowledge of the immunopathogenesis of atopic
dermatitis, new treatments have emerged such as dupilumab, an interleukin (IL)-4 receptor alpha subunit inhibitor,
and inhibitors of the phosphodiesterase enzyme (Eichenfield 2017). Treatment regimens can be time-consuming and
expensive for patients and their families, and new treatments that are effective, cheap, and simple to administer are needed.
Probiotics are live micro-organisms (e.g. Lactobacillus species) that when administered in adequate amounts
confer a health benefit on the host (FAO/WHO 2002). Minimum requirements for probiotic status have been
suggested to include assessment of strain identity, in vitro tests to screen potential probiotics, assessment of safety,
and in vivo studies for substantiation of effects (Pineiro 2007). Micro-organisms considered probiotics that are used in food
and pharmaceutical preparations are predominantly lactic acid bacteria, and of those, mainly Lactobacillus and Bifidobacteria
species, but also non-lactic acid bacteria such as Saccharomyces boulardii (Holzapfel 2001). Probiotics are not the same as
prebiotics, which are non-digestible sugars found in some foods that encourage the growth of certain types of bacteria in the
intestine.
How the intervention might work
Rationale for using probiotics to treat eczema
The intestinal microflora (or intestinal microbiota) is a large collection of micro-organisms that live in the human intestine and
confer intestinal, immune, and nutritional benefits on the host. The composition of the intestinal microflora has been found to
be different in those with eczema, and such differences may precede the development of active eczema. One consistent
finding in relevant studies is a reduced proportion of Bifidobacteria species in the faeces of infants with eczema (Bjorksten
2001; Kalliomaki 2001; Murray 2005), as well as in older children and young adults with atopic dermatitis (Watanabe 2003).
In the latter study, lower numbers of Bifidobacteria species also correlated with greater severity of the disease. Later
studies have shown that low microbial diversity in the neonatal period is associated with the development of eczema in
the first year of life (Ismail 2012), eczema with atopy in the first two years of life (Abrahamsson 2012), and IgE-
associated eczema in the first 18 months (Wang 2008). Another study found that patients with atopic dermatitis had
increased numbers of Faecalibacterium prausnitzii associated with low levels of short-chain fatty acids, possibly leading
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to aberrant T-helper type 2 cell (Th2) responses (Song 2016).
An intervention that has been proposed to influence the gut microbiome is the use of probiotics (Simonyte Sjödin 2016
). Probiotics may alter the intestinal microbiota of people with eczema and may improve symptoms and signs of
eczema. They are effective treatments for some gastrointestinal disorders characterised by a disturbed intestinal
microbiota, such as diarrhoea (Guarino 2015). Some evidence suggests that they may prevent the development of
eczema when given during pregnancy or in infancy (Dang 2013; Doege 2012; Mansfield 2014; Zhu 2010). Their
precise mode of action is not well established. Current research is focused on the immunomodulatory effects of
probiotics. Evidence indicates that several probiotic species stimulate regulatory T cells, which produce IL-10 and
tumour growth factor (TGF)-β, and control T-helper type 1 cell (Th1) and inhibition of Th2 responses (Vitaliti 2014). Th2
responses are particularly predominant in acute eczema and are increased in chronic eczema (Malik 2017).
Probiotics are widely consumed worldwide in the form of fermented milk, and they are potentially a cheap and
accessible treatment for eczema. Although all probiotics have certain properties in common (low pathogenicity,
resistance to gastric acid and bile salt digestion, and adherence to intestinal mucosa), the clinical and laboratory effects
of probiotics can vary markedly between species (Allen 2003; Christensen 2002).
Why it is important to do this review
Probiotics have been marketed in infant formula and are recommended by some practitioners for treatment of
eczema. They are increasingly used by consumers for treatment and prevention of a range of disorders, and they
have been formally investigated in several clinical trials for treatment of eczema. Their role in treating eczema is
nevertheless controversial (Williams 2005), and the first Cochrane Review on probiotics for treating eczema suggested
that probiotics may not be an effective treatment for eczema but identified areas in which evidence was lacking (Boyle 2008
). Moreover, reports suggest that probiotics can occasionally cause serious adverse effects (Besselink 2008; De Groote
2005; Hennequin 2000; Land 2005). It is therefore important to formally reassess the evidence for the efficacy of
probiotics in treating eczema. Since the first Cochrane Review on probiotics for treating eczema was published (Boyle 2008),
clinical trials have continued to investigate the use of probiotics for treating eczema, and more data are now available to
assess their efficacy. The first review included trials conducted only in children and mainly in Europe; data are now available
from trials conducted in adults and in Asian countries.
The rationale for this review comprises the following.
Eczema is a common disease with a negative impact on the individual, the family, and the community.
New treatments for eczema are needed.
Probiotics are increasingly used for treatment of eczema.
Cases of probiotic sepsis have been reported.
New clinical trials have been completed since publication of the first Cochrane Review on probiotics for treating eczema,
and it is necessary to reassess the evidence on use of probiotics for eczema treatment.
Plans for this review were published as a protocol (Boyle 2006a), This Cochrane Review is an update of Boyle 2008.
Objectives 
To assess the effects of probiotics for treating patients of all ages with eczema.
Methods 
Criteria for considering studies for this review 
Types of studies 
Randomised controlled trials (RCTs) of probiotics for the treatment of eczema.
Types of participants 
We included participants of any age or gender with eczema diagnosed by a doctor. We did not include participants with other
specific forms of eczema such as contact eczema.
The National Health Service Technology Assessment systematic review of treatments for eczema used specific terms
to identify trial participants (Hoare 2000). We used a modified classification of these terms as listed in Table 1. This list
classifies forms of eczema included in this review and specific forms of eczema not included in this review. One of the review
authors (RB) scrutinized identified studies that used terms in the 'possible atopic eczema' category (such as 'childhood
eczema') and included the study only if the description of participants indicated the absence of such specific forms as
'allergic contact eczema'.
Types of interventions 
We included interventions involving ingested live micro-organisms, including bacteria, fungi, or yeasts, ingested singly or in
combination. We placed no restrictions on the duration of the intervention.
Comparators could consist of no treatment, placebo, or another active intervention with no probiotics. We excluded studies
using other micro-organisms or microbial products as the sole comparator. We did not exclude from this review studies that
included an adjunct to the active treatment (such as antibiotics, other dietary management (e.g. allergen avoidance, prebiotic
supplementation), or standard eczema treatments such as topical corticosteroids).
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Types of outcome measures 
Primary outcomes
Changes in participant-rated, parent-rated, or principal carer-rated symptoms of eczema at the end of active treatment
Changes in quality of life at the end of active treatment
Secondary outcomes
Changes in participant-rated, parent-rated, or principal carer-rated symptoms of eczema during the six-month period after
active treatment has ceased
Changes in quality of life within the six-month period after active treatment has ceased
Changes in the need for other eczema treatment during active treatment or within the six-month period after active
treatment has ceased
Investigator-rated eczema severity
Changes in global eczema severity as measured by a trained investigator or a medical practitioner at the end of active
treatment
Changes in global eczema severity or change in the number of eczema flares as measured by participants, parents,
principal carers, or a medical practitioner in the six-month period after active treatment has ceased
Changes in the number of days lost from school or work due to eczema symptoms during active treatment
Adverse events during the active treatment period
For the above outcome measures:
parent-rated or principal carer-rated measurements of eczema symptoms and quality of life questionnaires refer to
outcomes reported by the parent or the principal carer when the patient could not complete the scores (e.g. because the
patient is an infant or a small child);
when available, we used changes in participant-rated, parent-rated, or principal carer-rated global eczema severity in
preference to assessments of specific eczema symptoms;
we assessed quality of life changes as measured by participants, their parent, or their principal carer on a published scale
(e.g. Chren 1997; Finlay 1996); and
in addition to assessment of global symptom or disease severity, when available, we assessed changes in a
composite rating scale using a published named scale (e.g. Severity Scoring of Atopic Dermatitis (SCORAD) (Kunz
1997)). When this was not available, we attempted to assess trial authors' modification of such a scale, or their own
composite rating scale.
Search methods for identification of studies 
We aimed to identify all relevant RCTs regardless of language or publication status (published, unpublished, in press, or in
progress).
Electronic searches 
For this update, we revised all our search strategies in keeping with current Cochrane Skin practices. We have provided
details of the previous search strategies in Boyle 2008. This review fully incorporates the results of searches conducted up to
26 January 2017.
Cochrane Skin Group Specialised Register, using the search strategy in Appendix 1.
Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 11), in the Cochrane Library, using the strategy
presented in Appendix 2.
Global Resource of EczemA Trials (GREAT) database (Centre of Evidence Based Dermatology; accessed at
www.greatdatabase.org.uk), using the browse function → Dietary interventions → Probiotics.
MEDLINE via Ovid (from 1946), using the strategy provided in Appendix 3.
Embase via Ovid (from 1974), using the strategy delineated in Appendix 4.
PsycINFO via Ovid (from 1806), using the strategy shown in Appendix 5.
Allied and Complementary Medicine Database (AMED) via Ovid (from 1985), using the strategy described in Appendix 6.
Latin American and Caribbean Health Science Information database (LILACS) (from 1982), using the strategy presented
in Appendix 7.
We identified three additional reports of relevant trials through an update search conducted on 30 January 2018. We have
added those three results to Studies awaiting classification and will incorporate them into the review at the next update.
Trials registers
We searched the following trials registers up to 10 March 2018, using the terms "eczema", "probiotic", and "probiotics".
International Standard Randomized Controlled Trials Number (ISRCTN) registry (www.isrctn.com).
ClinicalTrials.gov (www.clinicaltrials.gov).
Australian New Zealand Clinical Trials Registry (www.anzctr.org.au).
World Health Organization International Clinical Trials Registry Platform (ICTRP) (www.who.int/trialsearch).
EU Clinical Trials Register (www.clinicaltrialsregister.eu).
Searching other resources 
References lists
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We checked the bibliographies of included studies and some reviews for further references to relevant RCTs.
Unpublished literature
When possible, we contacted trial authors and investigators for further information regarding the nature and status of
identified studies.
Adverse events
We did not perform a separate search for adverse effects of probiotics for this update, but review authors conducted such a
search for the first publication of this review. For this update, we considered adverse effects described in the included RCTs,
and we reported the findings from the original additional adverse events search.
Handsearching
For this update, we handsearched the following conference proceedings.
European Academy of Allergology and Clinical Immunology Annual Meeting 2013 and 2014.
American Academy of Asthma, Allergy and Immunology Annual Meeting 2013 and 2014.
American Association of Immunologists Annual Meeting 2013, 2014, and 2015.
International Congress of Immunology 2013.
American Association of Dermatologists Annual Meeting 2013 and 2014.
International Investigative Dermatology Congress 2013.
International Symposium for Atopic Dermatitis 2014.
Data collection and analysis 
Selection of studies 
Two review authors (RB and AM) independently checked titles and abstracts identified through the searches.
We excluded studies that did not refer to a randomised controlled trial of orally ingested probiotics for treating
eczema. The same two review authors (RB and AM) independently assessed each study to determine whether
it met the predefined selection criteria. When necessary, we contacted the authors of studies in deciding their
eligibility for inclusion in the review. No major differences of opinion arose between the review authors. One
study was published in Russian (Ivankhnenko 2013), one in Chinese (Guo 2015), and another in Polish (Cukrowska 2008).
We assessed these studies after translation.
Data extraction and management 
Two review authors (RB and AM) independently extracted study data. No major differences of opinion arose, and it did not
prove necessary for a third review author to arbitrate over data extraction. We contacted trial authors for all included studies,
some excluded studies, and ongoing studies by email or by post to obtain complete data sets.
We piloted a data collection form and used this information to summarise the trials. Two review authors (JL and AM) checked
and entered the data. When complete data sets were available from trial authors, we used these data to calculate summary
statistics such as mean and standard deviation before performing data entry.
Assessment of risk of bias in included studies
Two review authors (RB and AM) independently assessed studies for risk of bias using the Cochrane 'Risk of bias' tool
(Chapter 8.5, in Higgins 2011), rating them as having 'low', 'unclear', or 'high' risk of bias. No major differences of opinion
arose, and it was not necessary for a third review author to arbitrate over risk of bias assessment. Assessment of risk of bias
included the following.
Method of generation of the randomisation sequence (selection bias): considered low risk of bias if the randomisation
sequence resulted in unbiased allocation to any of the study groups by investigators and to comparable study groups.
Method of allocation concealment (selection bias): considered 'low risk' if it was clear from publications or correspondence
with trial authors that the treatment assignment of each consecutive study participant could not be anticipated by
investigators. For example, if treatment allocation was done by a third party such as a pharmacy department, we
considered allocation concealment to have low risk of bias.
Blinding of participants and personnel (performance bias): judged as low risk if we found adequate information to ensure
that study personnel and participants could not have knowledge of the allocated intervention.
Blinding of outcome assessor (detection bias): judged as low risk if we found adequate information to exclude knowledge
of the allocated intervention by outcome assessors.
Incomplete outcome data (attrition bias): considered rates of loss to follow-up in total and in each study group, along with
reasons for these, and whether participants were analysed in the groups to which they were originally randomised
(available case analysis), whether any participants were excluded after randomisation, and whether data were imputed for
participants lost to follow-up. We judged low risk of bias when data were missing and reasons for missing data could not
have a clinically relevant impact on the effect size.
Selective reporting: considered low risk when all predefined outcomes of the study have been reported.
Other bias: considered low risk if we could detect no other sources of bias.
We defined studies with overall low risk of bias as studies when the randomisation process was clear; allocation concealment
was clear and done; participants, clinicians, or outcome assessors were blinded; and we detected no attrition bias
Quality assessment
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We also assessed factors contributing to the quality of the included trials.
Whether or not study aims, interventions (including doses of viable probiotic used, mode of administration, and duration of
treatment), and outcome measures were clearly defined.
Whether treatment compliance was assessed.
Whether non-study probiotics were adequately excluded from participants' diets.
Measures of treatment effect
We calculated a weighted pooled treatment effect across studies using a random-effects model.
For dichotomous outcomes, we expressed the results as risk ratios (RRs) and 95% confidence intervals (CIs) for
analyses containing only parallel-group trials, and we used odds ratios (ORs) when we included in the meta-
analysis data from both cross-over and parallel-group studies, because the method used for combining parallel-
group and cross-over study findings in meta-analysis did not allow findings to be expressed as RRs (Elbourne 2002).
For analyses that included both cross-over and parallel-group studies, we combined conditional (paired) ORs from
cross-over studies with ORs from parallel-group studies to estimate pooled ORs. We used conditional ORs because
they can be used to pool data from cross-over studies with data from parallel-group studies (Duffy 1989).
We used mean differences (MDs) and 95% CIs or standardised mean differences (SMDs) and 95% CIs to express results for
continuous outcomes. When studies reported participant- or investigator-rated symptoms on categorical scales (e.g.
Passeron 2006), we made the data dichotomous by defining a cutoff at good improvement in eczema versus mild
improvement, no change, or worsening of eczema.
Trial sequential analysis
For this review update, we used post hoc retrospective trial sequential analysis (TSA) for our first primary outcome.
Meta-analyses carry risk of type I errors (false significant results) due to limited data from few and small trials and
repetitive testing on updates as data from new trials accumulate (Brok 2008; Wetterslev 2008). TSA is a method that
quantifies the statistical reliability of data within a meta-analysis (Brok 2009; Wetterslev 2009). We estimated information size
(IS, i.e. the least number of participants needed for a statistically significant result) based on the mean difference derived
through clinical consensus, using a two-sided 5% significance level and 90% power, and we diversity-adjusted the data to
reflect the quantity of heterogeneity by performing a random-effects meta-analysis. For estimation of the mean in the control
group, which is a necessary step during TSA, we pooled control event rates for any low risk of bias trials contributing to the
relevant meta-analysis. In TSA, when the cumulative z-curve crosses the trial sequential monitoring boundary, sufficient
evidence of an association can be concluded and no further trials are needed. However, if the cumulative z-curve does not
cross the boundary and the IS is not reached, evidence is insufficient to reach a conclusion and further trials are required.
Other Cochrane groups have used TSA in their reviews (e.g. Allingstrup 2016 - Cochrane Anaesthesia, Critical and
Emergency Care Group). We used post hoc TSA for our first primary outcome - changes in participant-, parent-, or
principal carer-rated symptoms of eczema at the end of treatment (TSA software).
Unit of analysis issues 
We followed guidance from the Cochrane Handbook for Systematic Reviews of Interventions in addressing unit of analysis
issues (Chapters 9 and 16, in Higgins 2011).
Cross-over trials
When possible, we initially analysed cross-over trials using appropriate paired analyses to estimate paired MDs (continuous
outcomes) and paired ORs (dichotomous outcomes) with standard errors. We then combined outcome data from cross-over
trials and parallel-group trials using the generic inverse variance method. We also analysed data from parallel-group trials
and cross-over trials as separate subgroups, because cross-over studies may not be appropriate for probiotic studies, as the
duration of treatment effect is not well established.
Studies with multiple treatment groups
When studies reported more than one active intervention arm, we combined the two active interventions and analysed them
together. We also analysed data from these studies in a separate stratified analysis to assess the effects of different strains
of the probiotics.
Trials reporting non-parametric statistics
When trials reported non-parametric summary statistics, we attempted to convert data to parametric summary statistics by
assuming that the reported median was the mean, and we estimated the standard error as interquartile range (IQR)/1.35
(Chapter 7.7.3.5, in Higgins 2011); however, we acknowledge that these are strong assumptions because many of the
included trials did not include large sample sizes. Therefore we have added cautionary notes when we believe the
impact of these assumptions could have strongly influenced the overall findings of the meta-analysis. When non-
parametric statistics could not be converted to parametric statistics, we presented the data in an additional table (Table 2).
Dealing with missing data
We assessed pooled data using available case analysis rather than intention-to-treat analysis with imputation. When the
nature of missing data was not clear, we contacted study authors for clarification. When studies failed to report summary
statistics such as standard deviations, we contacted trial authors for further information.
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Assessment of heterogeneity 
We assessed statistical heterogeneity using I². When we found substantial statistical heterogeneity between studies (I² >
50%), we explored possible reasons for this heterogeneity, including participant factors such as disease severity, treatment
factors such as probiotic strain or dose, and study factors such as methodological quality criteria as described above. When
we detected extreme levels of statistical heterogeneity between trials (e.g. I² > 85%), we considered whether it was
appropriate to pool studies by considering their clinical and methodological differences.
Assessment of reporting biases
We performed formal assessment of reporting bias using a funnel plot for continuous outcomes when the number of studies
with data available for inclusion in primary analyses was greater than 10, and we performed statistical assessment using
Egger's test.
Data synthesis
When studies employed different tools to measure the same outcome, we calculated a pooled estimate of effect across
studies using standardised mean differences (SMDs) and 95% CIs. When it was not possible to perform a meta-analysis, we
described the findings narratively.
Subgroup analysis and investigation of heterogeneity 
We planned the following stratified analyses for this review.
Analysis by age (under 2 years vs 2 to 12 years vs over 12 years).
Concurrent treatment with antibiotics versus no concurrent treatment with antibiotics.
Atopic versus non-atopic study participants, with atopy defined as at least one positive skin prick test (SPT) or
radioallergosorbent test (RAST) to a common allergen.
Participants with a formally diagnosed (i.e. double-blind placebo-controlled food challenge) food allergy versus those
without a formally diagnosed food allergy.
Participants with evidence of intestinal inflammation versus those without such evidence.
Participants with mild eczema (SCORAD < 15) versus moderate eczema (SCORAD 15 to 40) versus severe eczema
(SCORAD > 40) at baseline.
We performed stratified analysis rather than subgroup analysis for the following reasons.
Some strata included small numbers of studies.
When differences were present, they were clearer to the observer.
Subgroup analysis assumes a fixed-effect model, and the high heterogeneity seen even with subgroups suggests that this
is not appropriate.
This approach is consistent with the approach used in the previous version of this review.
Use of multiple stratified analyses means that interpretation of 'significant' subgroup tests would be problematic due to the
risk of chance spurious findings.
Several of the stratified analyses included more than one group with the same participant count, for example, in the 'any
Lactobacillus species' group and in the 'other specific Lactobacillus species' groups.
Sensitivity analysis
When appropriate, we performed sensitivity analyses to examine the effects of excluding poor quality studies, defined as
studies for which the randomisation process is unclear; allocation concealment is not clear or was not done; participants,
clinicians, or outcome assessors were not blinded; no intention-to-treat analysis was performed; or risk of attrition bias is
high.
We also performed, when appropriate, sensitivity analyses based on changes in scores from baseline to end of treatment to
examine the effects of studies with baseline differences in eczema severity.
Assessment of quality of evidence
We applied the GRADE approach for the main comparisons to rate the quality of evidence for the prespecified outcomes
included in Summary of findings table 1 (Atkins 2004). We selected our primary outcomes; the secondary outcome 'Changes
in global eczema severity as measured by a trained investigator or a medical practitioner at the end of active treatment'; and
adverse events for inclusion in the Summary of findings table 1.
Other
For this update, our consumer co-author (AR) contributed to enhance the readability and clarity of the completed review.
Results 
Description of studies 
Results of the search
We updated the Electronic searches and fully incorporated the results to 26 January 2017. We identified 477 records from
eight databases, five trials registers, and other sources. After removing duplicates, we (AM and RB) screened 472 records.
We excluded 423 based on titles and abstracts, leaving a total of 49. Of these, six are ongoing studies (see Characteristics
of ongoing studies), and five studies are awaiting classification (see Characteristics of studies awaiting classification).
#102 Probiotics for treating eczema
10 / 151
We screened the remaining 38 records in full text when available. We excluded 11 records (see Characteristics of excluded
studies). Combined with the eight studies excluded from the previous version of this review, the total of excluded studies is
19. We included 27 new studies. We identified 12 included studies in the earlier version of this review, for a total of 39
included studies overall (see Characteristics of included studies).
We identified three of the studies awaiting classification through an update search conducted on 30 January 2018 (Hulshof
2017; NCT02585986; Prakoeswa 2017). We have not fully assessed these, and we will incorporate them into the review at
the next update.
We have presented the study flow diagram in Figure 1.
Included studies
We included 39 studies with 2599 participants (12 studies with 781 participants from the first review, and 27 new studies with
1818 participants identified for this update) and have described all studies in the Characteristics of included studies section.
The authors of seven studies supplied complete data sets (Brouwer 2006; Goebel 2010; Han 2012; Passeron 2006; 
Rosenfeldt 2003; Sistek 2006; Weston 2005). The authors of five studies supplied summary data (Drago 2014; Flinterman
2007; Nermes 2010; Roessler 2007; Viljanen 2005). The authors of four studies responded to our requests by
clarifying some questions relevant to their studies but did not provide additional data (Drago 2012; Iemoli 2012; Van der Aa
2010; Wang 2015). We received no response to requests for information from the authors of 17 studies (Cukrowska 2008; 
Farid 2011; Folster-Holst 2006; Gruber 2007; Guo 2015; Isolauri 2000; Ivankhnenko 2013; Lin 2015; Majamaa 1997; 
Matsumoto 2014; Shafiei 2011; Taniuchi 2005; Woo 2010; Wu 2012; Wu 2015; Yang 2014; Yesilova 2012). The
authors of one study responded that they were unable to supply their data for meta-analysis (Kirjavainen 2003).
We could not contact the authors of four studies (Gerasimov 2010; Hol 2008: invalid contact details; Gromert 2009: no
contact details found; Yoshida 2010: no contact details found and no response from Sponsor Tokiwa Pharmaceuticals).
Design
All studies were randomised controlled trials; 37 were parallel-group trials, and two were cross-over trials.
Sample sizes
Studies involved sample sizes ranging from 13 to 252 participants.
Setting
Studies took place in primary or secondary care settings at European (24 studies), Australian and New Zealand (two
studies), and Asian (13 studies in Korea, China, Iran, Japan, and Taiwan) centres.
Participants
Studies evaluated probiotics in children and adults of both genders. We could not calculate an accurate male/female ratio
because data from some studies are not available. Participants in 14 studies were under the age of 18 months, and overall
33 studies assessed children up to the age of 18. The remaining six studies assessed only adults. Study authors did not
mention the skin type of participants, and particularly did not mention whether studies included participants with skin of
colour. All studies included participants with doctor-diagnosed eczema.
Nineteen studies stated that eczema was diagnosed based on the criteria provided by Hanifin and Rajka. In three
studies, the diagnosis was based on the UK Working Party criteria. In two studies, the diagnosis was based on
the Consensus Guidelines for Diagnosis and Management of Atopic Dermatitis (Eichenfield 2004). One study used
the definition of atopic eczema dermatitis syndrome (AEDS) for diagnosis. Another study based the diagnosis on the
Guidelines for Management of Atopic Dermatitis provided by the Japanese Dermatological Association. In one
study, the diagnosis was based on Erlangen score > 10 (atopic score of Diepgen) (Diepgen 1996). One study stated that the
diagnosis of eczema was based on diagnostic criteria but did not specify which ones, and 11 studies did not specify the
diagnostic criteria applied.
The severity of participants' eczema ranged from mild to severe. Eighteen studies did not prespecify the severity of
eczema among participants (Brouwer 2006; Cukrowska 2008; Drago 2014; Flinterman 2007; Folster-Holst 2006; Goebel
2010; Guo 2015; Hol 2008; Isolauri 2000; Ivankhnenko 2013; Kirjavainen 2003; Lin 2015; Majamaa 1997; Nermes 2010; 
Rosenfeldt 2003; Taniuchi 2005; Viljanen 2005; Yoshida 2010). Nine studies recruited participants with moderate to
severe eczema (Drago 2012; Gerasimov 2010; Iemoli 2012; Matsumoto 2014; Shafiei 2011; Wang 2015; Weston 2005; Wu
2012; Yesilova 2012). Another study recruited participants with mild to severe eczema (Farid 2011). Nine studies
recruited participants with eczema scored above a minimum Severity Scoring of Atopic Dermatitis (SCORAD) value (Gore
2011; Gruber 2007; Han 2012; Passeron 2006; Roessler 2007; Sistek 2006; Van der Aa 2010; Woo 2010; Wu 2015;
with minimum SCORAD ≥ 10, 15 to 40, 20 to 50, 5 to 30, > 15, ≥ 25, ≥ 15, ≥ 10, and ≥ 15, respectively). One study
recruited participants with moderate eczema (Gromert 2009). Another study recruited participants with mild to moderate
eczema (Yang 2014).
Three studies assessed only children who had atopic eczema (Flinterman 2007; Sistek 2006; Wang 2015), and one study
assessed only children with low levels of Bifidobacteria in their faeces (Taniuchi 2005).
Interventions
Twenty-three studies used a single strain of probiotic with or without prebiotic (Brouwer 2006; Drago 2012; Drago 2014; 
Folster-Holst 2006; Goebel 2010; Gore 2011; Gromert 2009; Gruber 2007; Han 2012; Isolauri 2000; Kirjavainen 2003; Lin
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2015; Majamaa 1997; Matsumoto 2014; Nermes 2010; Passeron 2006; Taniuchi 2005; Van der Aa 2010; Weston 2005; 
Woo 2010; Wu 2012; Wu 2015; Yoshida 2010): 15 of these used Lactobacillus (L) species (L rhamnosus, L salivarius, L
reuteri, L GG, L plantarum, L fermentum, L sakei) (Brouwer 2006; Drago 2012; Drago 2014; Folster-Holst 2006; Gromert
2009; Gruber 2007; Han 2012; Kirjavainen 2003; Majamaa 1997; Nermes 2010; Passeron 2006; Weston 2005; Woo 2010; 
Wu 2012; Wu 2015); five used Bifidobacterium species (B lactis, B bifidum, B breve) with or without prebiotic (Lin 2015; 
Matsumoto 2014; Taniuchi 2005; Van der Aa 2010; Yoshida 2010); and three included one arm treated with Lactobacillus
species and one with Bifidobacterium species (Goebel 2010; Gore 2011; Isolauri 2000).
Fifteen studies used probiotic mixtures of mainly Lactobacillus and Bifidobacteria species with or without prebiotic
(Cukrowska 2008; Farid 2011; Flinterman 2007; Gerasimov 2010; Hol 2008; Iemoli 2012; Ivankhnenko 2013; Roessler 2007;
Rosenfeldt 2003; Shafiei 2011; Sistek 2006; Viljanen 2005; Wu 2015; Yang 2014; Yesilova 2012). One study had three arms,
all treated with Lactobacillus species (L paracasei, L fermentum); two arms used a single strain, and the third arm used
a combination of the two strains (Wang 2015).
Trials identified no standard dose, and researchers used a variety of doses and concentrations of probiotics. They
measured the daily dose most often in colony-forming units (CFUs)/d or CFU/dose or CFU/gr or 100 mL of formula.
Concentrations of probiotic bacteria varied from 10⁷/gr formula to 7.8 × 10¹⁰/d for different strains. One study reported the
dose of probiotics in mgr (Wu 2015), and two studies gave no information on the concentrations of probiotics used (Guo
2015; Lin 2015).
Co-interventions included extensively hydrolysed infant formula and prebiotic (Taniuchi 2005; Van der Aa 2010),
extensively hydrolysed formula and elimination diets (non-dairy, cow’s milk, or egg elimination diet) (Brouwer 2006; Gore
2011; Majamaa 1997; Viljanen 2005), extensively hydrolysed formula only (Hol 2008; Isolauri 2000; Kirjavainen 2003; 
Nermes 2010), a prebiotic (Farid 2011; Passeron 2006; Shafiei 2011; Wu 2012), and elimination diet alone (Cukrowska
2008; Ivankhnenko 2013). Placebo groups received the co-intervention alone (Hol 2008; Kirjavainen 2003; Nermes 2010; 
Taniuchi 2005; Van der Aa 2010; Wu 2012), or they were given microcrystalline cellulose alone or with the study’s
formula (Folster-Holst 2006; Sistek 2006; Viljanen 2005; Wang 2015; Woo 2010), maltodextrin alone or with rice
starch or anhydrous glucose or cellulose and silicone dioxide (Drago 2012; Drago 2014; Flinterman 2007; Gerasimov 2010; 
Goebel 2010; Gore 2011; Han 2012; Iemoli 2012; Weston 2005; Wu 2015), hydrolysed casein (Cukrowska 2008),
skim milk powder with either dextrose or potato starch and lactose and prebiotic, sucrose, skim milk with glucose,
inulin, dextrin, and silicon dioxide (Matsumoto 2014; Rosenfeldt 2003; Yesilova 2012), or glucose anhydrous crystalline
powder (Yang 2014).
Seven studies did not specify the placebo (Brouwer 2006; Farid 2011; Gromert 2009; Gruber 2007; Ivankhnenko 2013; 
Roessler 2007; Yoshida 2010). One study provided no placebo, and the control group received no treatment (Lin 2015),
and another study provided no placebo but participants in the control arm used the same topical treatment as those in
the intervention arm (Guo 2015).
Outcomes
From 13 studies (Goebel 2010; Gruber 2007; Han 2012; Nermes 2010; Passeron 2006; Roessler 2007; Rosenfeldt 2003; 
Sistek 2006; Weston 2005; Woo 2010; Wu 2012; Yang 2014; Yoshida 2010), we obtained data for the first
primary outcome of the review: changes in participant-, parent-, or principal carer-rated symptoms of eczema at
the end of active treatment. Five studies reported participant- or parent-rated changes from baseline in eczema
symptom scores at the end of active treatment (SCORAD part C or visual analogue scale (VAS) scores for
pruritus and sleep loss) (Gerasimov 2010; Gruber 2007; Weston 2005; Wu 2015; Yang 2014), and the authors of four
trials provided unpublished data for that outcome (Goebel 2010; Han 2012; Passeron 2006; Rosenfeldt 2003).
Three of these studies reported parent- or participant-rated overall change in eczema severity during study
treatment (Passeron 2006; Rosenfeldt 2003; Weston 2005). One study (abstract only) reported this change
narratively (Gromert 2009).
For the second primary outcome - changes in quality of life at the end of active treatment - 10 studies reported quality
of life measures (Dermatology Life Quality Index (DLQI), Infant's Dermatology Quality of Life Index (IDQoL), Children's
Dermatology Life Quality Index (CDLQI), Dermatitis Family Impact Scale (DFI), Skindex-29) (Drago 2012; Gerasimov 2010; 
Gore 2011; Folster-Holst 2006; Iemoli 2012; Wang 2015; Weston 2005; Wu 2012; Wu 2015; Yoshida 2010), and
one study reported quality of life changes using a non-validated questionnaire (Matsumoto 2014).
Three studies reported outcomes relevant to the first secondary outcome of the review - changes in participant-, parent-,
or principal carer-rated symptoms of eczema within six months after active treatment had ceased (Han 2012; Sistek 2006; 
Weston 2005).
Three studies reported data relevant to the secondary outcome - changes in quality of life within six months after active
treatment has ceased (Iemoli 2012; Wang 2015; Weston 2005).
Eleven studies reported assessments of the need for other eczema treatment during the study intervention (Folster-Holst
2006; Gerasimov 2010; Gore 2011; Gruber 2007; Han 2012; Rosenfeldt 2003; Van der Aa 2010; Weston 2005; Woo 2010; 
Wu 2012; Wu 2015), and two studies (one abstract only) reported this outcome narratively (Gromert 2009; Wang 2015).
For the fourth secondary outcome of the review, investigator-rated eczema severity, 32 studies reported global
eczema severity scores (total SCORAD index as absolute score or change from baseline) (Brouwer 2006; Cukrowska 2008; 
Drago 2012; Drago 2014; Farid 2011; Folster-Holst 2006; Gerasimov 2010; Goebel 2010; Gore 2011; Gruber 2007; Han
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2012; Hol 2008; Iemoli 2012; Ivankhnenko 2013; Lin 2015; Majamaa 1997; Nermes 2010; Passeron 2006; Roessler 2007; 
Rosenfeldt 2003; Shafiei 2011; Sistek 2006; Van der Aa 2010; Viljanen 2005; Wang 2015; Weston 2005; Woo 2010; Wu
2012; Wu 2015; Yang 2014; Yesilova 2012; Yoshida 2010), and one study provided unpublished data (Flinterman 2007
). Eight studies reported investigator-rated eczema severity scores (EASI, SCORAD part A/B, categorical
presentation of total SCORAD changes) (Cukrowska 2008; Majamaa 1997; Passeron 2006; Shafiei 2011; Weston 2005; 
Woo 2010; Yang 2014; Yoshida 2010), and the authors of four trials provided unpublished data on this outcome (Brouwer
2006; Goebel 2010; Han 2012; Sistek 2006). One study (abstract only) reported investigator-rated changes in
eczema severity narratively only (Gromert 2009). Twelve studies reported outcomes for changes in eczema
severity within six months after treatment had ceased (Cukrowska 2008; Folster-Holst 2006; Han 2012; Iemoli 2012; Isolauri
2000; Ivankhnenko 2013; Majamaa 1997; Roessler 2007; Sistek 2006; Viljanen 2005; Wang 2015; Weston 2005). One
study reported the rate of recurrence within three months after the end of treatment (Guo 2015).
Eleven studies reported adverse events (Folster-Holst 2006; Gerasimov 2010; Gore 2011; Gruber 2007; Matsumoto 2014; 
Passeron 2006; Sistek 2006; Wang 2015; Weston 2005; Wu 2012; Wu 2015), and four studies mentioned them (Drago
2012; Farid 2011; Iemoli 2012; Shafiei 2011).
Excluded studies
We excluded from the review 19 publications reporting RCTs; we have described these in the Characteristics of excluded
studies section.
For three studies (Burk 2013; Ou 2012; Rose 2010), we could not ascertain whether all participants had eczema.
In two studies (Arkwright 2003; Gueniche 2008), interventions were given topically, not orally as defined in the protocol of
this review.
In four studies, the intervention was not a probiotic, but this was not clear from the published abstracts (Foekel 2009; 
Ikezawa 2004; Leung 2004; Shibata 2009).
Two studies were quasi-RCTs (Aryayev 2006; Chernysov 2009).
In one study, the control was also a probiotic (Matsumoto 2007), and three studies used heat-killed bacteria (Moroi 2011; 
Murosaki 2006; Torii 2011); we excluded these studies because they did not fulfil the criteria set in the review protocol for
included studies.
One study did not study probiotics in humans (Ogawa 2006).
One study was a follow-up study of probiotics used for prevention, not treatment, of eczema (Laitinen 2005).
In two studies (Arvola 2006; Kalliomaki 2003), participants did not have eczema.
Ongoing studies
Among the "ongoing studies" identified for the first review, the Land study (NCT00378300) was withdrawn before recruitment
started because of lack of funding.
We identified four ongoing trials for this update: one examining a probiotic (IRT5) for the treatment of atopic
dermatitis conducted in Korea and currently recruiting (KCT0000914; which started in November 2013); one
conducted in Brazil to study a mixture of probiotics for atopic dermatitis in children (NCT02519556; which is
recruiting); one undertaken in Spain to study probiotics in children (NCT02585986a; which started in January 2016 and has
completed recruitment); and one reported from Italy to study Lactobacillus reuteri and vitamin D in children
with atopic dermatitis (NCT02945683; which is currently recruiting) (see Characteristics of ongoing studies).
Studies awaiting classification
We have identified four trials awaiting classification. One study from Australia studied probiotics in
the management of eczema with a start year of 2004 (ACTRN12605000615684). The current status is unknown. We
contacted the investigators but have received no response. One trial from the Netherlands studied the use of amino
acid-based formula with synbiotics in infants with non-IgE-mediated cow's milk allergy (Candy 2016). Some of the
participants have eczema, and SCORAD measurement is one of the secondary outcomes. Researchers have not yet
presented results for clinical outcomes of the study (see Characteristics of studies awaiting classification).
Risk of bias in included studies 
We have presented review authors' judgement for each risk of bias item across all studies in the 'Risk of bias' graph (Figure
2), and for each study in the 'Risk of bias' summary (Figure 3). We have presented in Table 3 the review authors' quality
assessment of other parameters of the included studies (clarity of statement of aims, interventions and outcomes,
compliance assessment, exclusion of non-study probiotics).
Allocation (selection bias)
Random sequence generation
For 20 studies, we judged the method used in generating the randomisation sequence as having low risk of bias, and
for 17 of those (Drago 2012; Drago 2014; Gerasimov 2010; Goebel 2010; Han 2012; Hol 2008; Iemoli 2012; Passeron 2006;
Roessler 2007; Shafiei 2011; Sistek 2006; Van der Aa 2010; Viljanen 2005; Wang 2015; Weston 2005; Wu 2012; Yang
2014), the randomisation sequence was computer generated. For 19 studies, trial authors did not describe the
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method used in generating the randomisation sequence, so we judged these studies as having unclear risk of bias;
this group included one trial in which trial authors provided no information on the randomisation sequence
generation method used, although we judged treatment allocation as adequate (Yesilova 2012). We found no trials to be at
high risk of bias for random sequence generation.
Allocation concealment
Authors of 25 studies did not describe concealment of treatment allocation, and we judged risk of bias as unclear for
this domain (Brouwer 2006; Cukrowska 2008; Drago 2014; Farid 2011; Folster-Holst 2006; Gerasimov 2010; Gore 2011; 
Gromert 2009; Gruber 2007; Guo 2015; Hol 2008; Isolauri 2000; Ivankhnenko 2013; Kirjavainen 2003; Lin 2015; Majamaa
1997; Matsumoto 2014; Nermes 2010; Roessler 2007; Rosenfeldt 2003; Shafiei 2011; Taniuchi 2005; Woo 2010; Wu 2015; 
Yoshida 2010).
We considered 14 trials to have low risk of selection bias due to allocation concealment. One trial described
treatment allocation by the "closed envelope method", which we judged as adequate (Yesilova 2012). For the
remaining 13 included studies, we did not consider treatment allocation concealment adequate because the allocating
process excluded access to the randomisation sequence and knowledge of the treatment given (Drago 2012; Flinterman
2007; Goebel 2010; Han 2012; Iemoli 2012; Passeron 2006; Sistek 2006; Van der Aa 2010; Viljanen 2005; Wang 2015; 
Weston 2005; Wu 2012; Yang 2014). For 10 of these studies, a pharmacy department or a blinded investigator
provided treatment using a computer-generated randomisation sequence (Drago 2012; Han 2012; Iemoli 2012; Passeron
2006; Sistek 2006; Van der Aa 2010; Viljanen 2005; Wang 2015; Weston 2005; Yang 2014). These studies
adequately concealed treatment allocation - the third party was not involved in screening or enrolling participants,
and the clinical trial staff enrolling participants did not have access to the randomisation sequence. One study
gave sealed boxes with allocation numbers to participants using a randomisation table (Flinterman 2007). Two
studies packed treatment in numbered sealed boxes and gave them to participants using a computer-generated
randomisation sequence (Goebel 2010; Wu 2012).
We found no studies at high risk of bias for allocation concealment.
Blinding (performance bias and detection bias)
We judged studies to be at low risk of performance bias when trial authors provided enough information to exclude
knowledge of the allocated intervention by participants or parents and personnel involved in the trial. We judged studies to be
at low risk of detection bias when trial authors provided enough information to exclude knowledge of the allocated
intervention by outcome assessors, but also by participants or parents for participant- or parent-rated outcomes.
One study was not blinded (open-label), so we judged it to be at high risk of bias in both domains (Ivankhnenko 2013). We
judged another study to be at high risk of performance bias because trial authors did not mention blinding and the control
group received no treatment and no placebo; hence we determined it was unlikely that blinding was done (Lin 2015). The
same study provided inadequate information on blinding of the outcome assessor, and so we judged this study to be at
unclear risk of detection bias.
We judged 16 studies to be at low risk for both performance and detection bias (Drago 2012; Drago 2014; Flinterman 2007; 
Goebel 2010; Gore 2011; Han 2012; Hol 2008; Iemoli 2012; Nermes 2010; Passeron 2006; Roessler 2007; Sistek 2006; 
Van der Aa 2010; Viljanen 2005; Wang 2015; Wu 2012). Authors of eight of these studies stated that participants,
clinicians, and outcome assessors were all blinded (Drago 2012; Gore 2011; Hol 2008; Roessler 2007; Sistek 2006; Van der
Aa 2010; Wang 2015; Wu 2012). For another eight studies, we confirmed blinding of participants, clinicians, and
outcome assessors through communication with trial authors (Drago 2014; Flinterman 2007; Goebel 2010; Han 2012; Iemoli
2012; Nermes 2010; Passeron 2006; Viljanen 2005).
We judged 18 studies to be at unclear risk of both performance and detection bias. Of these, trial authors described
14 studies as "double-blind" without further clarification or provided no information on blinding (Brouwer 2006; Cukrowska
2008; Gromert 2009; Gruber 2007; Guo 2015; Isolauri 2000; Kirjavainen 2003; Majamaa 1997; Matsumoto 2014; Rosenfeldt
2003; Taniuchi 2005; Woo 2010; Wu 2015; Yoshida 2010). The remaining four studies provided information on some
parts of the study but not on blinding of all participants/parents, clinicians, and outcome assessors (Folster-Holst 2006; 
Weston 2005; Yang 2014; Yesilova 2012).
We judged Farid 2011 as having unclear risk of performance bias, as study authors did not provide enough
information, but low risk of detection bias. Two studies provided enough information, and we judged them to be at
low risk of performance bias, but information on outcome assessment was inadequate, and we judged them to be
at unclear risk of detection bias (Gerasimov 2010; Shafiei 2011).
Incomplete outcome data (attrition bias)
Follow-up and exclusions
In this domain, we assessed rates of and reasons for losses to follow-up for overall participants and for each intervention
group, as well as exclusions from analysis for all outcomes.
We judged 24 studies to be at low risk of attrition bias with low rates of loss to follow-up overall (ranging from 0 to
14%) and for each intervention group, and low exclusion rates (Brouwer 2006; Drago 2012; Drago 2014; Flinterman 2007; 
Folster-Holst 2006; Gerasimov 2010; Goebel 2010; Gore 2011; Gruber 2007; Iemoli 2012; Ivankhnenko 2013; Nermes 2010;
Roessler 2007; Shafiei 2011; Sistek 2006; Van der Aa 2010; Viljanen 2005; Wang 2015; Weston 2005; Woo 2010; Wu 2012;
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Wu 2015; Yesilova 2012; Yoshida 2010). We judged losses to follow-up under 20% to show low risk of attrition bias and
20% or over to show high risk. Of these, one study used imputation for missing data (Gore 2011). Another study
reported different rates of loss to follow-up in the two groups (8.9% in the probiotic group and 21% in the placebo group,
with overall loss to follow-up of 14%) and found the difference to be statistically insignificant (P = 0.11) (Woo 2010).
Overall losses to follow-up when reported were low, with the exception of four studies, which reported losses to
follow-up ranging from 23% to 30% (Cukrowska 2008; Farid 2011; Han 2012; Yang 2014). We judged all of these
studies to be at high risk of attrition bias. Another study had high rates of exclusion from analysis (25.9%), and we
judged it to be at high risk of attrition bias (Rosenfeldt 2003). Passeron 2006 reported overall low rates of loss to follow-up,
but these varied significantly between the two groups (8% in the placebo group and 29% in the probiotic group). We judged
this difference and the reasons for it as likely to affect all outcomes, and we judged this study to be at high risk of attrition
bias.
For the nine remaining studies, we judged risk of attrition bias as unclear because trial authors provided inadequate
information on losses to follow-up and exclusions (Gromert 2009; Guo 2015; Hol 2008; Isolauri 2000; Kirjavainen 2003; Lin
2015; Majamaa 1997; Matsumoto 2014; Taniuchi 2005).
Selective reporting (reporting bias)
We found little evidence of reporting bias in the included studies. However, we judged two studies to be at high risk of
reporting bias (Drago 2012; Han 2012). One of these did not report scores for eczema symptoms (pruritus and sleep
loss) after treatment, but study authors provided this information to us after communication (Han 2012). The other
study reported and discussed only outcomes that were significant for the probiotic group (Drago 2012).
We judged six studies to be at unclear risk of reporting bias (Farid 2011; Gromert 2009; Guo 2015; Matsumoto 2014; Shafiei
2011; Wu 2015). Two of these reported baseline characteristics only for participants who completed the study (Farid 2011; 
Shafiei 2011). One study provided inadequate information to permit a judgement (Gromert 2009). We found this report
only as a conference abstract and could not find registration of the trial to determine whether all outcomes had been
reported. One study described all outcomes but did not provide most of the data numerically and did not provide
information on trial registration (Wu 2015). Another study reported all outcomes but not numerically (Matsumoto 2014).
However, study authors particularly analysed any favourable information/outcome for probiotics even if it was not
statistically significant. Another study did not provide information on the dose of the probiotic given and reported results
only narratively (Guo 2015).
The other 31 studies provided no evidence of selective reporting, and we judged them as having low risk of bias in
this domain. Trial authors reported all outcomes as described in the publication and/or the trial registration. One
study did not report the SCORAD score for eczema, which was a secondary outcome, but provided this
information on our request (Flinterman 2007).
Other potential sources of bias
For 16 studies, we identified no sources of other bias, and we judged studies to be at low risk of other bias (Brouwer 2006; 
Cukrowska 2008; Folster-Holst 2006; Gerasimov 2010; Goebel 2010; Gore 2011; Gruber 2007; Isolauri 2000; Kirjavainen
2003; Nermes 2010; Roessler 2007; Rosenfeldt 2003; Taniuchi 2005; Weston 2005; Woo 2010; Wu 2012). In particular,
study authors declared that they received funding for the study and stated "no conflicts of interest".
The probiotic supplier sponsored or co-sponsored 12 studies (Drago 2012; Flinterman 2007; Han 2012; Hol 2008; Iemoli
2012; Matsumoto 2014; Van der Aa 2010; Viljanen 2005; Wang 2015; Wu 2015; Yang 2014; Yoshida 2010). For four
of these studies (Drago 2012; Han 2012; Matsumoto 2014; Yoshida 2010), we judged that the sponsor was likely to have
influenced the study outcome or reporting of the study outcome, and we judged these studies to be at high risk of other bias.
In addition, for Han 2012, power calculations of the final numbers of participants suggest that the study did not meet
target recruitment and was discontinued "after the second interim analysis showed statistically significant differences
between the groups". In another of these studies (Yoshida 2010), researchers did not match probiotic and placebo groups for
eczema severity (total SCORAD score) at baseline.
Overall we assessed 19 studies as having unclear risk of other bias (Drago 2014; Farid 2011; Flinterman 2007; Gromert
2009; Guo 2015; Hol 2008; Iemoli 2012; Ivankhnenko 2013; Lin 2015; Majamaa 1997; Passeron 2006; Shafiei 2011; Sistek
2006; Van der Aa 2010; Viljanen 2005; Wang 2015; Wu 2015; Yang 2014; Yesilova 2012). Six of these studies did not
declare sponsorship of the trial nor conflicts of interest (Guo 2015; Ivankhnenko 2013; Majamaa 1997; Passeron 2006; 
Shafiei 2011; Yesilova 2012). Investigators reported one study in a conference abstract only and provided
inadequate information for risk of bias assessment (Gromert 2009). One of these studies did not match probiotic and
placebo groups for eczema severity (total SCORAD score) at baseline (Sistek 2006). For five studies (Drago 2014; Farid
2011; Iemoli 2012; Lin 2015; Wu 2015), trial authors did not make clear what role the supplier of the probiotic
played in the study and did not declare trial sponsorship. The other seven studies were sponsored by the supplier
of the intervention and the role of the sponsor in data analysis and publication was unclear (Flinterman 2007; Hol 2008; Van
der Aa 2010; Viljanen 2005; Wang 2015; Wu 2015; Yang 2014); therefore, we judged them to be at unclear risk of bias.
Effects of interventions 
Primary outcomes
Changes in participant-rated, parent-rated, or principal carer-rated symptoms of eczema at the end of active
treatment
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The authors of 13 studies with 795 randomised participants supplied published or unpublished data on parent- or
participant-rated symptom scores at the end of study treatments (SCORAD part C or equivalent) (Goebel 2010; Gruber
2007; Han 2012; Nermes 2010; Passeron 2006; Roessler 2007; Rosenfeldt 2003; Sistek 2006; Weston 2005; Woo 2010; 
Wu 2012; Yang 2014; Yoshida 2010). Researchers measured symptoms using a VAS for itch and sleep disturbance ranging
from 0 to 10 for each symptom, then a combined score ranging from 0 to 20. Pooled available data from 754 participants in
these studies show no significant improvement in favour of probiotic treatment (mean difference (MD) -0.44, 95% confidence
interval (CI) -1.22 to 0.33; Analysis 1.1). Results show significant statistical heterogeneity between studies for this outcome
measure (I² = 57%). The reason for this heterogeneity is not clear. We note here that authors of the Yang 2014 study
reported their results in non-parametric statistics, which we converted to parametric ones (see Methods: Unit of analysis
issues). Inclusion of data from this study in the meta-analysis did not change the overall significance of the outcome,
but data conversion is based on the assumption that the data are not skewed. Trial sequential analysis shows that
target sample sizes of 258 and 456, which are necessary to demonstrate a minimum mean difference of -2 (Figure 4)
and -1.5 (Figure 5), respectively, with 90% power have been exceeded, suggesting that further trials with similar
probiotic strains for this outcome may be futile. The sample size of 1026, which is necessary to demonstrate a
minimum difference of -1 at 90% power, has not been reached (Figure 6). This suggests that further studies to determine
whether these probiotics change the outcome by at least 1.5 points may be futile.
Four trials reported parent-rated overall evaluation of symptoms of eczema at the end of study treatment; however
one trial did not provide any numerical data for this outcome and reported no significant differences between groups (
Folster-Holst 2006). Therefore, we included the remaining three trials with 150 randomised participants in the
analysis, which comprised data for 135 participants (Passeron 2006; Rosenfeldt 2003; Weston 2005). We
dichotomised the scale of two studies as 'better' versus 'worse' or 'the same' (Rosenfeldt 2003; Weston 2005), and
the scale of one study measuring from 1 (worse) to 6 (much better) as '4 to 6' versus '1 to 3' (Passeron 2006). Pooling of
data from these studies shows no significant reduction in the risk of worsened/unchanged eczema among probiotic-treated
individuals (odds ratio (OR) 0.40, 95% CI 0.14 to 1.15; Analysis 1.2). We detected moderate levels of statistical
heterogeneity between trials (I² = 48%), which appeared to be related to the Rosenfeldt 2003 trial. Possible reasons for this
heterogeneity include adequate exclusion of other probiotic sources from this cross-over trial, or higher methodological
quality of parallel-group studies (defined as stating that an intention-to-treat analysis was performed, and that methods used
for allocation concealment and randomisation sequence generation were adequate). Trial sequential analysis showed that
the optimal information size for detecting a 30% difference in the probability of eczema improvement at 90% power is 1096,
so that information is currently insufficient to conclude whether probiotics might have an impact on this outcome measure.
One study (abstract publication only) reported significant reduction in symptoms of itching and loss of sleep in the
probiotic group (P = 0.024) (Gromert 2009).
Another study did not use a validated score for participant-rated symptoms of eczema (Matsumoto 2014). Study authors
reported that Itch improvement level in the probiotic group was significantly higher than that in the placebo group at week 8
(end of intervention) (P < 0.05). The proportion of participants whose condition improved and whose scores were 0
(improved remarkably) and 1 (improved) by diagnosis was significantly greater in the LKM512 group than in the placebo
group at week 8 (P < 0.05). However, results show no significant differences between groups with respect to other
symptomatic scores.
Nine further studies with 688 participants and available data from 627 participants reported changes from baseline in parent-
or participant-reported eczema symptoms and found no significant differences between the two groups (MD -0.70, 95% CI
-1.47 to 0.06; Analysis 1.3) (Gerasimov 2010; Goebel 2010; Gruber 2007; Han 2012; Passeron 2006; Rosenfeldt 2003; 
Weston 2005; Wu 2015; Yang 2014). Results show moderate statistical heterogeneity (I² = 33%) between studies for this
outcome measure, which is significantly reduced when Gerasimov 2010 is removed, but the reason for this heterogeneity is
not clear. Also we should note here that we converted non-parametric statistics from the Yang 2014 study to parametric ones
(see Methods: Unit of analysis issues), although inclusion of data from this study did not alter the significance of the outcome
of this analysis.
Changes in quality of life at the end of active treatment
Ten studies provided quality of life (QoL) data (Drago 2012; Folster-Holst 2006; Gerasimov 2010; Gore 2011; Iemoli 2012; 
Matsumoto 2014; Wang 2015; Weston 2005; Wu 2012; Yoshida 2010). We included data from six studies with
569 randomised participants and available data from 552 participants using four different scales in the meta-
analysis (Gerasimov 2010; Gore 2011; Iemoli 2012; Matsumoto 2014; Wang 2015; Yoshida 2010), which show no
differences in quality of life between treatment groups (standardised mean difference (SMD) 0.03, 95% CI -0.36 to 0.42; I² =
68%; Analysis 1.4). We noted significant statistical heterogeneity, but this finding may be related to the different scales used.
Three studies with 372 randomised participants assessed family QoL by using the Dermatitis Family Impact Questionnaire as
described in Lawson 1998, and the Family Dermatology Life Quality Index as discussed in Basra 2007 (Gerasimov 2010; 
Wang 2015; Weston 2005); pooled data from 358 participants show no significant differences (SMD -0.19, 95% CI -0.56 to
0.18; Analysis 1.5). Reasons for the significant statistical heterogeneity (I² = 59%) are not clear, but it is reduced when the
Gerasimov 2010 study is removed.
Wu 2015 reported no statistically significant differences between groups in results of the Infant Dermatology Life Quality
Index (P = 0.71) and the Dermatitis Family Impact Scale (P = 0.61). Three studies with 153 participants reported no
significant differences in QoL between groups at the end of treatment using the Dermatology Life Quality Index, a different
published scale - as described in Ruden 1999 - and an unpublished scale, respectively (Drago 2012; Folster-Holst 2006; 




Changes in participant-rated, parent-rated, or principal carer-rated symptoms of eczema during the six-month
period after active treatment has ceased
Data from three studies comprising 195 participants showing changes in eczema symptoms after active treatment had
ceased were available and could be pooled (Han 2012; Sistek 2006; Weston 2005). These three trials reported SCORAD
part C scores at four weeks, eight weeks, and two weeks after cessation of study treatment, respectively. A pooled analysis
of the data shows significant improvement in the participant-/parent-rated symptom score in favour of probiotic treatment (MD
-1.81, 95% CI -3.13 to -0.49 points on SCORAD part C; I² = 0%; Analysis 1.6). One of these studies also reported a
dichotomised global assessment by parents after cessation of probiotic treatment but no significant long-term
differences in the risk of worsened or unchanged eczema between probiotic and placebo interventions (OR 0.63,
95% CI 0.21 to 1.88; data not presented) (Weston 2005).
Changes in quality of life within the six-month period after active treatment has ceased
Three studies provided data for this outcome (Iemoli 2012; Wang 2015; Weston 2005). Two studies reported longest
follow-up of eight weeks (Iemoli 2012; Weston 2005), and one study described longest follow-up of one month after
cessation of treatment (Wang 2015). Weston 2005 reported that the median change in quality of life score eight weeks after
the end of study treatment was -2.5 points for the probiotic group and -3.0 for the placebo group. Statistical comparison of
available data was not possible due to lack of summary statistics. Pooled data from two studies with 261 participants show
no significant differences between the two groups (SMD -0.08, 95% CI -0.35 to 0.20, I² = 0%; Analysis 1.7) (Iemoli 2012; 
Wang 2015).
One study reported QoL measures for 12, 18, and 36 months post treatment, showing no significant differences
between groups (Gore 2011).
Changes in the need for other eczema treatment during active treatment and within the six-month period after
active treatment has ceased
Eleven studies with 634 participants reported this outcome but only for the period of active treatment (Table 4) (Folster-Holst
2006; Gerasimov 2010; Gore 2011; Gruber 2007; Han 2012; Rosenfeldt 2003; Van der Aa 2010; Weston 2005; Woo 2010; 
Wu 2012; Wu 2015). We could not pool the data due to differences in reporting of this outcome. For nine of these
studies, differences between treatment groups were not statistically significant (Folster-Holst 2006; Gore 2011; Gruber 2007;
Han 2012; Rosenfeldt 2003; Van der Aa 2010; Woo 2010; Wu 2012; Wu 2015), and for one study (Weston 2005), trial
authors reported no statistical analysis. The only study that reported significant differences was Gerasimov 2010, which
shows a less cumulative quantity of topical corticosteroids used in the probiotic group during the study period (P = 0.006);
however, study authors reported no significant differences in the frequency of use of topical corticosteroids at the final visit (P
= 0.130).
Two studies reported no recorded differences in steroid consumption between groups (Gromert 2009 (abstract publication
only); Wang 2015).
The sole study reporting changes in the need for other eczema treatment after treatment had ceased found no
significant differences between placebo and probiotic groups in median topical corticosteroid scores eight weeks after
cessation of the study intervention (Weston 2005).
Investigator-rated eczema severity
Changes in eczema severity as measured by a trained investigator or a medical practitioner at the end of active treatment
All studies reported assessments relevant to this outcome. Twenty-four studies with 1639 participants reported mean
total SCORAD (SCORAD parts A, B, C) scores at the end of treatment (Drago 2012; Drago 2014; Flinterman 2007; Folster-
Holst 2006; Goebel 2010; Gore 2011; Gruber 2007; Han 2012; Hol 2008; Iemoli 2012; Ivankhnenko 2013; Lin 2015; Nermes
2010; Passeron 2006; Roessler 2007; Rosenfeldt 2003; Sistek 2006; Viljanen 2005; Wang 2015; Weston 2005; Woo 2010; 
Wu 2012; Yesilova 2012; Yoshida 2010). Trial authors provided data for one of these studies (Drago 2014); however, the P
value for the difference between the two groups calculated via a two-sided unpaired t test shows a slight difference (P <
0.001) from that reported in the manuscript (P = 0.015). Pooled analysis of available data on 1596 participants from these
studies shows significant differences between probiotic and control treatments, with a mean difference of -3.91 points in
favour of probiotic treatment (95% CI -5.86 to -1.96; Analysis 1.8). We detected extreme levels of statistical
heterogeneity between trials (I² = 79%), which seemed to be related to parallel-group trials (I² = 81%). The reasons for
heterogeneity were not clear. Two studies reported significant baseline differences in eczema severity between
placebo- and probiotic-treated groups, which might have accounted for the increased difference in end of treatment
SCORAD scores (Sistek 2006; Yoshida 2010). Schram 2011 assessed the minimal clinically important difference (MCID) in
SCORAD, EASI, and Patient-Oriented Eczema Measure (POEM) scores; researchers used as anchor points changes in
Patient and Investigator Global Assessment (PGA and IGA). Schram suggested that the MCID in total SCORAD is 8.7, which
is higher than the difference of 3.91 points shown in our Analysis 1.8 (i.e. lower than this cutoff point). Although the study
data came from adult patients only, the mean difference of 3.91 points found in this analysis is of uncertain clinical
significance. Schram also suggested that a minimum change in total SCORAD of 4.1 is the optimal cutoff change that can
predict change in IGA, which is closer to the difference we found in Analysis 1.8.
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To explore this, we performed a sensitivity analysis using change scores (i.e. the difference in SCORAD score between
start and end of treatment for each individual). Fourteen studies with 1086 randomised participants provided these data
on 1035 participants (Farid 2011; Gerasimov 2010; Goebel 2010; Han 2012; Ivankhnenko 2013; Nermes 2010; Passeron
2006; Rosenfeldt 2003; Sistek 2006; Van der Aa 2010; Viljanen 2005; Weston 2005; Woo 2010; Wu 2015), which we have
presented in Analysis 1.9. The data show a mean difference in SCORAD change of -4.46 points (95% CI -6.49 to -2.43) in
favour of probiotic treatment, with substantial but diminished statistical heterogeneity between trials (I² = 51%). The reason
for this is not clear, but it seems to be attributed most to the Farid 2011 study, which reported high rates of loss to follow-up
(23%), which researchers excluded from analysis.
We also performed a sensitivity analysis using total SCORAD scores at the end of treatment only for studies with
low risk of bias (Analysis 1.10). We found nine studies with low risk of bias (Drago 2012; Flinterman 2007; Goebel 2010; 
Iemoli 2012; Sistek 2006; Van der Aa 2010; Viljanen 2005; Wang 2015; Wu 2012), but eight studies with 741
randomised participants provided data from 705 participants for analysis (Drago 2012; Flinterman 2007; Goebel 2010; 
Iemoli 2012; Sistek 2006; Viljanen 2005; Wang 2015; Wu 2012). Results show extreme levels of statistical heterogeneity
(88%), and so we have pooled the data in the subtotal. The reasons for this heterogeneity were not clear, but it may be
attributed to the use of different strains of probiotics.
The authors of 11 studies reported data for investigator-rated eczema severity using objective SCORAD (parts A/B)
scores (Brouwer 2006; Goebel 2010; Han 2012; Majamaa 1997; Passeron 2006; Shafiei 2011; Sistek 2006; Weston 2005; 
Woo 2010; Yang 2014; Yoshida 2010). Pooled data on 529 participants from 10 studies do not show a significant difference
between groups (MD -2.24, 95% CI -4.69 to 0.20; I² = 54%; Analysis 1.11) (Brouwer 2006; Goebel 2010; Han 2012; 
Majamaa 1997; Passeron 2006; Sistek 2006; Weston 2005; Woo 2010; Yang 2014; Yoshida 2010). It is noted again that
authors of the Yang 2014 and Majamaa 1997 studies reported their results using non-parametric statistics, which we
converted to parametric ones (see Methods; Unit of analysis issues). Inclusion of data from Yang 2014 in the meta-analysis
changed the overall significance of the outcome; this inclusion should be considered with caution.
In Cukrowska 2008, a categorical analysis of total SCORAD scores shows no significant differences between the two
groups. Gromert 2009 (abstract publication only) reported that "the extension of the eczema was significantly decreased over
time in the group given probiotic compared to the group given placebo (P = 0.024)".
We could not pool data from the other studies for this outcome measure. Taniuchi 2005 showed a significant reduction in
symptom scores from baseline in both probiotic and placebo groups, but study authors did not present any statistical
comparison between the two groups. Isolauri 2000 reported assessments as median scores with an interquartile range
(shown in Table 2) and showed a statistically significant difference between end of treatment SCORAD scores for probiotic
versus placebo groups. We could not pool the data from this study in Analysis 1.11, because SCORAD scores were so low
that it could not be assumed that the median score approximates the mean. Kirjavainen 2003 reported mean total SCORAD
score at the end of treatment (eight in the placebo group and five in the probiotic group) without statistical analysis of this
difference; additionally, the duration of active treatment varied greatly between participants in this study. Passeron 2006
reported an investigator's global assessment scale of eczema improvement at the end of treatment for 39 participants;
however, results show no significant differences in the risk of worse, unchanged, or mildly improved eczema between
probiotic and no probiotic treatments (OR 0.41, 95% CI 0.07 to 2.38; data not presented as a forest plot). We could not
include data from Shafiei 2011 in the meta-analysis, but study authors reported no significant differences between groups.
Matsumoto 2014 did not use a validated severity score and made no comment on study results in the publication. Guo 2015
did not use a validated score index to assess eczema severity but assessed improvement after interventions according to
four grades: "complete resolution", "good response", "partial response", and "no response". Researchers considered
participants who showed complete resolution and good response as responders, and those with partial and no response as
non-responders. At the end of treatment, study authors reported a response rate in the probiotic group of 91.1% and in the
control arm of 76.7%, which they found to be statistically significant (P < 0.05).
Changes in global eczema severity or change in the number of eczema flares as measured by participants, parents, principal
carers, or a medical practitioner in the six-month period after active treatment has ceased
Seven studies with 581 participants and available data on 509 participants reported total SCORAD scores after active
treatment had ceased for two (Han 2012; Roessler 2007), four (Ivankhnenko 2013; Sistek 2006; Wang 2015), and
eight weeks post end of active treatment (Iemoli 2012; Weston 2005). Results show significant differences favouring
probiotics over no probiotics (MD -7.72, 95% CI -11.85 to -3.59). We noted very high levels of statistical
heterogeneity (83%) between studies of this analysis (Analysis 1.12), for which reasons are not clear but may involve
differences in follow-up times between studies. Pooling of data from parallel trials shows significant differences favouring only
probiotics (MD -9.27, 95% CI -13.88 to -4.65), which exceeds the MCID of 8.7 in SCORAD demonstrated by Schram 2011.
Even so, very high levels of heterogeneity (82%) may be due to differences in follow-up duration between studies.
Majamaa 1997 reported median SCORAD scores of 16 (interquartile range (IQR) 6 to 25) in probiotic-treated infants, and 14
(IQR 2 to 38) in placebo-treated infants, one month after the study intervention had ceased with no statistical analysis
presented. Isolauri 2000 reported median SCORAD scores of 0 in all active and placebo-treated groups at six-month follow-
up; however, the duration of study interventions provided in this study is not clear. Viljanen 2005 reported mean changes in
SCORAD score four weeks after study interventions had ceased. Lactobacillus rhamnosus GG (LGG)-treated infants had a
mean reduction of 22.9 points, probiotic mix-treated infants 20.4 points, and placebo-treated infants 20.3 points, with no
statistically significant differences between treatment groups at this time point. Finally, Folster-Holst 2006 reported mean
SCORAD scores four weeks after study interventions had ceased - probiotic-treated participants had a mean score of 32.8
versus 30.1 for placebo.
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Pooled analysis of data from two studies with 102 participants show significant improvement in investigator-rated
eczema extent and severity (SCORAD parts A/B) in favour of probiotic treatment (MD -8.11, 95% CI -13.14 to -3.09)
eight and four weeks, respectively, after cessation of treatment (Weston 2005; Sistek 2006; Analysis 1.13). We detected no
statistical heterogeneity between these two studies (I² = 0%).
Cukrowska 2008 presented changes in total SCORAD five months after the end of intervention as categorical data
(improvement vs no improvement or exacerbation) and showed no significant differences between groups.
Gore 2011 and Van der Aa 2010 reported total SCORAD scores for longer than six months post treatment, hence longer
than the time period defined in our review protocol. Gore 2011 provided data for total SCORAD 12, 18, and 36 months post
treatment showing no significant differences between probiotic and placebo. Van der Aa 2010 showed total SCORAD scores
at one year post treatment without statistical analysis, reporting slightly higher scores in the probiotic group than in the
placebo group (mean ± SD: 35.4 ± 10.8 and 33.9 ± 10.6 in probiotic and placebo groups, respectively).
Guo 2015 reported recurrence rates over a period of three months after the end of treatment: 26.7% of participants in the
probiotic arm had recurrence versus 68.9% of those in the control arm, which researchers found to be statistically significant
(P < 0.05).
Changes in the number of days lost from school or work due to eczema symptoms during active treatment
No study reported this outcome.
Adverse events during the treatment period
Eight studies reported adverse events (AEs) in 105/624 participants (Folster-Holst 2006; Gruber 2007; Matsumoto 2014; 
Passeron 2006; Sistek 2006; Wang 2015; Weston 2005; Wu 2012). One of these participants with vomiting withdrew from
the study. Pooled data on gastrointestinal adverse events among 402 participants from seven of those trials with 427
randomised participants show no significant differences in adverse event rates between probiotic and control groups (RR
1.54, 95% CI 0.90 to 2.63; I² = 0%; Analysis 1.14) (Folster-Holst 2006; Gruber 2007; Matsumoto 2014; Passeron 2006; 
Sistek 2006; Weston 2005; Wu 2012). We could not pool data from Wang 2015 because it was not clear which of the
adverse events happened in each group. Trial authors stated that there were "no group differences in bowel cramps, fecal
frequency, and gastroenteritis".
Gerasimov 2010 found no significant differences in gastrointestinal and total adverse events. Investigators reported a total of
38 AEs in the probiotic group versus 35 in the control group, and a total of 14 gastrointestinal AEs (three diarrhoea, six
constipation, five abdominal colic) in the probiotic group versus 12 (two diarrhoea, six constipation, four abdominal colic) in
the control group. They considered no serious AEs (burn, croup, head injury, food poisoning) to be related to treatment.
Parents in Gore 2011 (42/137; 30.7%) reported some difficulties (e.g. green loose stools, increased vomiting, feed refusal,
colic) that were considered related to changes in formula, and 24/137 (17.5%) stopped the formula. It is uncertain whether
these difficulties were due only to the formula or to the probiotic, as researchers reported numbers from both groups.
Four studies reported no significant AEs during treatment (Drago 2012; Farid 2011; Iemoli 2012; Shafiei 2011). No other
study provided any data on AEs.
Authors in Wu 2015 reported 35 AEs in the probiotic group and 37 in the control group but provided no details on the nature
of these events or the statistical analysis. They stated that these events were not related to study products.
We did not update for this review update the separate search for adverse events that was done for the first review,
which included non-RCT data (Boyle 2006a). Please see Differences between protocol and review. This search
revealed four case reports of sepsis related to probiotic use (Cherifi 2004; De Groote 2005; Lestin 2003; Riquelme 2003
), including one death (Lestin 2003). It also revealed five reports of human safety assessments using probiotics (Burton 2006;
Connolly 2005; Makelainen 2003; Srinivasan 2006; Wolf 1998), as well as four review articles on probiotic safety (Borriello
2003; Boyle 2006a; Ishibashi 2001; Salminen 1998). Safety assessments demonstrated no adverse effects of
probiotics in humans, but case reports and review articles documented a total of 42 cases of suspected or proven
probiotic sepsis (Boyle 2006a). Study authors did not definitively identify the probiotic origin of the infective
organism in all of these 42 cases, and it is not possible to quantify the risk of such outcomes from available data. A
subsequent report described increased risk of fatal bowel ischaemia in critically ill patients treated with one
particular combination of probiotics (Besselink 2008). One review proposed some relative contraindications to probiotic
use in view of the risk of sepsis (Boyle 2006a).
Stratified analyses
We undertook the following planned stratified analyses.
Analysis by age
We analysed global change in eczema symptoms and symptom scores (SCORAD part C) as well as global eczema
severity scores from studies stratified by age (Analysis 1.15; Analysis 1.16; Analysis 1.17). Analysis of SCORAD part C
scores shows no significant differences in symptom scores between probiotic and control treatments (age under 2 years: MD
-0.39, 95% CI -2.20 to 1.42; I² = 58%; age 2 to 12 years: MD -0.63, 95% CI -2.04 to 0.78; I² = 64%; adults: MD 1.01, 95% CI
-0.82 to 2.84; I² = 0%; Analysis 1.16).
Analysis of total SCORAD scores by age group shows no significant differences in total SCORAD between probiotic and
control treatments among those under two years of age (MD -0.99, 95% CI -3.97 to 1.99; I² = 68%); however, data from older
age groups show a significant difference in favour of probiotics (age 2 to 12 years: MD -6.08, 95% CI -9.68 to -2.48; I² = 0%;
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adults: MD -6.51, 95% CI -10.09 to -0.07; I² = 78%; Analysis 1.17).
Analysis by antibiotic use during study intervention
Viljanen 2005 separately evaluated participants not exposed to antibiotics during the intervention period but did not report
any end-of-treatment outcomes for this group.
Analysis by atopy
Three studies included only participants with proven atopy (Flinterman 2007; Sistek 2006; Wang 2015), and another
study separately evaluated treatment effects in participants with atopy (Viljanen 2005). We could not pool SCORAD
scores at the end of treatment for these studies due to extreme levels of statistical heterogeneity between trials (I² = 91%).
We noted a significant difference in total SCORAD scores between probiotic and no probiotic groups when we analysed
studies with a mix of atopic and non-atopic participants (MD -4.15, 95% CI -6.02 to -2.27), and we detected high levels of
heterogeneity (I² = 74%) (Analysis 1.18).
Cukrowska 2008 presented results for IgE-dependent and IgE-independent eczema, defining IgE-dependent eczema as
raised total IgE or specific IgE to certain food allergens (not specified). Investigators reported data for total SCORAD as a
dichotomous outcome - "improvement versus no improvement/exacerbation" - and noted a significant difference between
groups favouring probiotics during the intervention period (P = 0.0329), but not during the five-month post-treatment period.
Van der Aa 2010, in a subgroup of participants with IgE-associated eczema, found a significant difference in reduction of
total SCORAD at the end of treatment compared with baseline, favouring probiotics (MD -4.6, 95% CI -9.1 to -0.1; P = 0.04).
Researchers defined IgE-associated atopic dermatitis as atopic dermatitis with raised total and/or specific serum IgE levels to
house dust mites, cat, cow's milk, peanut, and egg at baseline.
In Gerasimov 2010, 53 out of 96 participants (25 in the probiotic group and 28 in the placebo group) had raised IgE (> 50
IU/mL). Data on the subgroup of participants with raised IgE show a significant difference in reduction of total SCORAD at
the end of treatment favouring probiotics (P = 0.006). Data on the subgroup of participants without raised IgE (43 out of 96)
show differences in the reduction of total SCORAD at the end of treatment that were not significant (P = 0.068). Study
authors suggested that overall significant results for all participants favouring probiotics may be attributed to participants with
IgE-associated eczema, who constituted more than half of the study population.
Analysis by food allergy
Viljanen 2005 separately evaluated SCORAD scores in participants with proven cow's milk allergy. All participants in
Ivankhnenko 2013 had proven cow's milk allergy. In Hol 2008, in which all participants had proven cow's milk
allergy, data were available only for participants who had moderate to severe eczema. Results show no significant
differences in end of treatment SCORAD scores between probiotic and placebo groups (MD -1.84, 95% CI -6.22 to
2.54) with extreme levels of statistical heterogeneity between trials (70%) (Analysis 1.19). We found significant
differences in SCORAD scores favouring probiotics when we evaluated studies with a mix of food-allergic and non-
food-allergic participants (MD -3.21, 95% CI -5.63 to -0.79); however, we detected extreme levels of statistical
heterogeneity between trials (I² = 76%) (Analysis 1.19)
Analysis by intestinal inflammation
No study provided data for this subgroup analysis.
Analysis by disease severity
Six studies with 421 participants provided sufficient data to stratify end of treatment SCORAD scores by disease
severity (Analysis 1.20) (Goebel 2010; Gruber 2007; Han 2012; Passeron 2006; Sistek 2006; Weston 2005). No evidence
shows a difference in treatment efficacy according to disease severity (severe eczema: MD -3.71, 95% CI -10.05 to 2.64; I² =
0%; moderate eczema: MD -2.95, 95% CI -7.65 to 1.74; I² = 62%; mild eczema: MD -5.53, 95% CI -15.29 to 4.23).
Gerasimov 2010 reported changes in total SCORAD scores by disease severity at the end of treatment. For both moderate
and severe disease, the data favoured probiotics.
Analysis by probiotic species or strain
This stratified analysis was not a priori specified in the study protocol, but we undertook the analysis due to use of the same
probiotic strain in some studies and heterogeneity between study results noted for some outcomes in this review. For this
analysis, we analysed data for SCORAD part C and total SCORAD at end of treatment. We categorised studies as follows.
Lactobacillus GG, L rhamnosus, L salivarius, L casei and paracasei, and any Lactobacillus species alone or in
combination with or without probiotics.
Bifidobacterium lactis, B breve, or any Bifidobacterium species alone or in combination with or without prebiotics.
Single versus multiple probiotics, with or without prebiotics
Probiotics without prebiotics.
Results show no significant differences in participant-/parent-rated symptoms of eczema (SCORAD part C) between
groups for any of the probiotic subgroups (Analysis 1.21; Analysis 1.22; Analysis 1.23; Analysis 1.24).
Pooled data (Analysis 1.25) show significantly higher total SCORAD scores after treatment with Lactobacillus GG compared
with placebo (MD 3.37, 95% CI 0.55 to 6.20; I² = 0%). A significant difference in total SCORAD scores favoured probiotics
compared with no probiotics after treatment with Lactobacillus salivarius (MD -6.86, 95% CI -10.08 to -3.63; I² = 74%; data
from six studies: Drago 2012; Drago 2014; Flinterman 2007; Iemoli 2012; Wu 2012; Yesilova 2012), or with any Lactobacillus
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species (MD -3.80, 95% CI -6.06 to -1.54; I² = 79%; data from 21 studies: Drago 2012; Drago 2014; Flinterman 2007; 
Folster-Holst 2006; Goebel 2010; Gore 2011; Gruber 2007; Han 2012; Hol 2008; Iemoli 2012; Nermes 2010; Passeron
2006; Roessler 2007; Rosenfeldt 2003; Sistek 2006; Viljanen 2005; Wang 2015; Weston 2005; Woo 2010; Wu 2012; 
Yesilova 2012), but with significant heterogeneity. Results show no significant differences in total SCORAD scores between
probiotics and no probiotics after treatment with L rhamnosus, L casei, and L paracasei, and no significant differences in total
SCORAD scores between probiotics and no probiotics after treatment with Bifidobacterium lactis, B breve, and any
Bifiidobacterium species (Analysis 1.26). Data show a significant difference in total SCORAD scores between
probiotics and no probiotics when treatment consisted of a single or multiple probiotic species (Analysis 1.27). A
significant difference in total SCORAD scores favoured probiotics compared with no probiotics after treatment with
any probiotic alone with no prebiotic (Analysis 1.28) (MD -3.83, 95% CI -5.81 to -1.86), but data show very high levels of
heterogeneity (I² = 80%).
For the stratified analyses Analysis 1.16, Analysis 1.21, Analysis 1.22, Analysis 1.23, and Analysis 1.24, we used data from
Yang 2014, which we converted from non-parametric to parametric statistics (see Methods: Unit of analysis issues). Inclusion
of these data should be considered with caution but did not change the overall significance of the findings of analyses.
Assessment of reporting bias in the meta-analyses
We created funnel plots for continuous outcomes for which an adequate number of included studies provided data:
participant- or parent-rated symptoms of eczema at the end of treatment (Analysis 1.1), global eczema severity
score at the end of treatment (Analysis 1.8), and global eczema severity score/sensitivity analysis/change score (Analysis
1.9). See Figure 7, Figure 8 and Figure 9, respectively.
We performed Egger's test for asymmetry as a formal assessment of publication bias. For Analysis 1.1 and Analysis 1.9, P
values from Egger's test show no significant asymmetry (P = 0.18 and P = 0.479, respectively; Figure 7 and Figure 9).
However, for Analysis 1.8, the P value from Egger's test is significant, which indicates evidence of asymmetry in the
plot for this outcome (P = 0.007) (Figure 8); however, the asymmetry appears to be related to an over-influential study
(Drago 2012). A sensitivity analysis excluding this study yielded a P value from Egger's test that was non-significant (P =
0.357). Furthermore, we noted extreme levels of heterogeneity (I² = 79%) between studies for this outcome, which can lead
to funnel plot asymmetry; therefore this interpretation should be considered with caution.
Discussion 
Summary of main results
We included 39 randomised controlled trials (RCTs) with 2599 participants in the update of this review. Participants included
both males and females and infants and adults, although most were children. The probiotics used in these studies were
Lactobacillus and Bifidobacteria species, given as a single strain or in probiotic mixtures with or without prebiotics.
Evidence shows significant heterogeneity between studies for most of the outcomes of the review (Summary of findings
table 1). Apart from the large variety of probiotics used, the variety of doses and concentrations of probiotics in the
preparations used may have contributed to heterogeneity. For the following key results, the comparator was no probiotics,
active treatment ranged from six weeks to three months (apart from the investigator-rated eczema severity outcome, for
which the upper limit of active treatment was 16 weeks), and outcome measurement occurred at the end of active treatment
(except for adverse events, which were measured during the active treatment period).
Data from 13 studies with 754 participants contributed to our primary outcome - changes in participant-, parent-, or
principal carer-rated symptoms of eczema at the end of active treatment - and suggest that probiotics probably
make little or no difference in eczema symptoms (moderate-quality evidence). Post hoc trial sequential analysis shows that
our analysis exceeded the sample size necessary to demonstrate a minimum difference of 1.5 points on a 20-point scale in
eczema symptoms between probiotics and placebo, and suggested that further trials of similar probiotic strains for this
outcome at the end of active treatment may be futile.
Data from six studies with 552 participants were available for our other primary outcome - changes in quality of life at the
end of active treatment. We found no evidence that probiotics make a difference in quality of life for eczema sufferers (low-
quality evidence).
We found no data for our secondary outcome - changes in the number of days lost from school or work due to eczema
symptoms during treatment with probiotics.
For our fourth secondary outcome - investigator-rated eczema severity - data from 24 studies with 1596 participants
suggest that probiotics may slightly improve the composite severity score for Severity Scoring of Atopic Dermatitis
(SCORAD). However, this difference is of uncertain clinical significance (low-quality evidence).
Seven studies (402 participants) reported adverse effects during active treatment, and we found no evidence of a
difference between probiotic use and use of no probiotics (low-quality evidence). Adverse events related to treatment that
were reported during the treatment period were gastrointestinal in nature (e.g. diarrhoea, vomiting).
For the update of this review, we did not perform a new search for adverse events. The adverse events search
conducted for the first review found case reports of proven or suspected sepsis related to probiotic use (Boyle 2006a; Cherifi
2004; De Groote 2005; Lestin 2003; Riquelme 2003), including one death (Lestin 2003), and one report described increased
risk of fatal bowel ischaemia in critically ill patients treated with one particular combination of probiotics.
Despite the large number of studies and participants included in this review, several outstanding uncertainties still surround
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the use of probiotics for treatment of eczema. These include the following: reasons for heterogeneity among trials; shortage
of data on quality of life and other outcomes such as impact of probiotics on days lost from school/work or on use of other
eczema treatments; use of non-validated quality of life scores or recommended outcome measures by the HOME
(Harmonizing Outcome Measures for Eczema) initiative; effects of probiotics on specific groups of patients (i.e. patients with
atopy, food allergies, or skin of colour); effects of probiotics after the end of treatment; identification of the optimal
dose/concentration or strain of probiotics; and adverse effects of probiotics.
Overall completeness and applicability of evidence
The numbers of studies and participants included after an updated search were larger than in the first review. Studies
included all age groups, but only six studies looked at adults. Although the addition of studies to this update led to narrower
confidence intervals, significant statistical heterogeneity between studies for primary and secondary outcomes remains
evident.
Review results apply only to currently available and tested probiotic strains and at doses used in the included studies, which
included Lactobacillus and Bifidobacteria species given as a single strain or in probiotic mixtures with or without prebiotics,
and at varied doses and concentrations. We found no studies on non-lactic acid bacteria.
Only 11 studies reported quality of life data at the end of active treatment, and of these, we could include in our analysis data
from only six studies. The relatively small numbers of studies and participants reporting this outcome and the varied outcome
assessment scales used mean that conclusions in relation to quality of life are limited.
Only eight studies clearly stated the presence and nature of any adverse events and the treatment groups in which they
occurred.
Studies may be sufficient to show whether changes in participant- or parent-reported symptoms of eczema at the end of
active treatment are influenced by those probiotics studied in RCTs to date. However, for symptom changes during the six-
month period after active treatment has ceased and for other outcome measures (i.e. quality of life changes, days lost from
school or work during active treatment, changes in the need for other eczema treatment during active treatment or within the
six-month period after active treatment has ceased, global eczema severity changes, and adverse events during treatment,
as well as for other probiotics or the same probiotics but at different doses/concentration), studies are insufficient to provide
clear conclusions. One limitation of many of the probiotic studies is that diverse concentrations and doses of bacteria are
used without standardisation. We had to pool studies without assessing the rationale for strain selection or concentration. We
performed stratified analysis by probiotic species post hoc because studies used so many different types of probiotics.
Studies have assessed a wide range of participants who met the review inclusion criteria: they included both genders and all
age groups and individuals from differing countries of origin. Eczema ranged from mild to severe. This review includes data
from a large number of trials showing the effects of probiotics on symptoms of eczema, but several uncertainties remain
regarding the review's other outcomes of interest, as well as the optimal dose and strain of probiotics and the effects of
probiotics in specific groups of patients (e.g. those with different skin types, atopic patients). This review reveals the
uncertainty resulting from the suboptimal methodological quality of included studies and the need for use of validated
outcome measures to facilitate standardisation of clinical trials and comparison of their outcomes.
Quality of the evidence
The overall quality of studies was mixed, largely due to missing information regarding randomisation procedures,
blinding, and losses to follow-up. We assessed only nine studies as being at low risk of bias because the
randomisation process was clear; allocation concealment was clear and done; participants, clinicians, or outcome
assessors were blinded; and we noted no attrition bias. One of these studies reported a chance imbalance in disease
severity at baseline (Sistek 2006), and five were sponsored or co-sponsored by the probiotic supplier (Drago 2012; 
Flinterman 2007; Van der Aa 2010; Viljanen 2005; Wang 2015).
We assessed the quality of evidence using the GRADE tool for key outcomes (Summary of findings table 1). For 'changes in
the participant- or parent-/principal carer-rated score of symptoms of eczema at the end of active treatment' (measured using
SCORAD part C; continuous outcomes), we downgraded the quality of evidence to moderate because of significant
heterogeneity among studies. For the 'participant- or parent-/carer-rated global change of eczema symptoms at the end of
active treatment' (measured as 'worsened/unchanged or improved'; binary outcomes), we downgraded the quality of
evidence to low because of the small number of studies reporting this outcome and the moderate heterogeneity between
them. We downgraded the quality of evidence for 'changes in participant- or parent-rated quality of life at the end of active
treatment' to low because of the very small number of studies that reported this outcome and the significant heterogeneity
noted between them. For 'participant- or parent-rated family quality of life at the end of active treatment', we downgraded the
quality of evidence to very low because of the very small number of studies that reported this outcome and significant
heterogeneity. For 'global eczema severity score at the end of active treatment', we downgraded the quality of evidence to
low because of extreme levels of heterogeneity between studies and evidence of reporting bias. For 'adverse events', we
downgraded the quality of evidence to low due to the small number of studies reporting adverse events and the small
number of events that could be included in the analysis.
Potential biases in the review process
Our inability to contact all trial authors for original data sets and clarifications may have introduced some uncertainty into our
judgement on inclusion of studies and into our findings.
Analyses of SCORAD change scores and of SCORAD scores from studies with low risk of bias were post hoc analyses,
justified by the imbalance in treatment severity at baseline in one included study. Any conclusions based on these data must
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therefore be guarded. The subgroup analysis by probiotic strain used was not predefined in the study protocol, and we
undertook this due to the observation that some studies used the same probiotic strain. Analysis suggests that some
probiotic strains may be more effective than others for the treatment of eczema; however, conclusions based on this post hoc
analysis must also be guarded.
Also, investigators used variable concentrations and daily doses of different probiotics, which may have influenced study
findings. Some of the heterogeneity noted in analyses of outcomes may be attributable to varying timing of outcome
assessment; however, we performed no subgroup analysis by probiotic dose or concentration.
Agreements and disagreements with other studies or reviews
The data summarised in this review suggest that currently available probiotic strains that have been evaluated in RCTs
probably are not effective for the treatment of symptoms of eczema and may not be clinically effective in changing eczema
severity.
Previous studies found an association between the composition of the intestinal microbiota and eczema (Bjorksten 2001; 
Kalliomaki 2001), as well as increased gastrointestinal symptoms in children with eczema (Caffarelli 1998). These
previous studies suggest that the composition of the intestinal microbiota is important in the pathophysiology of
eczema, or that intestinal mucosal abnormalities associated with eczema lead to secondary changes in the
resident intestinal microbiota. Evidence suggests that probiotics can lower the increased intestinal permeability
associated with eczema (Rosenfeldt 2004), and studies such as Kalliomaki 2001, Kukkonen 2007, and Moro 2006, and
systematic reviews including Dang 2013, Doege 2012, Mansfield 2014, Osborn 2007, and Zhu 2010, suggest that use of
some probiotics or prebiotics during early infancy or pregnancy may prevent the development of eczema. Probiotics may
therefore be ineffective for treating eczema, as shown in this current review, because the decrease in intestinal permeability
associated with their use is insufficient to lead to resolution of established disease, or because the duration of treatment fails
to allow sufficient modulation of intestinal microbiota composition or function to result in clinically meaningful change.
In this review, we found no significant differences in adverse events between probiotic and control during active
treatment, and reported adverse events were of gastrointestinal upset. For the update of this review, we found three
systematic reviews on the safety of probiotics, which included RCT and non-RCT data. One systematic review did
not show any statistically significant increased risk for adverse events associated with probiotics used for short
periods in the setting of RCTs but noted lack of systematic reporting of adverse events in studies of probiotic
interventions (Hempel 2011). Another systematic review described no significant adverse events in the setting of RCTs
(Didari 2014). Both reviews found case reports of bacteraemia/fungaemia and sepsis and indicated that
immunocompromised, critically ill, and postsurgical patients may be at greater risk (Didari 2014; Hempel 2011).
Serious adverse events were rare. One systematic review of the safety of probiotics during pregnancy showed no
difference in caesarean section rates, birth weight, and gestational age between probiotic and control groups (Dugoua 2009).
Three recent systematic reviews have examined studies of probiotics for treatment of eczema (Chang 2016a; Huang 2017; 
Kim 2014). All systematic reviews evaluated a primary outcome of total SCORAD score.
The most recent systematic review gathered data from 13 studies and 1070 child participants up to 18 years of age
and showed a significant difference in SCORAD favouring probiotics over control, with mean reduction in SCORAD by
3.07 with a 95% confidence interval (CI) of -6.12 to -0.03 (Huang 2017). This review included studies published from 2000 to
2017 and only those published in English. Researchers did not find this favouring effect for probiotics among children under
one year of age, only among children between 1 and 18 years of age (mean difference (MD) -4.50, 95% CI -7:45 to -1.54).
These results are consistent with the data provided in our review, but in our review, we prioritised patient-reported outcomes
and noted that the size of effect on SCORAD is of uncertain clinical significance. Huang 2017 found greater differences
favouring probiotics in subgroup analyses by continent (Europe: no difference; Asia: MD -5.39, 95% CI-8.91 to -1.87;
Australia: MD -11.20, 95% CI -13.76 to -8.64).
A second systematic review limited its focus to the use of probiotics in combination with prebiotics (synbiotics) (Chang
2016a), although review authors also included trials of synbiotics versus prebiotics. This review did not have a registered
protocol and did not use GRADE to evaluate the quality of evidence. Review authors identified six trials with 369 child
participants 0 to 14 years of age, studying the role of synbiotics for treating eczema. Treatment duration was between eight
and 12 weeks, and review authors used pooled estimates for the change in SCORAD at eight weeks to assess clinical
effects. A decrease in SCORAD score of 6.56 favoured synbiotics with a 95% CI of -11.43 to -1.68 and high statistical
heterogeneity (I² = 77%). Results of this study are slightly more favourable towards probiotics compared with studies
included in our review, with a high mean decrease in SCORAD, but they reflect a small subset of the studies identified in our
systematic review. Differences in findings and conclusions may be due to different eligibility criteria, different outcome
measures, and a different methodological approach.
An older systematic review with data from 25 studies and 1599 participants of all age groups reported a difference in
SCORAD score of 4.51 points with a 95% CI of -6.78 to -2.24 favouring probiotics, and the same favourable effect of
probiotics in individuals 1 to 18 years of age and in adults (Kim 2014). Results show no differences between probiotic and
placebo in infants (< 1 year old).
Schram 2011 suggested that the minimally clinically important difference for SCORAD score is 8.7.
A World Allergy Organization position consensus statement did not recommend the use of probiotics for treatment of
allergic diseases, including eczema (Fiocchi 2012). This qualitative, narrative review of evidence was available in the
literature until the time of publication by an expert panel group.
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Authors' conclusions 
Implications for practice 
Data suggest that probiotics currently in use probably make little or no difference in patient-rated eczema
symptoms (moderate-quality evidence) and may make no difference in quality of life for people with eczema (low-quality
evidence). Analysis of composite severity score (Severity Scoring of Atopic Dermatitis (SCORAD)) data suggests that any
reduction in eczema severity from treatment with currently available probiotic strains is likely to be modest (< 5.86 points on
the total SCORAD score) and therefore of uncertain clinical significance. Current use of probiotics for treatment of eczema is
not evidence-based.
We found no evidence to suggest that probiotic treatment is unsafe; however, reports from non-randomised controlled trials
indicate that it can lead to adverse events including sepsis and bowel ischaemia.
Implications for research 
Post hoc trial sequential analysis suggests that further studies of the effect on eczema symptoms of already available
probiotic strains at varying concentrations at the end of treatment (up to three months) may be futile.
Future studies should report long-term (i.e. six months after active treatment has ceased) data on eczema symptoms and
quality of life, using validated quality of life scores, and should consider recommendations of the HOME initiative
(Harmonizing Outcomes Measures for Eczema) for reporting outcome measures. Furthermore, future studies should ensure
that they report methodological details regarding randomisation procedures, blinding, and loss to follow-up, to ensure that a
thorough risk of bias assessment can be done.
Further studies are needed to focus on the strain Lactobacillus salivarius versus placebo. Future studies should consider
studying subgroups of patients (e.g. patients with atopy, patients with food allergies, adults, patients with different skin types)
and testing new probiotic strains that have not yet been evaluated in randomised controlled trials versus no probiotic, at
standardised doses and concentrations.
Future probiotic studies should provide thorough reporting of adverse events. In addition, investigators in future clinical
studies should have a clearer understanding of the species and dosing (concentration of bacteria) used.
For future systematic reviews and meta-analyses, researchers should consider stratified analyses based on
dose/concentration of probiotics used because standardisation of dosing of probiotics is currently lacking.
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Differences between protocol and review 
Changes between protocol and first or updated review
We changed the title, which was "Probiotics for atopic eczema" in the protocol to "Probiotics for treating eczema", on the
advice of the referees.
We made small changes to the Background on the advice of referees of the first review.
We made small changes to the Criteria for considering studies for this review section to clarify issues.
In the protocol, we used the terms "short term" and "long term" for primary and secondary outcomes. We have replaced
these terms with the phrases "at the end of active treatment" and "within six months after active treatment has ceased",
respectively. We did this for clarity.
RB and FB completed data extraction in the first review, in place of RB and MT in the protocol, due to time availability.
In the review, when complete data sets were available from trial authors, we used these data to calculate summary statistics
such as mean and standard deviation before data entry, but this was not stated in the protocol.
In the review, when studies reported participant- or investigator-rated symptoms on categorical scales (e.g. Passeron 2006),
we made the data dichotomous by defining a cutoff at good improvement in eczema versus mild improvement, no change, or
worsening of eczema. This was not predefined in the protocol.
In the protocol, expressing numbers needed to treat was mentioned, but not in this review. We were going to estimate
numbers needed to treat provided clinically positive results favoured probiotics; therefore this was not done.
In the review, we had to deal with data from studies with multiple treatment groups by combining the data from these groups
and by converting non-parametric statistics to parametric summary statistics, but this was not mentioned in the protocol.
In the protocol, it was not described that for analyses with extreme heterogeneity (e.g. I² statistic > 85%), we would consider
not undertaking a meta-analysis.
In the review, we calculated the pooled estimate using standardised mean differences when studies used different tools to
measure the same outcome, which had not been stated in the protocol.
In the protocol, we did not mention that we would use available case analysis, rather than intention-to-treat analysis with
imputation.
In the protocol, we had planned some subgroup analyses, but in the review, we presented the data in a stratified analysis.
We have explained reasons for this in the Methods section and in the subsection Subgroup analysis and investigation of
heterogeneity.
In the review, we performed analysis stratified by severity (mild, moderate, severe) of eczema based on the Severity Scoring
of Atopic Dermatitis (SCORAD), which had not been clearly stated in the protocol. In the protocol, it was stated that we would
split the eczema into mild, moderate, and severe if enough data were available, but not that a stratified analysis would take
place.
Extra stratified analyses were undertaken in the review, and this had not been specified in the protocol - outcome
data were analysed according to the probiotic strain used (Analysis 1.21 to Analysis 1.28). We undertook these analyses
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because of unexplained heterogeneity between studies for primary and secondary outcomes and use of the same probiotic
strain in several studies. As discussed above, conclusions from this analysis must be guarded due to its post hoc nature.
We edited the Objectives in line with MECIR reporting standards.
Selection of studies: for the protocol, RB and MT performed study selection; for the review update, RB and AM performed
study selection. We encountered no differences that would require an arbitration.
For the update, RB and AM performed data extraction, but for the protocol, this was performed by RB and MT, and in the first
review, by RB and FB.
In the protocol and in the first review, RB and FB checked the data, but in the updated review, it was JL and AM.
Assessment of risk of bias in the updated version of the review: we used the Cochrane 'Risk of bias' tool (Chapter 8.5, in
Higgins 2011), which is not given in the protocol.
We reported dichotomous outcome data as odds ratios (ORs) in the first review, and risk ratios (RRs) were planned in the
protocol. In the update for dichotomous outcomes, we expressed the results as RRs and 95% confidence intervals (CIs) for
analyses containing only parallel-group trials, and we used ORs when data from cross-over studies were included in the
meta-analysis, in keeping with the methods stated in Elbourne 2002 and Duffy 1989.
We performed sensitivity analyses based on change in scores from baseline for both first and updated reviews and for
studies with low risk of bias in the update. In the update, we defined studies with overall low risk of bias as those studies for
which the randomisation process was clear; allocation concealment was clear and done; participants, clinicians, or outcome
assessors were blinded; and there was no attrition bias.
We assessed the quality of evidence in the update of the review by using the GRADE tool, as is now recommended by
Cochrane.
We used trial sequential analysis for our primary outcome in the update of this review (please see Methods).
For the update of the review, we performed assessments of reporting bias.
For the updated review, we revised the search methods in line with current Cochrane Skin practices. We included a search
of the GREAT database (Global Resources of Eczema Trials) and of the following trials registers: the Australian New
Zealand Clinical Trials Register (ANZCTR), the World Health Organization International Clinical Trials Registry platform, and
the EU Clinical Trials Register. We did not update previous searches of ISI Web of Science, or of the Ongoing Skin Trials
Register, whose content has now been migrated to ANZCTR. For full details of previous searches for the earlier review, see
Boyle 2008.
Previously, we searched MEDLINE for adverse effects of probiotics. We did not perform an adverse events search for this
update, but we recorded adverse events reported in included and excluded trials. Adverse events of probiotics have been
well established, and we have referred only to relevant review articles.
We added a consumer (AR) to the review authors' group, as required by Cochrane for the review update. We also added a
new review author (AM) to the review authors' group.




Characteristics of included studies 
Brouwer 2006
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Methods Three-month parallel-group randomised controlled trial
 
Participants Fifty-one infants under 5 months age with mild/moderate eczema diagnosed using
Hanifin and Rajka criteria, and a clinical history suggestive of cow's milk allergy.
Randomisation was done at a 1:1 ratio: 17 participants were randomised in each arm
(L rhamnosus, L GG, placebo). All participants were exclusively formula fed and
received an extensively hydrolysed formula for 3 to 5 weeks before receiving the study
intervention. Infants receiving antihistamines, oral corticosteroids, or any
probiotic/antibiotic/antimycotic in the preceding 4 weeks were excluded, as were those
with a congenital gastrointestinal malformation
Setting: primary care in the Netherlands
One participant lost to follow-up
 
Interventions Extensively hydrolysed whey-based formula given alone, with Lactobacillus
rhamnosus at 5 × 10⁹ CFUs/100 mL or with Lactobacillus GG at 5 × 10⁹ CFUs/100 mL.
The study formula was offered at all feeds during the intervention period
 
Outcomes SCORAD assessed at baseline, and at 1, 2, and 3 months*
Total IgE, specific IgE to food mix (cow's milk, egg white, soy, peanut, cod, and wheat)
and cow's milk, and skin prick test for cow's milk
*Denotes outcomes prespecified for this review
 
Notes Study was funded by unrestricted grant from Numico Research, Wageningen, the
Netherlands - not related to probiotic. No information on conflicts of interest
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "all patients were randomised to either one of the study
formulas..."





Unclear risk No information provided
 
Blinding of participants and
personnel (performance bias)
Unclear risk Quote: "We conducted a randomised, double-blind, placebo-controlled
study..."
Comment: no further information provided; unclear whether blinding
was adequate
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "We conducted a randomised, double-blind, placebo-controlled
study..."
Comment: no further information provided; unclear whether blinding
was adequate
 
Incomplete outcome data (attrition
bias)
Low risk Only 1 participant lost to follow-up after randomisation; available case
analysis without exclusions or imputation used
 
Selective reporting (reporting bias) Low risk No evidence of selective reporting found: all outcomes reported
 
Other bias Low risk No other bias found
 
Cukrowska 2008
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Methods Eight-month (3-month intervention and 5-month observation period) parallel-group
randomised double-blind controlled trial
 
Participants Sixty children aged up to 24 months with atopic dermatitis diagnosed according to the
criteria of Hanifin and Rajka (3 out of 4 major criteria had to be met) and with
symptoms of cow's milk allergy were recruited. Randomisation was done at a 1:1 ratio:
29 participants were randomised in the intervention arm and 31 in the placebo arm.
Participants and mothers of breast-fed children had to be on a non-dairy diet.
Participants who had used antibiotics and probiotics within 6 months before
recruitment were excluded from the trial. Recruitment took place at a secondary
paediatric centre in Poland
 
Interventions Probiotic mixture: Lactobacillus casei LOCK 0900, Lactobacillus casei LOCK 08,
Lactobacillus paracasei LOCK 0919 at a total daily dose of 10⁹ CFUs/d given orally for
3 months
Placebo: hydrolysed casein given orally for 3 months
 
Outcomes Improvement vs exacerbation/no improvement based on SCORAD*
• If SCORAD reduction > 2: improvement
• If SCORAD reduction 0 to 2: lack of improvement
• If SCORAD increased: deterioration
*Denotes outcomes prespecified for this review
 
Notes Study financed by Ministry of Education grant
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote from translation from Polish: "The study carried out was
randomised, double-blinded..."





Unclear risk Quote from translation from Polish: "The study carried out was
randomised, double-blinded..."
Comment: no information given on allocation concealment
 
Blinding of participants and
personnel (performance bias)
Unclear risk Quote from translation from Polish: "The study carried out was
randomised, double-blinded..."
Comment: no information given on blinding method
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote from translation from Polish: "The study carried out was
randomised, double-blinded..."
Comment: no information given on blinding method
 
Incomplete outcome data (attrition
bias)
High risk 29% of participants in probiotic group and 32% in placebo group lost to
follow-up at the end of the intervention
Comment: losses to follow-up similar in both groups but high in both and
may have influenced the outcome of short-term change in global eczema
severity; no information provided on whether available case analysis was
used. No reasons for losses to follow-up given
 
Selective reporting (reporting bias) Low risk All outcomes reported as predefined
 
Other bias Low risk No other bias found
 
Drago 2012
Methods Twenty-week parallel-group double-blind placebo-controlled randomised trial
 
Participants Thiirty-eight adult participants between 18 and 46 years with moderate to
severe atopic dermatitis diagnosed according to "Consensus guidelines in
diagnosis and treatment of atopic dermatitis" (Eichenfield 2004). Randomisation was
done at a 1:1 ratio: 19 participants were randomised in each arm. Patients who had
received probiotics or antibiotics or who had used immunomodulators (tacrolimus or
pimecrolimus) within 6 months from enrolment were excluded from the trial. Also
excluded were patients with active allergic disease of the skin or the respiratory tract
or chronic infectious disease, and pregnant or lactating patients. All participants
completed the study
Secondary care setting; recruiting from an Allergy and Immunology Unit in Italy
 
Interventions Probiotic: Lactobacillus salivarius LDR0723 in maltodextrin, given in sachets dissolved
in water or other cold liquid of preference twice daily at a dose of 1 × 10⁹ CFUs/g for
16 weeks. Placebo: maltodextrin alone given twice daily for 16 weeks
 
Outcomes • SCORAD at baseline and at end of treatment at 16 weeks*
• DLQI at baseline, and at 4, 8, 16, and 20 weeks*
*Denotes outcomes prespecified for this review
 
Notes Probiotics supplied by Probiotic Company. No information about conflicts of interest
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "A computerised randomisation schedule was prepared..."




Low risk Quote: "...allocation and dispensing by a blind clinical investigator..." - "the
probiotic and placebo sachets were matched for size, shape and volume
of contents"
Comment: judged as adequate allocation concealment and hence at low
risk of bias
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "...allocation and dispensing by a blind clinical investigator..." - "the
probiotic and placebo sachets were matched for size, shape and volume
of contents"
Comment: judged as adequate and hence at low risk of bias.
 
Blinding of outcome assessment
(detection bias)
Low risk Quote for participants who completion of the DLQI questionnaires: "the
probiotic and placebo sachets were matched for size, shape and volume
of contents"
Quote for clinical assessor: "a single investigator who was blind to the
treatment intervention performed all SCORAD assessment at the
beginning.... and at the end of treatment..."
Comment: judged as adequate and hence at low risk of bias
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "All patients completed the study"
Comment: no losses to follow-up; all participants analysed in the group to
they were randomised; therefore, no incomplete data
 
Selective reporting (reporting bias) High risk All outcomes reported with numerical data or narratively
Comment on SCORAD reporting: significance or non-significance of
difference in global eczema severity (SCORAD) between probiotic and
placebo groups not reported. Only scores at baseline and end of treatment
and at baseline and 4 weeks after treatment reported and commented on
Quote: "the mean SCORAD score in the probiotic group was 27.57±3.4
versus 24.28±3.8 in the placebo group. After 4 months we observed a
significant reduction in the SCORAD score in the probiotic-treated group
only (T0: 27.57±3.4 vs T16: 13.14±0.27, P<0.001) whereas no changes
were reported in the placebo group (T0: 24.28±2.15 vs T16: 20.14±0.27,
NS)"
Comment on DLQI reporting: data presented at end of treatment and 4
weeks after end of treatment for the probiotic group only. Significant
difference from baseline stated. Data for the placebo group not reported
and given only narratively; no difference from baseline
Quote: "DLQI progressively decreased in probiotic patients during
treatment. This significant modification was observed after 8 weeks of
treatment (T8) and was also maintained after 4 weeks after the end of the
treatment (T20) (T0: 8.28±1.79 vs T8: 4.57±1.11, P=0.02; T0: 8.28±1.79
vs T16: 4.42±0.27, P=0.04; T0: 8.28±1.79 vs T20: 3.71±0.27, P=0.02). No
differences were reported in the placebo group"
Comment: only outcome data that were significant for the probiotic group
reported. No comparison between probiotics and placebo. Report judged
to be at high risk of reporting bias
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Bias Authors'judgement Support for judgement
Other bias High risk Commercial bias: probiotics supplied by Probiotic Company. Study
double-blind and randomised; unlikely that the commercial bias had an
effect on the outcome. However, it had an impact on reporting because
only positive outcomes for the probiotic group were reported
Study assessed as having high risk of other bias
 
Drago 2014
Methods Thirty-day randomised placebo-controlled parallel pilot trial
 
Participants Twenty-five adults 25 to 63 years of age with diagnosis of atopic dermatitis according
to Hanifin and Rajka, with predominant rough fissured skin as well as pruritus for at
least 2 months were recruited. Randomisation was done at a 1:2 ratio: 13 participants
were randomised in the intervention arm and 12 in the control arm
Pregnant and lactating women were excluded. Also excluded were patients with
chronic dermatoses such as seborrhoeic dermatitis, contact dermatitis, nummular
eczema, psoriasis, ichthyosis, immunodeficiency or any immunological disorder,
scabies, cutaneous fungal infection, HIV-associated skin disorders, malignant disease,
T-cell lymphoma, Letterer-Siwe disease, progressive systemic disease, serious
internal disease (e.g. serious decompensated diseases of the heart, liver, and/or
kidneys, diabetes mellitus), or hypersensitivity toward one of the ingredients in the
investigational product. Excluded were patients who had been taking part in another
study or had taken an investigational product during the last 4 weeks before the start
of treatment, or who had been receiving treatment with physical ultraviolet therapy,
anti-inflammatory medications used to treat atopic dermatitis, or immunomodulating
medications 30 days before the start of the study, or non-steroidal antirheumatic
drugs, systemic glucocorticosteroids, tranquillisers, or antiemetic agents from the
phenothiazine group 14 days before the start of the study, or antidepressants 7 days
before the study
All participants completed the study
Country: Italy
Setting: secondary Dermatology Unit
 
Interventions Participants in the probiotic group (n = 13) received freeze-dried mixture of 5 × 10⁹
CFUs/sachet of Lactobacillus salivarius LS01 (DSM 227775), 2 × 10⁹ CFUs/sachet of
Streptococcus thermophilus ST10 (DSM 25246), and tara gum (125 mg)
Participants in the placebo group (n = 12) received treatment with sachets containing
gluten-free maltodextrins
Sachets were dissolved in water and were taken once daily for 30 days
Study participants were allowed to continue to use any medication that they had been
taking before the study at the same dose, unless the medication could be discontinued
 
Outcomes Objective SCORAD index before treatment and after 30 days of treatment*
Staphylococcus aureus and clostridial faecal counts before treatment and after 30
days of treatment
*Denotes outcomes prespecified for this review
 
Notes The study has not been registered
Probiotics were supplied by the manufacturer. Investigators declared no conflicts of
interest
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Participants randomised at a 1:1 ratio to receive treatment or placebo
Quote from communication with study author: "Which was the method of
randomisation? Patients were randomised to either probiotic or placebo
groups with a 1:1 allocation according to computer-generated random
numbers"








Blinding of participants and
personnel (performance bias)
Low risk Quote from correspondence with study author: "Was there any blinding?
Clinicians, microbiologists and participants were blinded"
Judgement: probably adequate, i.e. low risk of bias
 
Blinding of outcome assessment
(detection bias)
Low risk Quote from correspondence with study author: "Was there any blinding?
Clinicians, microbiologists and participants were blinded"
Judgement: probably adequate, i.e. low risk of bias
 
Incomplete outcome data (attrition
bias)
Low risk Quote: "All of the 25 patients who agreed to commence the protocol
completed the study"
Judgement: low risk of bias
 
Selective reporting (reporting bias) Low risk Quote: "The SCORAD index significantly diminished in the active group
from T0 to T1 (P<0.0001, Fig. 1), whereas no variations were observed in
the placebo group (P=0.274, Fig. 1). After 1 month of treatment, the
SCORAD index in group A was significantly lower than in group B
(P=0.015)"
Judgement: SCORAD changes reported narratively and not numerically
(P value only) between baseline and end of treatment for each group only
and between the 2 groups at end of treatment




Probiotics supplied by the manufacturer. Investigators declared no
conflicts of interest but did not report numerical results. Also inadequate
information on allocation concealment, and not clear whether the
manufacturer had any influence on this. Study not registered
For these reasons, study judged to be at unclear risk of commercial bias
 
Farid 2011
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Methods Eight-week parallel-group double-blind placebo-controlled randomised trial conducted
between November 2007 and March 2009
 
Participants Fifty-two children from 3 months to 6 years of age with mild to severe atopic dermatitis.
Randomisation was done at a 1:1 ratio, but no exact numbers were given for
randomised participants in each arm. Patients who had prior exposure to probiotics, or
who were at the time taking antibiotics, or who had major medical problems, were
excluded from the trial. Twelve patients were lost to follow-up
Setting: secondary care, paediatric Allergy and Immunology Department in Iran
 
Interventions Synbiotic mixture: Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus
thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium
infantis, Lactobacillus bulgaricus, and fructo-oligo-saccharide in 1-gram sachets
dissolved in water or breast milk, at a dose of 1 × 10⁹ CFUs/g twice daily for 8 weeks.
Placebo not specified
 
Outcomes SCORAD change from baseline to 4 and 8 weeks and from 4 to 8 weeks*
*Denotes outcomes prespecified for this review
 
Notes "No conflicts of interest" declared but funding not declared; probiotic provided by the
manufacturer
 
Risk of bias table
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Quote: "Participants were randomly divided into two groups..."
Comment: no other information provided; method of randomisation






Quote: "Participants were randomly divided into two groups..."
Comment: unclear whether allocation was concealed; no more information
provided
 




Participant: "placebo powder was matched for size, shape and volume of
contents"
Clinicians: "this randomised, double blind, placebo controlled trial..." -
"SCORAD index assessment was performed by a single clinician who was
blinded to intervention"
Comment: risk of bias unclear regarding blinding of personnel allocating
participants to treatment; no relevant information
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "SCORAD index assessment was performed by a single clinician
who was blinded to intervention" - "placebo powder was matched for size,
shape and volume of contents" - "placebo powder was matched for size,
shape and volume of contents"
Comment: blinding of participants and investigators who assess the global
eczema severity score (the only clinical outcome of this study) judged to
be adequate; therefore study judged to be of low risk of detection bias
 
Incomplete outcome data (attrition
bias)
High risk High rate of losses to follow-up: 12 participants (23%) lost to follow-up and
excluded from analysis. We judged this to lead to high risk of attrition bias.
Not clear whether rates of loss to follow-up were similar in both groups.
Reasons for loss to follow-up given, but treatment group from which losses
occurred not specified
 
Selective reporting (reporting bias) Unclear
risk
Twelve participants (23%) lost to follow-up and excluded from analysis.
Baseline characteristics and outcomes reported only for participants
completing the trial. Unclear whether reporting only characteristics of
participants can lead to reporting bias. Trial registered in the Iranian
Registry for Clinical Trials retrospectively, and number of participants
registered pertains to those who completed the study only. Unclear risk of
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Methods Three-month parallel-group randomised double-blind placebo-controlled trial
 
Participants Thirteen children from 0 to 3 years of age with atopic dermatitis, skin prick test ≥ 2+ for
at least 2 food allergens, strong clinical history suggestive of food allergy, or positive
placebo-controlled challenge and IgE RAST. Randomisation was done at a 1:2 ratio: 7
participants were randomised in the intervention arm, and 6 in the control arm
≥ 0.7 KU/L for at least 2 food allergens were recruited in the trial. Patients on systemic
immunomodulating drugs and those with other systemic diseases or immunodeficiency
were excluded from the trial
Recruitment took place at a secondary care setting in the Netherlands
 
Interventions Probiotic mixture:
Lactobacillus acidophilus W55, Lactobacillus casei W56, Lactobacillus salivarius W57,
Lactobacillus lactis W58, Bifidobacterium infantis W52, Bifidobacterium lactis W18,
Bifidobacterium longum W51
In rice starch and maltodextrin powder dissolved in warm water or infant formula
before administration given once daily at a dose of 1 × 10⁹ CFUs for 3 months
Placebo: rice starch and maltodextrin powder dissolved in warm water or infant
formula before administration given once daily for 3 months
 
Outcomes • Total SCORAD: secondary outcome for the trial - not reported in relevant publication*
• Allergen-specific T- and B-cell response in vivo and ex vivo
• RAST (IgE levels)
• Skin prick test
*Denotes outcomes prespecified for this review
 
Notes Study sponsored by probiotic manufacturer; no information on conflicts of interest
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote from communication with author: "Randomization was performed by
the sponsor (Winclove Bio Industries BV), by using a randomisation table.
They provided us with boxes with blinded sachets, with only study
numbers on it. We anticipated to include 12 children (6 in each group), so
Winclove made sure that the randomisation was performed as such that
the first 12 numbers included 6 verum and 6 placebo" - "We had 20 sets of
blinded sachets at start of the study, to be able to include more children if
there would be dropouts during the study"




Low risk See above quote. Study author confirmed that the allocation sequence
was concealed
Comment: judged as adequate for low risk of bias
 
Blinding of participants and
personnel (performance bias)
Low risk See above quote and: "The participants, clinician and outcome assessor
were blinded until after the analysis of the results had been performed"
Comment: judged as adequate for low risk of bias
 
Blinding of outcome assessment
(detection bias)
Low risk See above quote and: "The participants, clinician and outcome assessor
were blinded until after the analysis of the results had been performed"
Comment: judged as adequate for low risk of bias
 
Incomplete outcome data (attrition
bias)
Low risk 1/13 participants lost to follow-up but no exclusions from analysis. Reason
for exclusion given by study author: "one child had to stop during the study
because of the use of antibiotics and high fever"
Judged as low attrition bias
 
Selective reporting (reporting bias) Low risk All primary outcomes reported
SCORAD - secondary outcome - not reported in the publication but




Study sponsored by probiotic manufacturer. Role of the sponsor in data
analysis and publication unclear; hence study was judged to be at unclear
risk of other bias
 
Folster-Holst 2006
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Methods Eight-week parallel-group randomised controlled trial from 2001 until 2002
 
Participants Fifty-four children 1 to 55 months of age with eczema diagnosed using Hanifin and
Rajka criteria
Setting: German Dermatology Centre
Randomisation was done at a 1:1 ratio: 27 participants were randomised in each arm.
Two-centre trial. Six participants were lost to follow-up, and 1 participant dropped out
post randomisation but before treatment started
 
Interventions Lactobacillus GG at 10¹º CFU/d as a twice-daily dose, or microcrystalline cellulose
placebo. Interventions given as capsules, which were mixed with milk if bottle fed, or
mixed with water if not bottle fed
 
Outcomes • Parent global assessment of disease severity*
• Quality of life score (Ruden 1999)*
• SCORAD*
• Use of topical corticosteroid and systemic antihistamine treatment. Assessments
made at 2, 4, 6, and 8 weeks after the start of the study*
*Denotes outcomes prespecified for this review
 
Notes Study was supported by InfectoPharm GmbH (Heppenheim, Germany) and Pharmacia
GmbH (Freiburg, Germany) - not related to probiotic
"No conflicts of interest" declared
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "...randomly allocated"





Unclear risk No information provided. Unable to assess the risk of bias
 
Blinding of participants and
personnel (performance bias)
Unclear risk Quotes: "double blind..." - "...placebo preparation (microcrystalline
cellulose) with identical appearance"
Comment: inadequate information for a judgement on risk of bias.
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quotes: "double blind..." - "...placebo preparation (microcrystalline
cellulose) with identical appearance"
Comment: inadequate information for a judgement on risk of bias
 
Incomplete outcome data (attrition
bias)
Low risk Seven participants lost to follow-up post randomisation (13%); of those, 1
after randomisation (not clear from which group) but before treatment
started. Low rates of loss to follow-up in both groups (15.4% in probiotic
group and 7.4% in placebo). Available case analysis used without
exclusions
Comment: low incomplete data and judged as low risk for attrition bias for
all outcomes
 
Selective reporting (reporting bias) Low risk No evidence of selective reporting found. All outcomes reported
 
Other bias Low risk No other bias found
 
Gerasimov 2010
#102 Probiotics for treating eczema
37 / 151
Methods Eight-week parallel-group randomised double-blind placebo-controlled trial held
between June 2007 and June 2008
 
Participants Ninety-six children between 1 and 3 years of age with moderate to severe atopic
dermatitis diagnosed according to the criteria of Hanifin and Rajka were recruited
Randomisation was done at a 1:1 ratio: 48 participants were randomised in each arm.
Only patients whose parents or legal guardians had the ability to comprehend the
study requirements and to provide informed consent and those with direct telephone
access were recruited
Patients with clinically evident bacterial skin lesions, chronic concomitant disease that
would likely require use of immunosuppression or antihistamines during research
period, presence of severe systemic disease or cancer at any site and stage,
suspected or established primary/secondary immune deficiency, and food allergy other
than egg or cow’s milk were excluded from the study. Also excluded were patients with
mild disease and those currently taking systemic corticosteroids
Six participants were lost to follow-up
Recruitment took place at a paediatric secondary care unit in Ukraine
 
Interventions Synbiotic: mixture of Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis
UABLA-12 with fructo-oligosaccharide in a rice maltodextrin powder given twice daily
reconstituted in tepid water or juice or baby food and immediately fed for 8 weeks.
Dose given: 5 × 10⁹ CFU/gr for the 2 probiotics and 50 mgr/gr of fructo-
oligosaccharide
Placebo: rice maltodextrin powder only given twice daily reconstituted in tepid water or
juice or baby food and immediately fed for 8 weeks
Parents were given 140 doses of the intervention and were asked to give 112 doses in
total
Treatment of atopic dermatitis during intervention: skin hydration, emollients,
avoidance of allergens and irritants according to PRACTALL (Practical Allergology)
recommendations. Hydrocortisone 1% or Mometasone 0.1% ointment was allowed as
rescue medication. Elimination diet for 2 months before and during trial period. Diet
was cow's milk or egg free, depending on which food allergy the participant had. No
elimination diet for participants without food allergies
 
Outcomes • IDQoL changes at 4 and 8 weeks*
• DFI at 4 and 8 weeks*
• SCORAD parts A, B, and C at 2, 4, and 8 weeks*
• Frequency of topical corticosteroid use (days per week) at 8 weeks*
• Cumulative use of topical corticosteroids during intervention period*
*Denotes outcomes prespecified for this review
 
Notes Study was funded by the Lviv National Medical University of Ukraine. "No conflicts of
interest" declared
Twenty-six participants in the probiotic group (60.5%) and 24 in the placebo group
(51.1%) developed adverse effects: upper respiratory tract infection, lower respiratory
tract infection, herpetic stomatitis, diarrhoea, constipation, abdominal colic. Two
children in the probiotic group (4.7%) and 3 in the placebo group (6.4%) experienced
severe adverse events (head injury and food poisoning) that were reported to be
unrelated to the intervention under investigation
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "patients were randomised using computer-generated random
codes to receive either probiotic or placebo treatment"




Unclear risk Inadequate information; study judged to be at unclear risk of bias
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "probiotic and placebo were identical in appearance, taste, smell,
packing and manner of administration. All formulations were dispensed by
a technician with investigator and patient blinded regarding the identity of
the treatment"
Comment: judged as adequate for low risk of performance bias
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "probiotic and placebo were identical in appearance, taste, smell,
packing and manner of administration. All formulations were dispensed by
a technician with investigator and patient blinded regarding the identity of
the treatment"
Comment: judged as having unclear risk of bias; no information on
blinding of outcome assessor
 
Incomplete outcome data (attrition
bias)
Low risk Six participants lost to follow-up (6.25%): 5/48 (10%) in the probiotic group
and 1/48 (2%) in the placebo group. Reasons for losses to follow-up
given: intercurrent illness (2 in probiotic and 1 in placebo group, 1 protocol
violation in probiotic group and 1 diet deviation in probiotic group).
Participants analysed in the group to which they were randomised
Comment: judged as low risk, as rates for follow up are low and were
unlikely to have influenced outcomes
 
Selective reporting (reporting bias) Low risk All outcomes reported
 
Other bias Low risk No other bias found
 
Goebel 2010
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Methods Eight-week 3-arm parallel-group randomised double-blind placebo-controlled trial
 
Participants Fifty children from 7 to 24 months of age with atopic dermatitis diagnosed by general
practitioner or dermatologist were recruited. Randomisation was done at a 1:1 ratio: 17
participants were randomised in the 2 intervention arms and 16 in the control arm. All
participants completed the trial
Setting: Danish primary care centre
 
Interventions First arm/probiotic: Lactobacillus acidophilus NCFM in cellulose, silicon dioxide, and
rice maltodextrin in a capsule given daily at a dose of 10¹º CFUs for 8 weeks
Second arm/probiotic: Bifidobacterium animalis subsp lactis (B lactis Bi-07) in
cellulose, silicon dioxide, and rice maltodextrin in a capsule given daily at a dose of
10¹º CFUs for 8 weeks
Third arm/placebo: cellulose, silicon dioxide, and rice maltodextrin in a capsule given
daily
 
Outcomes Total and subjective SCORAD at baseline and end of treatment at 8 weeks*
*Denotes outcomes prespecified for this review
 
Notes Funding was by Danish Directorate of Food Fisheries and Agri Business Danish Dairy
Research Foundation. "No conflicts of interest" declared
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote from communication with author: "Randomization sequence was
generated by the online available program http://www.randomizer.org/"




Low risk Quote from communication with author: "The producer of the intervention
product blinded the capsules as A, B and C before shipment"
Comment: allocation sequence judged as adequate for low risk of bias
after the study author's assurance
 
Blinding of participants and
personnel (performance bias)
Low risk Quote from communication with author: "The producer of the intervention
product blinded the capsules as A, B and C before shipment, and blinding
was maintained for participants, clinician and outcome assessor until
finalized data analysis"
Comment: judged as adequate for low risk
 
Blinding of outcome assessment
(detection bias)
Low risk Quote from communication with author: "The producer of the intervention
product blinded the capsules as A, B and C before shipment, and blinding
was maintained for participants, clinician and outcome assessor until
finalized data analysis"
Comment: judged as adequate for low risk.
 
Incomplete outcome data (attrition
bias)
Low risk No losses to follow-up. All participants analysed in the group were
randomised
 
Selective reporting (reporting bias) Low risk All outcomes reported
 
Other bias Low risk No other bias found
 
Gore 2011
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Methods Twelve-week 3-arm parallel-group randomised double-blind placebo-controlled trial
with follow-up up to 36 months
 
Participants One hundred thirty-seven infants between 3 and 6 months of age with physician-
diagnosed atopic dermatitis, in good general health, with normal growth, and
consuming > 200 mL standard formula/d were recruited. Randomisation was done at a
1:2 ratio: 45 participants were randomised in the 2 intervention arms, and 45 in the
control arm. SCORAD score at recruitment had to be ≥ 10 after standardised skin
treatment for 2-week run-in period: 1% hydrocortisone ointment twice daily and
emollients 2 to 4 times daily. Infants who were taking antibiotics or were on soya or
extensively hydrolysed formula, those with congenital abnormalities or chronic
disease, and those at less than 34 weeks' gestation were excluded from the trial
Participants who were exclusively breastfed and those whose parents declined use of
extensively hydrolysed formula were followed up as an open observational group
Four participants were lost to follow-up at 12 weeks
Participants were recruited from primary care community clinics in the United Kingdom
 
Interventions First probiotic arm: Bifidobacterium lactis in powder sachets at a dose of 10¹º CFUs/d
given with meals for 12 weeks
Second probiotic arm: Lactobacillus paracasei in powder sachets at a dose of 10¹º
CFUs/d given with meals for 12 weeks
Placebo arm: maltodextrin in powder sachets given with meals for 12 weeks
All arms followed a dairy elimination diet and used an extensively hydrolysed whey
formula
 
Outcomes • Total SCORAD before 2-week run-in period, at baseline, at 4 and 12 weeks, and at
12, 18, and 36 months*
• IDQoL before 2-week run-in period, at baseline, at 12 weeks, and at 12, 18, and 36
months*
• Use of other eczema treatment at 12 weeks (end of intervention period)*
• Number of infants receiving standard skin care: combination of topical steroids (TSs),
emollients (≥ twice/d), and bath emollient*
• Potency of TS*
*Denotes outcomes prespecified for this review
 
Notes Funding and "no conflict of interest" declared
Forty-two out of 137 (30.7%) parents reported some difficulties, e.g. green loose
stools, increased vomiting, feed refusal, or colic thought to be related to change in
formula), and 24 of 137 (17.5%) stopped the formula
 
Risk of bias table
#102 Probiotics for treating eczema
41 / 151
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "Minimization method was applied to allocate subjects to study
groups applying breast feeding, family history and initial SCORAD as
stratification factors (TrialBalance randomisation programme; Nestec,
Lausanne, Switzerland)"




Unclear risk No information to confirm whether treatment allocation could be predicted
 
Blinding of participants and
personnel (performance bias)
Low risk All interventions identical
Blinding of clinicians confirmed by study author
 
Blinding of outcome assessment
(detection bias)
Low risk Confirmed by study author
 
Incomplete outcome data (attrition
bias)
Low risk 2/45 (4.4%) participants in L paracasei group, 1/45 (2.2%) in B lactis
group, and 1/47 (2.1%) in placebo group lost to follow-up. 10/45 (22.2%)
participants in L paracasei group, 9/45 in B lactis group, and 9/47 (19.1%)
in placebo group stopped the study diet as per protocol but continued the
intervention. Available case analysis used without exclusions, with
imputation for missing data
Comment: judged as unlikely to have influenced outcomes on eczema
severity and quality of life, as similar and low rates of loss to follow-up in
all groups
Also similar rates of stopping study formula in all groups
 
Selective reporting (reporting bias) Low risk All outcomes reported
 
Other bias Low risk No other bias found
 
Gromert 2009
Methods Twelve-month parallel-group double-blind placebo-controlled randomised trial
 
Participants Fifty children from 3 months to 4 years of age with moderate atopic dermatitis. No
additional information provided on randomised numbers of participants in each arm
 
Interventions Probiotic: Lactobacillus reuteri at a dose of 1 × 10⁸ CFUs/d taken orally suspended in
5 drops of food oil for 12 months
Placebo: not specified but also given for 12 months
 
Outcomes • SCORAD*
• Subjective symptoms of atopic dermatitis: itching and loss of sleep*
• Use of steroid treatment*
*Denotes outcomes prespecified for this review
 
Notes All available information taken from a conference abstract. No publication found, and
study authors could not be contacted
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "In this prospective, double blind, randomised study..."





Unclear risk Inadequate information: information on this study taken only from a
conference abstract
 
Blinding of participants and
personnel (performance bias)
Unclear risk Quote: "In this prospective, double blind, randomised study..."
Inadequate information: information on this study taken only from a
conference abstract
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "In this prospective, double blind, randomised study..."
Inadequate information: information on this study taken only from a
conference abstract
 
Incomplete outcome data (attrition
bias)
Unclear risk Inadequate information: information on this study taken only from a
conference abstract
 
Selective reporting (reporting bias) Unclear risk Inadequate information: information on this study taken only from a
conference abstract
 




Methods Twelve-week parallel-group randomised controlled trial
Last observation carried forward approach used for missing continuous data
 
Participants 106 children 3 to 12 months of age with mild/moderate eczema and SCORAD 15 to
40, not receiving anti-inflammatory treatment. Randomisation was done at a 1:1 ratio:
56 participants randomised in the intervention arm and 50 in the control arm. Four
participants excluded from analysis after randomisation due to protocol breaches
 
Interventions Lactobacillus GG at 10¹º CFUs/d as a twice-daily dose, or placebo
 
Outcomes • SCORAD*
• Use of 1% hydrocortisone ointment*
*Denotes outcomes prespecified for this review
 
Notes Funding declared and provided by InfectoPharm Arzneimittel und Consilium GmbH,
Heppenheim, Germany (not linked with probiotics). No information on conflicts of
interest
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)




Unclear risk No information provided
 
Blinding of participants and
personnel (performance bias)
Unclear risk Described as double-blind but no details given
 
Blinding of outcome assessment
(detection bias)
Unclear risk Described as double-blind but no details given
 
Incomplete outcome data (attrition
bias)
Low risk No losses to follow-up. Four participants (3.9%) excluded from analysis
after randomisation because of protocol breaches. Unlikely to have an
impact on effect estimate
 
Selective reporting (reporting bias) Low risk No evidence of selective reporting found
 





Participants 180 children with eczema, from 2 months to 3 years of age. No additional information
provided on exact ratio of randomisation into 2 arms. Patients with other medical
conditions excluded
 
Interventions Active: routine symptomatic treatment and combination of 4 living
bacterium tablets (Bifidobacterium, Lactobacillus, Enterococcus, and Bacilus cereus)
taken orally at a dose of 1 tablet twice a day for 1 month
Control: routine symptomatic treatment
Routine symptomatic treatment: mild disease – calamine lotion and zinc oxide
ointment, 3 times daily for 2 weeks
Severe disease – loratadine syrup, topical mometasone and topical mupirocin to stop
after disease control
All participants advised to avoid washing with hot water/spa products and scratching,
and to look for potential allergens and avoidance advice
 
Outcomes IL-4, IL-10, IgE, IFN-γ, and Th1:Th2 ratio
Relapse rate of the 2 groups in the 3-month follow-up visit. Relapse is defined as
recurrence of rash within the 3 months
Eczema improvement:
• Complete resolution: - complete clearance of rash and itch; and normal eating and
sleeping patterns
• Good response: > 70% eczema clearance, no obvious lichenification, almost
complete resolution of itch/intermittent itch, eating and daily activities not affected
• Partial response: 30% to 70% clearance, symptom improvement
• No response: < 30% rash clearance, no obvious reduction in itch




Trial was conducted in a secondary care setting at a paediatric clinic
No information provided on sponsorship/conflicts of interest
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Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)




Unclear risk Inadequate information for a judgement
 
Blinding of participants and
personnel (performance bias)
Unclear risk Inadequate information for a judgement
 
Blinding of outcome assessment
(detection bias)
Unclear risk Inadequate information for a judgement
 
Incomplete outcome data (attrition
bias)
Unclear risk Inadequate information for a judgement
 
Selective reporting (reporting bias) Unclear risk All outcomes reported; however dose of probiotics not given, and
results reported only narratively
 
Other bias Unclear risk No information on trial registration and sponsorship
 
Han 2012
Methods Sixteen-week parallel-group double-blind placebo-controlled randomised trial
 
Participants One hundred eighteen children between 1 and 13 years of age with atopic dermatitis
diagnosed according to Hanifin and Rajka criteria with SCORAD between 20 and 50
Randomisation was done at a 1:1 ratio: 58 participants were randomised in the
intervention arm, and 60 in the control arm. After selection, participants went through a
2-week washout period, when both groups were administered placebo only. Patients
who had taken systemic corticosteroids, probiotics, or phototherapy within a month
before enrolment, with systemic immunosuppression within 3 months before
enrolment, with SCORAD < 20 after a 2-week washout period, or with other
concomitant skin disease or systemic illness were excluded from the study. One
recruiting centre was located in Korea. Thirty-five participants were lost to follow-up
 
Interventions Probiotic: Lactobacillus plantarum CJLP 133 given orally twice daily at a dose of 0.5 ×
10¹º CFUs for 12 weeks
Placebo: maltodextrin and anhydrous glucose twice daily for 2 weeks as a washout
period by both groups, and then for 12 weeks by the control group
 
Outcomes • Total SCORAD at baseline, after 2-week washout period, and at 8, 14, and 16
weeks, and changes from week 2 (start of intervention) to week 14 (end of
intervention) and week 16 (2-week follow-up after end of intervention)*
• Amount in weight of topical corticosteroids used during the whole study and during
intervention only*
• Number of participants using topical corticosteroids during the study*
*Denotes outcomes prespecified for this review
 
Notes Trial sponsored by probiotic supplier; 2 investigators are employed by this company.
No other information on conflicts of interest
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "...using a computer-generated list of random numbers"




Low risk Quote: "The random number list was prepared and posted on the fronts
of the bags containing the materials by an investigator who was not
involved clinically in the trial", "...placebo preparation with identical
appearance and taste"
Comment: probably done and judged as adequate for low risk.
 
Blinding of participants and
personnel (performance bias)
Low risk Intervention and placebo identical in appearance and taste
Also quote from correspondence with study author: "clinicians and
outcome assessors had been blinded during the study period"
Comment: judged as adequate for low risk
 
Blinding of outcome assessment
(detection bias)
Low risk Quote from correspondence with study author: "clinicians and outcome
assessors had been blinded during the study period"
Comment: judged as adequate for low risk
 
Incomplete outcome data (attrition
bias)
High risk Intention-to-treat analysis used but high rates of losses to follow-up
(30%). 14/58 (24%) participants from probiotic group and 21/60 (35%)
from placebo group lost to follow-up. Reasons for losses to follow-up
given and similar in both groups
Incomplete data likely to have an impact on the effect estimate; judged as
high risk
 
Selective reporting (reporting bias) High risk Symptom scores (i.e. for pruritus, sleep loss, and SCORAD part C) after
intervention not reported
 
Other bias High risk Commercial bias: trial sponsored by probiotic supplier, and 2 of the
investigators employed by the company. It is likely that the sponsor had
an influence on the outcome and on selective reporting
Selection bias: power calculation and final numbers of participants
suggest that study did not meet the target
According to publication: "Study discontinued after the second interim
analysis showed statistically significant differences between the groups"
Study assessed to be at high risk of bias
 
Hol 2008
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Methods Eighteen-month multi-centre double-blind randomised controlled parallel-group trial
conducted from March 2004 until May 2007
 
Participants One hundred nineteen infants younger than 6 months of age with documented cow's
milk allergy, judged by an elimination challenge test (open) and re-elimination, in
conformity with guidelines of the European Society for Pediatric Gastroenterology,
Hepatology and Nutrition (ESPGHAN). Randomisation was done at a 1:1 ratio.
Excluded from the study were infants breastfeeding during the study, infants older than
6 months of age, patients with chronic disease that may be relevant to this study, such
as pre-existing chest abnormalities (e.g. bronchopulmonary dysplasia (BPD), relevant
congenital abnormalities), gastrointestinal disease (coeliac disease, enzyme
disorders), and metabolic disease, premature infants at less than 32 weeks, infants
with congenital abnormalities that may be relevant to this study, and infants using
systemic drugs for allergy (corticosteroids and antihistamines)
Multi-centre trial recruiting in a paediatric secondary care setting in the Netherlands
One hundred six infants completed the study (89%)
 
Interventions Probiotic group: Lactobacillus casei CRL431 (Lactobacillus paracasei, subsp
paracasei) and Bifidobacterium lactis Bb-12 (B animalis subsp lactis). For each
probiotic, 10⁷ CFUs/gr of formula was provided. This was given for 6 months in
extensively hydrolysed formula and was continued in standard formula if infants
became cow's milk tolerant, or in the same extensively hydrolysed formula if not
Control group: extensively hydrolysed formula for 6 months and continued in standard
formula if infants became cow's milk tolerant, or in the same extensively hydrolysed
formula if not
 
Outcomes • Development of tolerance for cow's milk, observed by a challenge test (double-blind)
at 6 months
• Eczema severity by SCORAD index at 6 and 12 months*
• T- and B-lymphocyte subsets at 12 months
*Denotes outcomes prespecified for this review
 
Notes Study co-sponsored by probiotic/formula supplier. No information on conflicts of
interest
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "A computerized randomisation schedule was prepared by a
statistician" - "the groups were stratified and block randomised according
to age at inclusion (<20 weeks and >20 weeks), birth weight (<2500gr or
>2500gr) and (reported) atopic diseases in first-degree relatives (yes or
no)"




Unclear risk No information available to allow a judgement
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "Probiotics and formula were image and taste matched, and
participants and researchers remained blinded to group assignment for
the duration of the study"
Comment: probably done for all parties
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "Probiotics and formula were image and taste matched, and
participants and researchers remained blinded to group assignment for
the duration of the study"
Comment: probably done for all parties
 
Incomplete outcome data (attrition
bias)
Unclear risk Overall losses to follow-up 11%. No data available for the 2 groups
separately, and no data available for the subgroup of participants who had
eczema
Inadequate for a judgement for that subgroup only
Low risk of attrition bias for the primary outcome of the study
(development of tolerance to cow's milk)
 
Selective reporting (reporting bias) Low risk All outcomes reported. No detailed data reported on all eczema
participants (only moderate to severe), but significance of the difference
noted
Quote: "The probiotic group (n=51) showed improvement at 6 and 12
months, and the placebo group (n=54) showed improvement only at 6
months. However, after adjusting for the baseline values there were no
significant differences in the change from baseline between probiotics and
placebo treatment at 6 months (P=.9) and at 12 months (P=.14)"
 
Other bias Unclear risk Commercial bias: formula and probiotics supplied by producer company.
The role of the manufacturer in data analysis and publication is unknown;
therefore we assessed this study to be at unclear risk of other bias
 
Iemoli 2012
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Methods Twenty-week parallel-group double-blind placebo-controlled randomised trial from
April until September 2010
 
Participants 48 adults between 18 and 55 years of age with moderate to severe atopic
dermatitis diagnosed according to "Consensus guidelines in diagnosis and
treatment of atopic dermatitis" (Eichenfield 2004). Participants were randomised at a
2:1 intervention:control ratio (32 participants in intervention arm/16 participants in
control arm). Patients who had taken probiotics in the 6 months before enrolment, or
topical immunomodulators, corticosteroids, or antihistamines; who had chronic
disease, congenital or acquired immunosuppression, acute or chronic infection, or
allergic contact dermatitis; and pregnant or lactating patients were excluded from the
trial. Also excluded were patients who were on elimination diets without a known food
allergy and those with hypersensitivity to the components of the probiotics
Participants were recruited at a secondary Immunology centre in Italy
Two participants were lost to follow-up
 
Interventions Mixture of probiotics in maltodextrin: Lactobacillus salivarius LS01 DSM 2275,
Bifidobacterium breve BR03 DSM 16604, given twice daily at a dose of 1 × 10⁹
CFUs/gr for each probiotic for 12 weeks
Placebo: maltodextrin given only twice daily for 12 weeks
 
Outcomes • DLQI at baseline and at 12 and 20 weeks*
• SCORAD at baseline and at 12 and 20 weeks*
*Denotes outcomes prespecified for this review
 
Notes "No conflicts of interest" declared. No information on funding. Probiotics provided by
the manufacturer
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "patients were randomised with a 2:1 ratio..."
Quote from communication with study author: "A computerized
randomisation schedule was prepared..."




Low risk Quote from communication with study author: "allocation and dispensing
by blind clinical investigator"
Comment: judged as adequate for low risk of bias
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "Probiotic and placebo sachets were matched for size, shape and
volume of contents"
Quote from communication with study author: "allocation and dispensing
by blind clinical investigator"
Comment: judged as adequate for low risk of bias
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "A single investigator blinded to the treatment arm, performed all
SCORAD assessments..."
Comment: judged as adequate for low risk of bias
 
Incomplete outcome data (attrition
bias)
Low risk Low rates of loss to follow-up (4%) overall. 1 participant lost to follow-up
in each arm: 3% in probiotic group and 6% in placebo group. Different
reasons for losses to follow-up given but overall low rates unlikely to have
a significant influence on effect estimates for all outcomes
 




"No conflicts of interest" declared. Unavailable information on funding.
Probiotics provided by the manufacturer
 
Isolauri 2000
Methods Parallel-group three-arm randomised controlled trial. Duration of treatment unclear
 
Participants Twenty-seven infants - ages not stated - with eczema diagnosed using the Hanifin and
Rajka criteria. Randomisation was done at a 1:1 ratio: 9 participants were randomised
in each arm. All infants were exclusively breastfed and were tolerant of the study
formula without added probiotic
Setting: paediatric service in Finland
Unclear how many participants lost to follow-up
 
Interventions Extensively hydrolysed whey-dominant cow's milk formula with no probiotic added,
with Lactobacillus GG added at 3 × 10⁸ CFUs/g, or with Bifidobacterium lactis Bb-12
added at 1 × 10⁹ CFUs/g
 
Outcomes SCORAD - interval of assessment unclear*
*Denotes outcomes prespecified for this review
 
Notes Study funded by the Academy of Finland, European Union (FAIR CT96-1028), and the
Medical Research Funds of Tampere and Turku University Hospital
"No conflict of interest" declared
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "In this randomised, double blind study, the patients were
divided into three groups..."




Unclear risk No information given. No assessment of risk of bias can be done
 
Blinding of participants and
personnel (performance bias)
Unclear risk Quote: "In this randomised, double blind study, the patients were
divided into three groups..."
Comment: inadequate information for a judgement on risk of bias
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "In this randomised, double blind study, the patients were
divided into three groups..."
Comment: inadequate information for a judgement on risk of bias
 
Incomplete outcome data (attrition
bias)
Unclear risk Information on losses to follow-up not given. Inadequate information
for a judgement on risk of bias
 
Selective reporting (reporting bias) Low risk No evidence of selective reporting found
 
Other bias Low risk No other bias found
 
Ivankhnenko 2013
Methods Eight-week parallel-group open-label randomised placebo-controlled trial
 
Participants Sixty full-term infants 3 to 12 months of age with clinically diagnosed eczema and
challenge proven cow's milk allergy, breast and formula fed. Randomisation was done
at a 1:1 ratio: 30 participants were randomised in each arm. Excluded were patients
who had received any probiotics within a month before recruitment and those with
other allergies, severe comorbidities, and malformations
Country: Ukraine
5 participants lost to follow-up
 
Interventions Probiotic: Bifidobacterium lactis BB-12 and Streptococcus thermophilus TH-4 for 4
weeks
No information on placebo
Daily dose of probiotics: 1 × 10⁹ CFUs for BB-12 and 1 × 10⁸ CFUs for TH-4. Both
groups on cow's milk elimination diet
 
Outcomes SCORAD at 4 and 8 weeks*
*Denotes outcomes prespecified for this review
 
Notes No mention of sponsor. No declaration of conflicts of interest
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear riskQuote from translated Russian article: "In this open label randomised
prospective clinical study..."




Unclear riskInadequate information for assessment, so study judged as having unclear
risk of bias
 
Blinding of participants and
personnel (performance bias)
High risk Open-label study
 
Blinding of outcome assessment
(detection bias)
High risk Open-label study
 
Incomplete outcome data (attrition
bias)
Low risk Five participants lost to follow-up (8%), with 2 participants from probiotic
group (6.6%) and 3 participants (10%) from placebo group. Reasons for
losses to follow-up not given for each group. Not clear whether losses to
follow-up were excluded from analysis. However overall rates of loss to
follow-up were low and were unlikely to have a significant influence on
effect estimates for study outcomes
 
Selective reporting (reporting bias) Low risk All outcomes reported
 
Other bias Unclear riskNo mention of sponsor. No declaration of conflicts of interest
 
Kirjavainen 2003
Methods Parallel-group randomised controlled trial. Intended duration of treatment not clear
 
Participants Twenty-seven infants (mean age 5.5 months) with eczema and suspected cow's milk
allergy. Method for diagnosing eczema not described
Setting: hospital paediatric department in Finland
Unclear how many participants lost to follow-up
Participants randomised 2:1, probiotic:control
 
Interventions Lactobacillus GG at 3 × 10¹º CFUs/kg/d, mixed with extensively hydrolysed whey
formula, or the same formula without probiotic. A third treatment arm (excluded from




*Denotes outcomes prespecified for this review
 
Notes Study terminated early due to adverse effects in a third treatment arm. Third treatment
arm not included in this systematic review because it involved the use of killed bacteria
Study funded by the Academy of Finland
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "These infants were randomly assigned into placebo, viable
LGG..."




Unclear risk No information reported. Inadequate information for a judgement on risk
of bias
 
Blinding of participants and
personnel (performance bias)
Unclear risk Quote: "These infants were randomly assigned into placebo, viable
LGG or heat-inactivated LGG groups and accordingly given in a double
blind manner..."
Comment: inadequate information for a judgement on risk of bias
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "These infants were randomly assigned into placebo, viable
LGG or heat-inactivated LGG groups and accordingly given in a double
blind manner..."
Comment: inadequate information for a judgement on risk of bias
 
Incomplete outcome data (attrition
bias)
Unclear risk No data given on losses to follow-up. Inadequate information for a
judgement on risk of bias
 
Selective reporting (reporting bias) Low risk No evidence of selective reporting
 
Other bias Low risk No other bias found
 
Lin 2015
Methods Four-week randomised parallel controlled trial
 
Participants Forty-four infants of both genders with newly diagnosed eczema based on the
diagnostic criteria for eczema up to 3 years of age were recruited. Randomisation was
done at 1:2 ratio: 22 participants were randomised in each group. Infants who had
been treated with antibiotics, probiotics, or other drugs and food at least 2 weeks
before the start of the study were excluded. Also excluded were children suffering from
pneumonia, capillary bronchitis, and other diseases, or who had been treated with
antibiotics or hormones during the experimental process
Infants were treated with antiallergic therapy and dietary guidance
Recruitment took place in a secondary paediatric setting in China between December
2010 and March 2011
 
Interventions Intervention group received triple viable capsules containing Bifidobacterium bifidum 3
times daily for 4 weeks
Control group received no treatment
 
Outcomes • Total SCORAD index at baseline and after 4 weeks of intervention
• Bifidobacterium bifidum stool levels at baseline and after 4 weeks of treatment
 
Notes Sponsorship of the trial not declared. Not clear what role the supplier of the probiotic
played in the study
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "The 40 infants were randomly divided into treatment and
control groups"
Judgement: inadequate information on randomisation method; risk of




Unclear risk Inadequate information for a judgement
 
Blinding of participants and
personnel (performance bias)
High risk Quote: "The control group … did not receive any special treatment and
were not administered a placebo drug"
Judgement: unlikely to be done adequately with no treatment and no
placebo in the control group
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "The control group … did not receive any special treatment and
were not administered a placebo drug"
Otherwise no information on blinding of outcome assessors; hence
risk of detection bias judged to be unclear
 
Incomplete outcome data (attrition
bias)
Unclear risk No information provided on losses to follow-up and missing outcome
data
Judgement: unclear risk of bias
 
Selective reporting (reporting bias) Low risk All outcomes reported
 
Other bias Unclear risk Not clear what role the supplier of the probiotic played in the study.
Sponsorship of the trial not declared
Judgement: unclear risk of commercial bias
 
Majamaa 1997
Methods One-month parallel-group randomised controlled trial
 
Participants Thirty-one children 2 to 16 months of age with eczema diagnosed using the Hanifin
and Rajka criteria, and a history suggestive of cow's milk allergy. Randomisation was
done at a 1:1 ratio. Children currently receiving systemic corticosteroid treatment were
excluded
Setting: paediatric clinic in Finland
Unclear how many participants were lost to follow-up
 
Interventions Cow's milk elimination diet, topical eczema treatment, and extensively hydrolysed
cow's milk formula with or without addition of probiotic Lactobacillus GG. Probiotic
given at 5 × 10⁸ CFUs/g formula
 
Outcomes SCORAD assessed at 1 and 2 months*
*Denotes outcomes prespecified for this review
 
Notes No information available on funding or conflicts of interest
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "The patients....participated in a randomised double blind
study"




Unclear risk No information provided
 
Blinding of participants and
personnel (performance bias)
Unclear risk Quote: "The patients....participated in a randomised double blind
study"
Comment: inadequate information for a judgement on risk of bias
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "The patients....participated in a randomised double blind
study"
Comment: inadequate information for a judgement on risk of bias
 
Incomplete outcome data (attrition
bias)
Unclear risk No data on losses to follow-up. Inadequate information for a
judgement on risk of bias
 
Selective reporting (reporting bias) Low risk No evidence of selective reporting
 
Other bias Unclear risk No information on funding available
 
Matsumoto 2014
Methods Eight-week multi-centre randomised double-blind placebo-controlled parallel trial
 
Participants Forty-four adults with moderate to severe atopic dermatitis diagnosed according to the
criteria of Hanifin and Rajka were recruited. Randomisation was done at a 1:1 ratio: 22
participants were randomised in each arm. Participants continued to use their
medications as usual and did not change quantities or levels of corticosteroid medicine
during the experimental period. Participants were asked to avoid probiotic
supplements, fermented milk, lactic acid bacterial drinks, and fermented soybean
(natto) during the experimental period
Recruitment took place at 8 dermatology clinics in Japan
 
Interventions Participants in the intervention group received capsules containing approximately 6 ×
10⁹ CFUs of Bifidobacterium animalis subsp lactis and an excipient that consisted of
skim milk, glucose, inulin, dextrin, and silicone dioxide for 8 weeks
Control group received capsules containing the excipient only for 8 weeks
 
Outcomes • Itch score by behavioural rating scales and by 100-mm visual analogue scale (VAS)
at baseline and at 4 and 8 weeks
• Skin severity score using the reference proposed by the Research Group granted by
the Japanese Ministry of Health, Labor and Welfare at baseline and at 4 and 8 weeks
• Quality of life using Skindex-29 (Japanese version) at baseline and at 4 and 8 weeks
• Faecal levels of B lactis at baseline and at 4 and 8 weeks
 
Notes Trial registration: UMIN000005695
Four of the investigators/study authors are employed by the supplier
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "The 44 participants eligible for the study were randomly
assigned to receive LKM512 capsule or a placebo by the masked quota
director"
Judgement: inadequate information on randomisation method; hence




Unclear risk Inadequate information for a judgement
 
Blinding of participants and
personnel (performance bias)
Unclear risk "Double-blind" mentioned, but trial registration shows open-label
 
Blinding of outcome assessment
(detection bias)
Unclear risk "Double-blind" mentioned, but trial registration shows open-label
 
Incomplete outcome data (attrition
bias)
Unclear risk No information provided
 
Selective reporting (reporting bias) Unclear risk All outcomes reported but not numerically, and any favourable
information/outcome for probiotics particularly analysed, even if not
statistically significant
 
Other bias High risk Commercial bias: 4 investigators/study authors employed by supplier;
likely that this has influenced the design and outcome of the trial
 
Nermes 2010
Methods Three-month parallel-group randomised placebo-controlled trial
 
Participants Thirty-nine full-term and otherwise healthy infants with atopic dermatitis diagnosed
according to the Hanifin and Rajka criteria were recruited. Randomisation was done at
a 1:1 ratio: 19 participants were randomised in the intervention arm, and 20 in the
control arm. Patients with skin or other severe infections were excluded
Recruitment was done at a paediatric secondary care setting in Finland
Two participants were lost to follow-up
 
Interventions Probiotic: Lactobacillus rhamnosus GG in extensively hydrolysed casein formula given
at a dose of 5.0 × 10⁷ CFUs/gr, achieving a daily dose of 3.4 × 10⁹ CFUs/d for 3
months
Placebo: extensively hydrolysed casein formula for 3 months
 
Outcomes • Total SCORAD*
*Denotes outcomes prespecified for this review
 
Notes Study was partially funded by the formula manufacturer and a grant from the Academy
of Finland. No conflicts of interest declared
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote from correspondence with study author: "the randomisation was
carried out by the formula supplier (Mead Johnson, Evansville, IN, USA).
The method used was block randomisation..."




Unclear risk No information given; inadequate information for a judgement
 
Blinding of participants and
personnel (performance bias)
Low risk Quote from correspondence with study author: "The study was a double-
blind, placebo controlled intervention study" - "The information disclosing
the codes of the study products was kept by a person not involved in the
study and opened after the study was completed"
Comment: probably done; judged as adequate for low risk of bias
 
Blinding of outcome assessment
(detection bias)
Low risk Quote from correspondence with study author: "The study was a double-
blind, placebo controlled intervention study" - "The information disclosing
the codes of the study products was kept by a person not involved in the
study and opened after the study was completed"
Comment: probably done; judged as adequate for low risk of bias
 
Incomplete outcome data (attrition
bias)
Low risk Two participants lost to follow-up, all from placebo group. Available case
analysis unclear but very low rates of loss to follow-up (5% in total and
10% in placebo group) unlikely to change the effect estimate. Reasons
for losses to follow-up given
 
Selective reporting (reporting bias) Low risk All outcomes reported
 
Other bias Low risk No other bias found
 
Passeron 2006
Methods Three-month parallel-group randomised controlled trial
 
Participants Forty-eight children 2 to 12 years of age with moderate/severe eczema diagnosed by
UK Working Party Criteria and total SCORAD over 14. Randomisation was done at a
1:1 ratio: 24 participants were randomised in each arm. Exclusion criteria included
current flare of eczema, exposure to systemic corticosteroids or immunosuppressants
in the previous 3 months, and other known immune deficiency
Setting: hospital dermatology clinic in France
Nine participants lost to follow-up
 
Interventions Skim milk powder, potato starch, and lactose-containing prebiotic, with or without
Lactobacillus rhamnosus Lcr35 at 3.6 × 10⁹ CFUs/d, given as a 3-times-daily dose
mixed with cold water or other liquid
 
Outcomes • Parent or participant global assessment of eczema severity*
• SCORAD*
• Investigator global assessment of eczema severity*
Assessments were done at baseline and at 1, 2, and 3 months
*Denotes outcomes prespecified for this review
 
Notes Three episodes of mild abdominal pain reported - 2 in probiotic group, 1 in placebo
(prebiotic alone) group
Funding and conflict of interest not reported
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Computer-generated randomisation sequence as confirmed by study




Low risk Adequate as confirmed by study authors and judged as having low risk
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "The patients, their parents and the dermatologists were blinded to
the treatment the patient was receiving" - "Each patient was examined by
the same dermatologist at each visit"
Study authors confirmed blinding of all parties in the trial
Comment: probably done and judged as adequate for low risk of bias
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "The patients, their parents and the dermatologists were blinded to
the treatment the patient was receiving" "Each patient was examined by
the same dermatologist at each visit"
Study authors confirmed blinding of all parties in the trial
Comment: probably done and judged as adequate for low risk of bias
 
Incomplete outcome data (attrition
bias)
High risk Available case analysis used without exclusions after randomisation with
low total rates of loss to follow-up (18.7%). Losses to follow-up per group:
29% in synbiotic group and 8% in placebo group. Reasons for losses in
the synbiotic group were non-attendance at follow-up visits (5/24
participants) and withdrawal of consent (2/24). In the prebiotic group, 2/24
participants did not attend for follow-up
Significant differences in rates of loss to follow-up in the 2 groups, which
probably had an impact on all outcomes
 
Selective reporting (reporting bias) Low risk No evidence of selective reporting
 
Other bias Unclear riskFunding and conflict of interest not reported
 
Roessler 2007
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Methods Twenty-week cross-over randomised double-blind placebo-controlled trial
 
Participants Sixteen adults between 18 and 40 years of age with eczema diagnosed based on
Erlangen score > 10 (atopic score of Diepgen) and SCORAD severity score 5 to 30
were recruited. Only patients who were willing to apply cosmetic products and the
Class II topical corticosteroid Advantan were recruited. Exclusion criteria were
disease necessitating medication with systemic corticosteroids, immunosuppression,
or cytostatics within 4 weeks before the start of the study; phototherapy or systemic
treatments within 4 weeks before the start of the study; long-acting antihistamines,
antibiotics, long-term systemic corticosteroids, depot steroids, tranquillisers, and
psychopharmaceuticals with antihistamine effect or within 7 days from skin prick test;
or astemizole intake within 4 weeks before prick testing. Also excluded were patients
with active skin infection; asthma needing treatment with corticosteroids;
indigestibility/allergy to milk components (including skin prick test); lactose intolerance;
acute or chronic symptomatic heart disease or severe internistic disease; autoimmune
disease; immune deficiency (including immune suppressive treatment); immune
complex-induced immunopathy or malignant tumour; or abuse of alcohol, drugs, or
medicaments, as well as pregnant and breastfeeding women
Recruitment was done at a secondary care centre in Germany
One participant withdrew after randomisation and before treatment started
 
Interventions Probiotic yoghurt drink containing Streptococcus thermophilus enriched with
Lactobacillus paracasei Lpc-37 (3.9 × 10⁸ CFUs/g), Lactobacillus acidophilus 74-2 (2.9
× 10⁴ CFUs/g), Bifidobacterium lactis DGCC 420 (5.9 × 10⁴ CFUs/g) taken as 100 mL
twice daily for 8 weeks
Total daily dose was Lpc-37: 7.8 × 10¹º CFUs/d, 74-2: 5.8 × 10⁶ CFUs/d, and DGCC
420: 1.2 × 10⁷ CFUs/d
Placebo drink not otherwise specified given as 100 mL twice daily
Crossing over from one to the other intervention involved a washout period of 2 weeks
Instructions were given for elimination of other probiotic and prebiotic products for 3
weeks before the start of treatment and during the 20 weeks of intervention
 
Outcomes Total SCORAD and SCORAD part C at baseline and after 8 weeks of each
intervention*
*Denotes outcomes prespecified for this review
 
Notes Study was sponsored by a grant from Zott Dairy GmbH (not the probiotic supplier). It
was declared that Zott had no involvement in study design, data analysis, and
publication, and study authors declared no conflict of interest
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "all subjects were randomly assigned to 2 treatment groups (1:1)
according to a computer generated blocked randomisation list (blocked
randomisation)"




Unclear riskComment: not clear whether treatment allocation was concealed
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "The placebo drink had an identical composition except for the
probiotic cultures and had the same appearance, taste and smell as the
probiotic drink" - "Enrollment and assignment to interventions were
performed by the trial physician and AR. All involved persons (trial
physician and scientific staff) were blinded. In addition study products
were blinded and labelled with a numerical code by the production dairy"
Comment: judged as adequate for low risk of bias
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "The placebo drink had an identical composition except for the
probiotic cultures and had the same appearance, taste and smell as the
probiotic drink" - "Enrollment and assignment to interventions were
performed by the trial physician and AR. All involved persons (trial
physician and scientific staff) were blinded. In addition study products
were blinded and labelled with a numerical code by the production dairy"
Comment: judged as adequate for low risk of bias
 
Incomplete outcome data (attrition
bias)
Low risk One participant (6.6%) withdrew after randomisation and before the start
of treatment and was excluded from analysis. All other participants were
analysed in the group to which they had been randomised. Low rates of
loss to follow-up were unlikely to have a significant influence on effect
estimates
 
Selective reporting (reporting bias) Low risk All outcomes reported
 
Other bias Low risk No other bias found
 
Rosenfeldt 2003
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Methods Six-week randomised controlled cross-over trial
 
Participants Fifty-eight children 1 to 13 years of age with eczema diagnosed using the UK Working
Party Criteria. Children who had received systemic corticosteroids at any time were
excluded
Setting: hospital paediatric and dermatology departments in Denmark
15 participants lost to follow-up
 
Interventions Skimmed milk powder with dextrose anhydrate 2 g/d or a mix of Lactobacillus
rhamnosus 19070-2 and Lactobacillus reuteri DSM12246 at 2 × 10¹º CFUs/d of each
strain. Both placebo and probiotic preparations administered twice daily with 2.5 to 5
mL water
 
Outcomes • Global self-assessment by participant or parent*
• SCORAD*
• Need for other treatment - topical corticosteroid*
*Denotes outcomes prespecified for this review
 
Notes Study was supported by Danish Research and Development Programme for Food
Technology
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "The patients were randomised in a double-blind crossover
design...." - "Blocked randomisation with 4 patients in each block was
applied"




Unclear risk No information provided. Inadequate information for a judgement
 
Blinding of participants and
personnel (performance bias)
Unclear risk Quote: "The patients were randomised in a double-blind crossover
design...."
Comment: inadequate information for a judgement on risk of bias
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "The patients were randomised in a double-blind crossover
design...."
Comment: inadequate information for a judgement on risk of bias
 
Incomplete outcome data (attrition
bias)
High risk Fifteen participants (25.9%) excluded from analysis. Five of these
excluded during active treatment and 9 during placebo. Reasons for
exclusion reported
Comment: high rates of exclusion probably affecting all outcomes
 
Selective reporting (reporting bias) Low risk No evidence of selective reporting
 
Other bias Low risk No other bias found
 
Shafiei 2011
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Methods Parallel-group double-blind placebo-controlled randomised trial conducted between
December 2008 and November 2009
 
Participants Forty-one children from 1 to 36 months of age with moderate to severe (SCORAD >
25) atopic dermatitis diagnosed according to Hanifin and Rajka criteria were recruited.
Randomisation was done at a 1:1 ratio: 20 participants were randomised in the
intervention arm, and 21 in the control arm. Exclusion criteria were administration of
systemic steroids, recurrent infection, evidence of immunodeficiency, congenital
abnormality, chronic disease, and problems in eating. Five participants were lost to
follow-up
Setting: Iranian Paediatric Allergy and Immunology Department
 
Interventions Synbiotic: 7-strain probiotic and synbiotic in a sachet given daily at a dose of 1 × 10⁹
CFUs of probiotic and 990 mgr of fructo-oligosaccharide for 2 months (59 days)
Placebo: sucrose in a 1000-mgr sachet given daily for 2 months (58 days)
Both interventions were prepared by mixing with water, breast milk, formula, or solid
food
 
Outcomes Total and objective SCORAD changes from baseline to end of intervention after 2
months*
*Denotes outcomes prespecified for this review
 
Notes Sponsorship is unclear. Conflicts of interest are not declared
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "Randomisation was performed according to a computer-
generated balanced block randomisation to synbiotic and placebo groups"




Unclear risk Quote: "At enrolment we assigned the study number and provided the
participants with the appropriate sachet"
Comment: not clear whether allocation to a treatment could have been
predicted
 
Blinding of participants and
personnel (performance bias)
Low risk It is stated: "Partcipants and investigators blinded for the duration of the
trial" - "Placebo and intervention image-matched and identical in
appearance, taste and smell"
Comment: judged as adequate for low risk of bias
 
Blinding of outcome assessment
(detection bias)
Unclear risk It is stated: "Partcipants and investigators blinded for the duration of the
trial", but no specific information provided on outcome assessor
Comment: judged as unclear risk due to lack of specific information
 
Incomplete outcome data (attrition
bias)
Low risk Five participants out of 41 (12%) were lost to follow-up: 2 participants
were from the probiotic group (10%) and 3 from the placebo group (14%).
Reasons for loss to follow-up were given and were similar in both groups.
Case analysis was available. Low rates of loss to follow-up unlikely to
have a significant impact on the effect estimate
 
Selective reporting (reporting bias) Unclear risk Baseline characteristics and outcomes reported only for participants who
completed the trial. Unclear whether groups were matched at baseline
 
Other bias Unclear risk Sponsorship unclear
 
Sistek 2006
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Methods Twelve-week parallel-group randomised controlled trial
 
Participants Sixty children 1 to 10 years of age with eczema diagnosed by UK Working Party
criteria, SCORAD of at least 10 at recruitment, and a positive skin prick or RAST test
to at least 1 common environmental or food allergen. Randomisation was done at a
1:1 ratio: 30 participants were randomised in each arm. Exclusion criteria were oral
corticosteroid, immunosuppressant, or antibiotic in the previous month; previous
immune deficiency or malignancy; and greater than 10-point improvement in SCORAD
during 2 weeks before the start of study treatment
Setting: hospital clinic in New Zealand
One participant lost to follow-up
 
Interventions Microcrystalline cellulose placebo or Lactobacillus rhamnosus and Bifidobacterium
lactis given together once daily at a combined total dose of 2 × 10¹º CFUs/d.
Treatment capsules administered as a powder mixed with food or drink, or taken in
capsule form
 
Outcomes SCORAD assessed at 2 weeks before treatment, at the start of treatment, and 2, 12,
and 16 weeks later*
*Denotes outcomes prespecified for this review
 
Notes One participant noted to be taking another non-investigational probiotic
Study was was funded by New Zealand Research Council. No conflicts of interest
were declared
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "Children were randomly assigned to treatment or placebo
groups, using computer-generated random numbers"




Low risk Adequate: treatment allocated by third party as confirmed by study
authors
 
Blinding of participants and
personnel (performance bias)
Low risk Quotes: "The control group received a placebo....that looked and tasted
the same as the probiotic" - "Both subjects and investigators were blind
to the treatment groups"
Comment: judged as adequate for low risk of bias
 
Blinding of outcome assessment
(detection bias)
Low risk Quotes: "The control group received a placebo....that looked and tasted
the same as the probiotic" - "Both subjects and investigators were blind
to the treatment groups"
Comment: judged as adequate for low risk of bias
 
Incomplete outcome data (attrition
bias)
Low risk Available case analysis used without exclusions after randomisation and
very low rates of loss to follow-up (1/60 participants, 1.7%)
Comment: low risk of attrition bias
 
Selective reporting (reporting bias) Low risk No evidence of selective reporting
 
Other bias Unclear risk Significant differences in baseline SCORAD in the 2 groups, with more
severe mean SCORAD in the placebo group. Study authors state that
this could have been avoided if randomisation had been blocked




Methods Three-month parallel-group randomised controlled trial
 
Participants Seventeen children 3 to 18 months of age with eczema diagnosed by Hanifin and
Rajka criteria, and with cow's milk hypersensitivity diagnosed by suggestive history
plus evidence of cow's milk-specific IgE. No information on the randomisation ratio
was given. All participants had reduced levels of Bifidobacteria in their faeces (< 30%
of total bacteria) and were receiving extensively hydrolysed cow's milk formula for at
least 2 weeks before randomisation
Setting unclear
Unclear how many participants were lost to follow-up
 
Interventions Raffinose prebiotic containing extensively hydrolysed cow's milk formula with or
without Bifidobacterium breve M-16V at 5 to 15 × 10⁹ CFUs/d
 
Outcomes Investigator-rated eczema scoring system*
*Denotes outcomes prespecified for this review
 
Notes No numerical outcome data available
Study was supported by Grants-in-Aid from the Morianga Houshikai and the Mami
Mitzutani Foundation. No conflicts of interest reported
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "The 17 infants were divided into 2 groups at random"
Comment: inadequate information; inadequate information for a




Unclear risk No information; inadequate information for a judgement on risk of
bias
 
Blinding of participants and
personnel (performance bias)
Unclear risk No information available
 
Blinding of outcome assessment
(detection bias)
Unclear risk No information available
 
Incomplete outcome data (attrition
bias)
Unclear risk No information on losses to follow-up or data analyses
 
Selective reporting (reporting bias) Low risk No risk found
 
Other bias Low risk No other bias found
 
Van der Aa 2010
Methods Twelve-week multi-centre parallel-group double-blind placebo-controlled randomised
trial
 
Participants Ninety infants 0 to 7 months of age, exclusively formula fed, with a diagnosis of atopic
dermatitis based on Hanifin and Rajka diagnostic criteria and SCORAD > 15 were
recruited in the study. Randomisation was done at a 1:1 ratio: 46 participants were
randomised in the intervention arm, and 44 in the control arm
Infants who had received systemic corticosteroids, antibiotics, antimycotics,
calcineurin inhibitors, or probiotics during 4 weeks or antihistamines during 2 weeks
before enrolment were excluded from the study. Also excluded were infants needing
systemic treatments other than antibiotics during the study and infants with major
medical problems or GI or skin conditions other than atopic dermatitis
Setting: participants recruited at 7 paediatric and dermatology secondary care centres
in the Netherlands
Eight participants were lost to follow-up. Five participants (4 in the symbiotic group and
1 in the placebo group) were excluded from analysis because no SCORAD
assessment was undertaken after baseline assessment
 
Interventions Synbiotic: extensively hydrolysed whey-based formula with Bifidobacterium breve
M-16V with 90% scGOS and 10% lcFOS given on demand at a dose of 1.3 × 10⁹
CFUs/100 mL of probiotic and 0.8 gr/100 mL of prebiotic for 12 weeks
Placebo: formula given only on demand for 12 weeks
 
Outcomes • Changes in total SCORAD from baseline to 4, 8, and 12 (end of treatment) weeks*
• Total SCORAD in 1 year after the intervention
• Frequency and mean class of topical steroids used at baseline and at end of
treatment*
*Denotes outcomes prespecified for this review
 
Notes Two participants experienced severe adverse events: RSV bronchiolitis and severe
cow's milk allergy. These were not related to the intervention
Sponsored by a probiotic/formula company
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "Participants were randomised, using computer-generated 4-
blocked design lists, drawn up by a statistician with stratification according
to recruiting hospital and current use of topical steroids..."




Low risk Quote: "Formulas were prepared and coded by Danone Research and
dispensed by the pharmacy of the Academic Medical Centre", "both
formulas were identical with respect to smell, taste, texture, colour and
packaging"
Comment: third party involved; judged as adequate for low risk of bias
 
Blinding of participants and
personnel (performance bias)
Low risk Quotes: "both formulas were identical with respect to smell, taste, texture,
colour and packaging. The investigator, participants' own physicians and
parents were all blind to the treatment groups"
Comment: judged as adequate for low risk of bias
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "The investigator, participants' own physicians and parents were all
blind to the treatment groups. Participants were clinically assessed by one
investigator (L.B.A.), at weeks 0, 4, 8 and 12"
Comment: judged as adequate for low risk of bias
 
Incomplete outcome data (attrition
bias)
Low risk 6/46 (13%) participants from the probiotic group and 2/44 (4.5%) from the
placebo group discontinued treatment but were not excluded from
analysis. Five participants (5.5%) were excluded post randomisation
because of unavailable assessment data after baseline. Four were from
the probiotic group, and one from the placebo group. Losses to follow-up
included in analysis but not certain how missing data were handled
Comment: overall low rates of missing data; judged to have low risk of
attrition bias
 




Sponsored by a probiotic/formula company. The role of the sponsor in
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Methods Four-week parallel-group randomised controlled trial
 
Participants 252 infants younger than 12 months of age with a clinical diagnosis of eczema and a
clinical history suggestive of cow's milk allergy. Randomisation was done at a 1:1 ratio:
84 participants were randomised in each arm. Infants who had received a probiotic
preparation for over a week in the preceding 6 weeks were excluded
Participants were selected from primary care referrals to a hospital clinic in Finland
Twenty-two participants were lost to follow-up
 
Interventions Cow's milk elimination diet, extensively hydrolysed formula, and capsules of
microcrystalline cellulose placebo, Lactobacillus GG (10¹º CFUs/d), or
probiotic mix (Lactobacillus GG 10¹º CFUs/d, Bifidobacterium breve Bbi 99 4 × 10⁸
CFUs/d, Lactobacillus rhamnosus LC705 10¹º CFUs/d, and Propionibacterium JS 4 ×
10⁹ CFUs/d). Capsules were mixed with food twice daily
 
Outcomes SCORAD assessed at end of treatment and 4 weeks later*
*Denotes outcomes prespecified for this review
 
Notes Study was supported by Finnish Research foundations and the probiotic supplier. No
information on conflicts of interest
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "Infants were randomised at the first visit according to computer-
generated block randomisation..."




Low risk Adequate: treatment allocated by third party as confirmed by study author
 
Blinding of participants and
personnel (performance bias)
Low risk Participants and clinician blinded as confirmed by study author
 
Blinding of outcome assessment
(detection bias)
Low risk Outcome assessor blinded as confirmed by study author
 
Incomplete outcome data (attrition
bias)
Low risk Analysis was by "treatment received", and 4 participants (1.6%) were
excluded from analysis because they did not tolerate the study formula.
Twenty-two (8.7% to 5.9% in LGG group, 10.6% in probiotic mix group,
and 9.75% in placebo group) losses to follow-up occurred. Unlikely to
have an impact on effect estimate and judged as having low risk of
attrition bias
 
Selective reporting (reporting bias) Low risk No evidence of selective reporting
 
Other bias Unclear risk Study was supported by Finnish Research foundations and the probiotic
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Methods Four-arm parallel-group double-blind randomised placebo-controlled trial conducted
from December 2011 until September 2013
 
Participants 220 children and adolescents from 1 to 18 years of age with moderate to severe atopic
dermatitis (SCORAD > 15) diagnosed according to the criteria of Hanifin and Rajka
with symptoms present for at least 6 months before the study and with atopy as shown
by at least 1 positive skin test (weal size ≧ 3 mm) or 1 positive RAST (IgE ≥ 0.7 kU/L)
test to any common food or environmental allergens. Randomisation was done at a
1:1 ratio: 55 participants were randomised in each arm
Excluded were patients on systemic corticosteroids, immunosuppressive therapy, or
antibiotic or antimycotic treatment 4 weeks before the study, or using antihistamine 3
days before enrolment; and those who used probiotic preparations within 4 weeks
before the study. Also excluded were patients with immune deficiency or other major
medical problems
Setting: secondary paediatric centre
Country: Taiwan
 
Interventions Four intervention arms: first arm received Lactobacillus paracasei GMNL-133 (LP) at a
dose of 2 × 10⁹ CFUs/d. Second arm received Lactobacillus fermentum GM-090 (LF)
at a dose of 2 × 10⁹ CFUs/d. Third arm received Lactobacillus paracasei GMNL-133
(LP) and Lactobacillus fermentum GM-090 (LF) at a dose of 4 × 10⁹ CFUs/d. Fourth
arm received placebo. Interventions were given orally in capsule form for 3 months
During the study, corticosteroids, antibiotics, calcineurin inhibitors, antihistamines, and
other probiotics were not permitted, with the exception of topical corticosteroids
(fluticasone propionate) in case of severe flares and itching. All patients applied
emollients and were educated on skin care
 
Outcomes For AD: SCORAD, Children's Dermatology Life Quality Index (CDLQI) and Family
Dermatology Life Quality Index (FDLQI) at baseline and at 1, 2, 3, and 4 months
Changes in total serum IgE and skin prick test reactivity, serum and urine biomarkers,
and faecal probiotic species composition at baseline and at 3 months
For asthma: GINA guideline asthma severity
 
Notes Trial registration: NCT01635738. Approval by the Ethics Committee of the Taipei
Hospital Ministry of Health and Welfare
GenMont Biotec Inc.: probiotic manufacturer that provided study costs for probiotics.
No information on conflicts of interest
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "Participants were randomised, using computer-generated 4-block
design lists, drawn up by a statistician, with stratification according to age,




Low risk Comment: probably done and judged as having low risk of bias
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "Patients were enrolled by the investigator and sequentially
assigned a patient number connected to a code. Capsules were prepared
and coded by GenMont Biotec Inc, with cGMP facilities and dispensed by
the study nurse" - "All investigators, study nurses and participants were
blind to treatment assignment for the duration of the study"
Judgement: probably done
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "Patients were enrolled by the investigator and sequentially
assigned a patient number connected to a code. Capsules were prepared
and coded by GenMont Biotec Inc, with cGMP facilities and dispensed by
the study nurse" - "All investigators, study nurses and participants were
blind to treatment assignment for the duration of the study"
Judgement: probably done
 
Incomplete outcome data (attrition
bias)
Low risk Quotes: "Finally analysed 100% of LP, 96% of LF, 98% of LP + LF group,
and 96% of placebo" - "Intention-to-treat analysis regardless of
compliance"
Judgement: low risk of attrition bias
 
Selective reporting (reporting bias) Low risk All outcomes reported
 
Other bias Unclear risk GenMont Biotec Inc.: probiotic manufacturer that provided study costs for
probiotics. It is not clear what the role of the sponsor was in data analysis
and publication; hence the study was judged to be at unclear risk of bias
 
Weston 2005
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Methods Eight-week parallel-group block randomised controlled trial
 
Participants Fifty-six children 6 to 18 months of age with moderate/severe eczema diagnosed by
Hanifin and Rajka criteria and modified SCORAD score of at least 25 at enrolment
Randomisation was done at a 1:1 ratio: 28 participants were randomised in each arm.
Those previously exposed to probiotics, currently receiving antibiotics, or with other
major medical problems were excluded
Setting: community and hospital outpatient clinic in Australia
Three participants lost to follow-up
 
Interventions Lactobacillus fermentum VR1-003PCC 2 × 10⁹ CFUs/d as a sachet reconstituted by
parents with 5 to 10 mL water twice daily, or maltodextrin placebo
 
Outcomes • Global self-assessment by parent*
• Dermatitis Family Impact Questionnaire (Lawson 1998)*
• SCORAD*
• Need for other eczema treatment - topical corticosteroid. Assessments made at
baseline and at 2, 4, 8, and 16 weeks*
*Denotes outcomes prespecified for this review
 
Notes One probiotic-treated participant withdrew due to gastrointestinal illness (vomiting)
Funding for principal investigator was provided by Research Fellowship by television
channel and funding for IgE assay by VRI Biomedical. Probiotics and placebo supplied
by manufacturer. No conflicts of interest declared
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "A computerised randomisation schedule was prepared by the
hospital biostatistician with allocation and dispensing of sachets by the
pharmacy department" - "The groups were stratified and block
randomised according to following criteria: (a) modified SCORAD (25-50;
50 and over), (b) current topical corticosteroid potency.... and (c) age..."




Low risk Quote: "A computerised randomisation schedule was prepared by the
hospital biostatistician with allocation and dispensing of sachets by the
pharmacy department. The probiotic and placebo sachets were matched
for size, shape and volume of contents"
Comment: third party involved in the allocation process and interventions
were identical. Judged as adequate for low risk of bias
 
Blinding of participants and
personnel (performance bias)
Unclear risk Quotes: "The probiotic and placebo sachets were matched for size, shape
and volume of contents" - "A SCORAD assessment was also performed
by a clinician blind to the intervention" - "...a single investigator performed
all SCORAD assessments at week 0, 8, and 16"
Comment: outcome assessor clearly stated as blinded and interventions
probably identical. However no other information provided to clarify
whether other personnel and the parents of infants were blinded
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quotes: "The probiotic and placebo sachets were matched for size, shape
and volume of contents" - "A SCORAD assessment was also performed
by a clinician blind to the intervention" - "...a single investigator performed
all SCORAD assessments at week 0, 8, and 16"
Comment: outcome assessor clearly stated as blinded and interventions
probably identical. However no other information provided to clarify
whether other personnel and the parents of infants were blinded, which
may have affected patient/parent-reported outcomes (DFI and global self-
assessment)
 
Incomplete outcome data (attrition
bias)
Low risk Available case analysis was used without exclusions after randomisation.
Low rates of loss to follow-up (5.4% overall; 7.1% in probiotic group and
3.6% in placebo group). Reasons for losses to follow-up presented
Low risk of attrition bias for all outcomes
 
Selective reporting (reporting bias) Low risk No evidence of selective reporting
 
Other bias Low risk No other bias found
 
Woo 2010
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Methods Twelve-week parallel-group randomised double-blind placebo-controlled trial
conducted between January 2007 and August 2008
 
Participants Eighty-eight children between 2 and 10 years of age with atopic eczema-dermatitis
syndrome (AEDS) defined as pruritic chronic or chronically relapsing non-infectious
dermatitis with features and distribution as suggested by Hanifin. Randomisation was
done at a 1:1 ratio: 45 participants were randomised in the intervention arm, and 43 in
the control arm. Participants had to have the disease for at least 6 months, with
SCORAD ≥ 25 and change in SCORAD not more than 10% within the first 2 weeks
Excluded from the trial were patients who had used cyclosporine, systemic
corticosteroids, topical calcineurin inhibitors, or Chinese herbal medicine during the 3
months before recruitment
Recruitment was carried out at a secondary care paediatric unit in Korea
Thirteen participants were lost to follow-up
 
Interventions Probiotic: freeze-dried Lactobacillus sakei KCTC 10755BP in microcrystalline cellulose
dissolved in 2.5 to 5 mL of water or any liquid preferred by the participant at a dose of
5 × 10⁹ CFUs not otherwise specified for 12 weeks
Placebo: microcrystalline cellulose dissolved in 2.5 to 5 mL of water or any liquid
preferred by the participant for 12 weeks
Standardised topical treatment for all participants: take a bath once daily with warm
water for 5 to 10 minutes and apply an emollient immediately after bathing. Permitted
to use topical corticosteroids as required but only 0.1% prednicarbate
 
Outcomes • Total SCORAD and SCORAD part C*
• Amount of topical corticosteroid (TCS) used during the study, change in TCS use
from baseline, and number of participants using TCS during the intervention*
*Denotes outcomes prespecified for this review
 
Notes Research supported by the Basic Science Research Program, National Research
Foundation of Korea
Funded by the Ministry of Education, Science and Technology, Korea. No conflicts of
interest reported
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "patients were randomised in a double-blind design..."




Unclear risk No information given
 
Blinding of participants and
personnel (performance bias)
Unclear risk Quote: "patients were randomised in a double-blind design..."
Comment: inadequate information on which part was blinded and the
method of blinding interventions; inadequate information for a judgement
on risk of bias for blinding
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "patients were randomised in a double-blind design..."
Comment: inadequate information on which part was blinded and the
method of blinding interventions; inadequate information for a judgement
on risk of bias for blinding
 
Incomplete outcome data (attrition
bias)
Low risk All participants were analysed in the group to which they were initially
randomised. 4/45 participants (8.9%) from the probiotic group and 9/43
(21%) from the placebo group were lost to follow-up and were excluded
from analysis. The difference in losses to follow-up in the 2 groups was
found to be statistically insignificant (P = 0.11). Overall losses to follow up
were low (14%)
Comment: judged as low risk for attrition bias
 
Selective reporting (reporting bias) Low risk All outcomes reported
 
Other bias Low risk Baseline characteristics presented only for participants who completed the
study, but low rates of loss to follow-up; hence the study was judged to be
at low risk of bias
 
Wu 2012
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Methods Ten-week parallel-group double-blind randomised placebo-controlled trial
 
Participants Sixty children from 2 to 14 years of age with eczema diagnosed by Hanifin and Rajka
criteria and moderate to severe disease (SCORAD > 25) who had eczema symptoms
for at least 4 days before diagnosis. Randomisation was done at a 1:1 ratio: 30
children were randomised in each arm
Setting: secondary care with 1 recruiting centre in Taiwan
Six participants were excluded post randomisation but before treatment started
 
Interventions Synbiotic: Lactobacillus salivarius PM-A0006 2 × 10⁹ CFUs/25 mgr and fructo-
oligosaccharide 475 mgr in a capsule preparation twice daily




• 13-item quality of life daily diary
• Global eczema severity
• SCORAD parameters for pruritus and sleep loss*
• Frequency of use of topical corticosteroid or calcineurin inhibitor (times/month)*
*Denotes outcomes prespecified for this review
 
Notes Two probiotic-treated participants initially had mild diarrhoea but overall tolerated
treatment well
Sponsorship declared and no conflicts of interest reported
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "The children were randomised into two groups...in a double-blind
manner using a computer-generated blocked randomisation list provided
by ProMD Biotech Co., Taiwan. A block size of four was used and
stratified according to sex, age and diagnosis of moderate to severe AD"




Low risk Quote: "The code was opened only after all data were analysed."
Comment: probably done, so judged as adequate for low risk of bias
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "The synbiotic and prebiotic products, which were identical in
appearance, odour and taste, were delivered in numbered packages
directly to the parents according to randomisation list. The code was
opened only after all data were analysed" - "the same investigator (KGW),
who was blinded to group assignment, enrolled patients and performed all
SCORAD assessments at weeks 0, 4, 8 and 10"
Comment: judged as adequate for low risk of bias
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "The synbiotic and prebiotic products, which were identical in
appearance, odour and taste, were delivered in numbered packages
directly to the parents according to randomisation list. The code was
opened only after all data were analysed" - "the same investigator (KGW),
who was blinded to group assignment, enrolled patients and performed all
SCORAD assessments at weeks 0, 4, 8 and 10"
Comment: judged as adequate for low risk of bias
 
Incomplete outcome data (attrition
bias)
Low risk Six participants (10% in total and in each group) withdrew after
randomisation but before treatment initiation and were excluded from
analysis. Reasons for withdrawal given and similar in both groups
Comment: low rates of excluded patients unlikely to have a significant
impact on effect estimate; hence low risk of attrition bias
 
Selective reporting (reporting bias) Low risk No evidence of selective reporting
 
Other bias Low risk No other bias found
 
Wu 2015
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Methods Eight-week parallel-group 2-centre randomised double-blind placebo-controlled trial
 
Participants Sixty-seven children 4 to 48 months of age with atopic dermatitis diagnosed using
Hanifin-Rajka criteria with SCORAD > 15 at enrolment. Randomisation was done at a
1:1 ratio: 34 participants were randomised in the intervention arm, and 33 in the
control arm
Exclusion criteria: clinically evident infection in skin lesions, severe asthma or acute
asthma attack within 3 months, autoimmune disease, immunodeficiency, exposure to
phototherapy, use of systemic corticosteroids within 1 month
 
Interventions Active: 1 capsule of ComProbi containing 350 mg of Lactobacillus rhamnosus (MP108)
and maltodextrin per day
Control: 1 capsule of maltodextrin per day
If capsule could not be swallowed, parents were instructed to mix the powder in water,
breast milk, milk, or food heated to < 40°C




• Change in SCORAD after 8-week treatment
Secondary
• Change in SCORAD at post-baseline visits
• Frequency and total quantity of corticosteroids used during 8-week treatment
• Comparison of frequency of atopic dermatitis and symptom-free duration
• Comparisong of mean changes from baseline in IDQoL at weeks 4 and 8
• Comparisong of mean changes from baseline on Dermatitis Family Impact




Study registration not given
CY Biotech provided probiotic, but it is not clear whether the company had a role in
study design, data analysis, or interpretation or other aspects of the study. However,
study authors declared no conflicts of interest
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)




Unclear risk No information provided
 
Blinding of participants and
personnel (performance bias)
Unclear risk Study stated as "double-blind", but no information provided to explain
who was blinded and how blinding was done
 
Blinding of outcome assessment
(detection bias)
Unclear risk Study stated as "double-blind", but no information provided to explain
who was blinded and how blinding was done
 
Incomplete outcome data (attrition
bias)
Low risk 3 (9%) from the probiotic arm and 1 (3%) from the control arm
Study authors present data derived from intention-to-treat analysis
 
Selective reporting (reporting bias) Unclear risk All predefined outcomes were at least described, but not all data were
given. No clinical trial registration was given
 
Other bias Unclear risk CY Biotech provided probiotic, but it is not clear whether the company
had a role in study design, data analysis or interpretation, or other
aspects of the study. However study authors declared no conflict of
interest
Hence we judged the study to be at unclear risk of commercial bias
 
Yang 2014
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Methods Six-week parallel-group double-blind placebo-controlled randomised trial conducted
between November 2010 and October 2011
 
Participants One hundred children from 2 to 9 years of age with mild to moderate (SCORAD < 40)
atopic dermatitis diagnosed according to the criteria of Hanifin and Rajka were
recruited. Randomisation was done at a 1:1 ratio: 50 participants were randomised in
each arm
Exposure to commercial probiotic products during the 4 weeks before the study
Premature children and those receiving antibiotic, systemic corticosteroid,
immunosuppressive, or Chinese herbal therapies within 4 weeks before enrolment
were excluded form the study. Also excluded were patients with acute gastrointestinal
infection, chronic underlying disease, or baseline factors predisposing to infection (e.g.
neurological disease; metabolic disease; chronic respiratory disease; congenital
anomaly of the heart, gastrointestinal system, or lung; known or suspected
immunodeficiency)
Recruitment took place at a tertiary paediatric centre in Korea
Twenty-nine participants were lost to follow-up
 
Interventions Probiotic mixture: Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus
plantarum, Bifidobacterium lactis in glucose anhydrous crystalline powder derived from
cornstarch prepared in warm water or juice given orally immediately after meals twice
daily at a dose of 1 × 10⁹ CFUs of each probiotic strain for 6 weeks
Control (placebo): glucose anhydrous crystalline powder prepared in warm water or
juice given orally immediately after meals twice daily for 6 weeks
Instructions given to stop topical corticosteroids and calcineurin inhibitors, oral
antihistamines, and any commercial probiotic-containing products 2 weeks before
study initiation
Parents were trained in appropriate bathing and skin care practices and were given
instructions on application of emollients
 
Outcomes • EASI score at baseline and end of treatment and change from baseline*
• VASP score at baseline and end of treatment and change from baseline*
*Denotes outcomes prespecified for this review
 
Notes Study sponsored by the probiotic supplier; the supplier's role in data analysis and
publication is unclear
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "Randomisation software was used to randomly allocate
children..."





Low risk Comment: third party - not involved in the trial - allocated treatment. Study
judged as adequate for low risk of bias
 
Blinding of participants and
personnel (performance bias)
Unclear risk Quote: "The probiotics mixture and placebo controls were identical in
colour, taste, smell, packing and manner of administration. All
formulations were dispensed by a pharmacist not associated with the
study.", "both investigators and study subjects were blinded to the identity
of the intervention"
Comment: not clear if clinicians were blinded; patients were blinded;
judged as having unclear risk of bias
 
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "The probiotics mixture and placebo controls were identical in
colour, taste, smell, packing and manner of administration. All
formulations were dispensed by a pharmacist not associated with the
study" - "both investigators and study subjects were blinded to the identity
of the intervention"
Comment: not clear if outcome assessor was blinded; judged as having
unclear risk of bias
 
Incomplete outcome data (attrition
bias)
High risk Available case analysis but high rates of loss to follow-up (29%: 26% in
probiotic group and 32% in placebo group), which were excluded from
analysis
Comment: effect estimate for all outcomes may have been affected;
judged as having high risk of attrition bias
 
Selective reporting (reporting bias) Low risk No evidence of selective reporting
 
Other bias Unclear risk Study sponsored by the probiotic supplier, and the supplier's role in data
analysis and publication is unclear. Therefore the study was judged to be
at unclear risk of bias
 
Yesilova 2012
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Methods Eight-week parallel-group double-blind randomised placebo-controlled trial
 
Participants Forty children 1 to 13 years of age with atopic dermatitis diagnosed according to
Hanifin and Rajka criteria and with moderate to severe disease. Randomisation was
done at a 1:1 ratio: 20 participants were randomised in each arm. Excluded were
patients on medication including antihistamines and corticosteroids for 14 days before
recruitment, as well as those with malabsorption. One participant was lost to follow-up
 
Interventions Probiotic mixture: Bifidobacterium bifidum, Lactobacillus acidophilus, Lactobacillus
casei, Lactobacillus salivarius given orally at a dose of 2 × 10⁹ CFUs and a total daily
dose of 4 × 10⁹ CFUs for 8 weeks
Placebo: skim milk powder and dextrose
 
Outcomes SCORAD at baseline and at 8 weeks*
*Denotes outcomes prespecified for this review
 
Notes Conflicts of interest/sponsorship not declared
 
Risk of bias table
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Quote: "The patients were referred to a nurse who was involved in the
study to receive either probiotic or placebo. The nurse randomised each
patient to two different treatment groups using the closed-envelope
method"
Comment: not clear how the "closed envelopes" had been created and
whether the sequence generation had been random. Judged as having




Low risk Quote: "Closed envelope method"
Comment: probably done; judged as adequate for low risk of bias
 




Quote: "The patients were referred to a nurse who was involved in the
study to receive either probiotic or placebo. The nurse randomised each
patient to two different treatment groups using the closed-envelope
method. The authors had no role in the treatment decision and were
blinded to the treatment groups"
Comment: inadequate information provided on which parts were blinded
and whether the interventions were identical. Judged as having unclear
risk of bias
 




Quote: "The patients were referred to a nurse who was involved in the
study to receive either probiotic or placebo. The nurse randomised each
patient to two different treatment groups using the closed-envelope
method. The authors had no role in the treatment decision and were
blinded to the treatment groups"
Comment: inadequate information on which parts were blinded and
whether interventions were identical. Judged as having unclear risk of bias
 
Incomplete outcome data (attrition
bias)
Low risk One participant from the placebo group was lost to follow-up (2.5%).
Available case analysis was used. Very few losses to follow-up were
unlikely to affect the effect estimate for any outcome
 
Selective reporting (reporting bias) Low risk All outcomes reported. Differences between probiotic and placebo not
given but reported narratively: "Our results demonstrated an improved
SCORAD index in both groups, but with higher levels in the probiotic group
(65%) than in the placebo group (46%). In the probiotic group, a greater
decrease of SCORAD index scores was shown after treatment in patients





Conflicts of interest/sponsorship not declared
Baseline characteristics of 2 groups not given. Uncertain if they were
matched
Judged to be at uncertain risk of other bias
 
Yoshida 2010
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Methods Eight-week parallel-group placebo-controlled trial
 
Participants Twenty-four adults with atopic dermatitis diagnosed according to the Guideline for
Management of AD by the Japanese Dermatological Association were recruited and
randomised at a 2:1 ratio of intervention:control (16 participants in intervention arm/8
participants in control arm)
Recruitment took place in a centre in Japan
No participants were lost to follow-up
 
Interventions Probiotic: Bifidobacterium breve (lyophilised powder of live B breve YY) in a capsule
preparation at a dose of 1.0 × 10¹º CFUs/capsule taken twice daily after breakfast and
after dinner for 8 weeks
Placebo not described
 
Outcomes • SCORAD: total, objective, subjective*
• Japanese version of Skindex-29*
*Denotes outcomes prespecified for this review
 
Notes Sponsorship was not declared, but 2 of the authors of the report are linked to the
supplier of the probiotic
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "Test meals for 24 subjects were randomly allocated..."




Unclear risk No information given
 
Blinding of participants and
personnel (performance bias)
Unclear risk No information given
 
Blinding of outcome assessment
(detection bias)
Unclear risk No information given
 
Incomplete outcome data (attrition
bias)
Low risk No losses to follow-up. All participants analysed
 
Selective reporting (reporting bias) Low risk No evidence of selective reporting
 
Other bias High risk Selection bias: baseline SCORAD scores not matched between the 2
groups
Commercial bias: sponsorship not declared but 2 of the authors of the
report linked to the supplier of the probiotic; this may have affected the
outcome




AEDS: atopic eczema-dermatitis syndrome.
BPD: bronchopulmonary dysplasia.
CDLQI: Children's Dermatology Life Quality Index.
CFU: colony-forming unit.
cGMP: cyclic guanosine monophosphate.
DFI: Dermatology Family Impact.
DLQI: Dermatology Life Quality Index.
EASI: Eczema Area Severity Index.
FDLQI: Family Dermatology Life Quality Index.
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RSV: respiratory syncytial virus.
SCORAD: Severity Scoring of Atopic Dermatitis.
TCS: topical corticosteroid.
TS: topical steroid.
VAS: visual analogue scale.
VASP: Visual Analogue Scale of Pruritus.
Characteristics of excluded studies 
Arkwright 2003
Reason for exclusion Intradermally given probiotic
 
Arvola 2006
Reason for exclusion Participants did not have eczema
 
Aryayev 2006
Reason for exclusion Not an RCT. Only a quasi-RCT
 
Burk 2013
Reason for exclusion Not all participants had eczema
 
Chernysov 2009
Reason for exclusion Not an RCT. Quasi-RCT
 
Foekel 2009
Reason for exclusion Not a trial on probiotics. Unpasteurised mare's milk trial
 
Gueniche 2008
Reason for exclusion Topical intervention
 
Ikezawa 2004
Reason for exclusion Intervention was not a probiotic
 
Kalliomaki 2003
Reason for exclusion Participants did not have eczema
 
Laitinen 2005
Reason for exclusion Not a study of changes in eczema symptoms or severity. Follow-up of a study on
probiotics for prevention, not treatment, of allergies
 
Leung 2004
Reason for exclusion Intervention was not a probiotic
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Matsumoto 2007
Reason for exclusion Control is also a probiotic. Exclusion criteria in protocol
 
Moroi 2011
Reason for exclusion Heat-killed bacteria. Not live micro-organisms; exclusion criteria in protocol
 
Murosaki 2006
Reason for exclusion Heat-killed bacteria. Not live micro-organisms; exclusion criteria in protocol
 
Ogawa 2006




Reason for exclusion Not all participants had eczema
 
Rose 2010
Reason for exclusion Not all participants had eczema
 
Shibata 2009
Reason for exclusion Not a probiotic - a prebiotic only
 
Torii 2011
Reason for exclusion Heat-killed bacteria. Not live micro-organisms; exclusion criteria in protocol
 
Footnotes
RCT: randomised controlled trial.
Characteristics of studies awaiting classification 
ACTRN12605000615684
Methods Eight-week parallel-group randomised placebo-controlled trial
 
Participants Children from 6 months to 12 years of age with eczema and SCORAD > 15
Inclusion criteria: guardians proficient in English. Not previously actively treated with





Interventions Probiotic: Lactobillus GG 3 × 10⁸ to 1 × 10⁹ CFUs twice daily for 8 weeks vs placebo
 
Outcomes SCORAD at 0, 8, and 16 weeks.
 
Notes ACTRN12605000615684. Unknown current status
 
Candy 2016
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Methods Eight-week prospective randomised multi-centre double-blind controlled study
 
Participants Seventy-one full-term infants with suspected non-IgE-mediated cow's milk allergy (36
infants in control group, 35 in active group)
Cow's milk allergy participants presented predominantly with gastrointestinal
symptoms, and 10% with dermatological symptoms
Country: Netherlands
 
Interventions Active: amino acid-based formula (AAF) with synbiotics designed for dietary
management of cow's milk allergy (prebiotic: chicory-derived neutral oligofructose,
long-chain inulin 9:1 ratio, and concentration 0.63 g/100 mL; probiotic: Bifidobacterium
breve M-16V at a concentration 1.47 × 10⁹ CFUs/100 mL formula)
Control: commercially available formula with AAF only
Intake/instructions: participants were instructed to consume a minimum, age-specific,
daily formula intake from the end of week 2 (infants 0 to 6 months of age, 500 mL; 6 to
8 months of age, 450 mL; and 49 months of age, 350 mL)
Duration of intervention: 8 weeks
 
Outcomes Primary
Bifidobacteria and Eubacterium rectale/Clostridium coccidioides (ER/CC) cluster as
percentage of total faecal bacteria determined by fluorescent in situ hybridisation at
8 weeks
Secondary
SCORAD at 0 and 8 weeks
Parents' diary data on (allergic) symptoms and stool characteristics at weeks 0 and
8
Secretory IgA and short-chain fatty acids (SCFAs) in stool samples at 0 and 8
weeks. Same data collected also from reference group of non-randomised healthy
breastfed infants age-matched with infants with cow's milk allergy at week 8 of
intervention
 
Notes Trial acronym: ASSIGN-1
Register: NTR3979 (Netherlands Trial Register)
Funding/Sponsor: Nutricia Research BV
Contact: Willemien Sinke; willemien.sinke@nutricia.com
 
Hulshof 2017
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Methods Randomised double-blind controlled trial
 
Participants 31 infants with objective SCORAD (score > 20; moderate to severe atopic dermatitis)
up to and including 11 months of age, with elevated total IgE or specific IgE levels, or
both, were included (n = 31)
Country: Netherlands
 
Interventions Synbiotic: extensively hydrolysed whey-based formula with mixture of short-chain
galacto-, long-chain fructo-oligosaccharides (scGOS/lcFOS, ratio 9:1) and
Bifidobacterium breve M-16V (active) at a dose of 1.0 × 10⁹ CFUs/g
Control: extensively hydrolysed whey-based formula
Duration of intervention: 4 months
 
Outcomes Severity of atopic dermatitis and correlation to serum chemokines
Objective SCORAD at 0 and 4 months
Chemokines: Th2 chemokines (CCL17, CCL20, and CCL22); Th1 chemokine
(CXCL9) at 0 and 4 months
 
Notes Study presented at Conference
Registered in the Dutch Trial Register: NTR3447
 
NCT02585986
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Methods Randomised double-blind placebo-controlled clinical trial
 
Participants Children of both genders between 4 and 17 years of age. Estimated enrolment: 50.
Country: Spain
Inclusion criteria:
4 to 17 years of age
Diagnosis of atopic dermatitis according to Hanifin and Rajka diagnostic criteria for
atopic dermatitis
SCORAD score ranging from 20 to 40
Using topical corticosteroids to treat atopic dermatitis flare-ups
Parent or legal representative has signed informed consent. If the patient is 12




Women of childbearing age who do not make a commitment to use any effective
contraceptive method
Phototherapy treatments for atopic dermatitis
Systemic corticoid therapy in the last 2 months
Immunosuppressive or cytostatic treatment in the last 2 months
Probiotic treatment in the last 2 months
Systemic antibiotic in the last 4 months
Fever (axillary temperature > 37°C or equivalent)
Severe allergic disease
Immunodeficiency or cancer-related processes
Other dermatological pathologies that could make the atopic dermatitis evaluation
difficult, or that require continued use of topical corticosteroids
Any contraindication to any product or drug used during the trial, according to
technical files
Participation in any drug clinical trial in the last 3 months
 
Interventions Dietary supplement: probiotic - daily intake of 1 capsule. Freeze-dried powder: 10⁹
CFUs of Bifidobacterium lactis CECT 8145, Bifidobacterium longum CECT 7347,
and Lactobacillus casei CECT 9104 and maltodextrin
Dietary supplement: placebo - daily intake of 1 capsule containing maltodextrin
Duration of intervention: 12 weeks
 
Outcomes Primary outcome measures
Time of use of topical corticosteroids (time frame: 12 weeks)
Variation in SCORAD score during treatment (time frame: 12 weeks)
Secondary outcome measures
Variation in the Global Clinical Impression (CGI) score during treatment (time
frame: 12 weeks)
Exposure to other treatments (time frame: 12 weeks)
Duration of treatment with systemic corticosteroids or antihistamine drugs
Side effects due to treatment in 2 treatment arms (time frame: 12 weeks)
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Methods Randomised double-blind placebo-controlled trial
 
Participants 22 children 0 to 14 years of age (12 probiotic and 10 placebo) with mild to moderate
atopic dermatitis meeting the Hanifin-Rajka diagnostic criteria. New outpatients from
the clinic at the Allergy Immunology Division of the Dermatology and Venereology
Department, Faculty of Medicine, Indonesia. Participants had to have age-related total
serum IgE levels: 10 to 15 years > 200 IU/mL, 6 to 9 years > 90 IU/mL, 1 to 5 years >
60 IU/mL, < 1 year > 1.5 IU/mL. Participants had to be in apparent good health and
willing to participate in the study, and had to sign informed consent
Exclusion criteria: use of systemic corticosteroids or phototherapy in the previous
month, systemic immunosuppressive drugs in the previous 3 months, probiotic use in
the previous 4 weeks, use of topical medications such as corticosteroids or calcineurin
inhibitors in the previous week, immunosuppressive conditions or other serious
disease, clinical skin disease, and other systemic disease
Country: Indonesia
 
Interventions Intervention: microencapsulated L plantarum IS-10506 at a dose of 10¹º CFUs/d
Control: placebo; skim milk - Avicel
Duration: 12 weeks
 
Outcomes SCORAD score at 0, 2, 8, and 14 weeks





AAF: amino acid-based formula.
CC: Clostridium coccidioides.
CFU: colony-forming unit.





SCFA: short-chain fatty acid.
SCORAD: Severity Scoring of Atopic Dermatitis.
Characteristics of ongoing studies 
ChiCTR1800015330
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Study name Study on the effect and mechanism of probiotics on patients with atopic dermatitis
 
Methods Randomised parallel controlled trial with 4 intervention groups
 
Participants Participants randomised in 4 groups. Aim is to recruit 30 participants in each group
Inclusion criteria: meet the diagnostic criteria of Hanifin and Rajka; from 7 to 60 years
old; have not taken probiotics (such as lactic acid bacteria, bifidobacteria, etc.)
yoghourt, beverages, etc. (in the past 2 months, adherence to requirement of taking
probiotic productions for 2 months, co-operation with survey and collection of blood
samples, faeces, and other biological samples); volunteers who sign informed consent
Exclusion criteria: pregnant or lactating women; short-term or long-term use of
antibiotics, accompanied by diabetes, cardiovascular disease, history of malignant
disease complications, and any other interference with results of tests evaluating skin




Bifidobacterium F35 (dose: 10⁹)
















Starting date Date of registration: 23/03/2018. Prospective registration
 
Contact information Wenwei Lu; Tel: +8618762691080; email: luwenwei@jiagnan.edu.cn
1800 Lihu Avenue, Binhu District, Wuxi, Jiangsu, China
 
Notes Open for recruitment
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Study name A study to observe if probiotics supplementation is helpful in atopic dermatitis in
children
 
Methods Phase III randomised placebo-controlled parallel-group trial. Blinded investigator.
Randomisation computer generated
 
Participants Children of both genders, from 6 months to 12 years of age who have atopic dermatitis
of any severity diagnosed based on the Hanifin and Rajka criteria
Exclusion criteria: immunocompromised children; children with severe kidney, liver, or
systemic disease; other ages
Target sample size = 114
 
Interventions Probiotics and placebo. No other information available
 
Outcomes Primary outcomes
Mean difference in SCORAD among children with atopic dermatitis treated with
conventional treatment plus probiotic supplementation vs conventional treatment
alone at 0, 12, and 24 weeks
Mean difference in the numbers of days of treatment required to achieve 90%
reduction in SCORAD among children with atopic dermatitis treated with
conventional treatment plus probiotic supplementation vs conventional treatment
alone
Number of children with atopic dermatitis who relapse after stoppage of treatment
at 24 weeks
Secondary outcomes
Comparison of IL-17 level in treatment vs control at 0 and 12 weeks
Comparisong of CDLQI and IDLQI at baseline and at 12 and 24 weeks
 
Starting date Date of first enrolment: 02/07/2016
 
Contact information Professor Sanjeev Handa, Professor of Dermatology, Venereology, and Leprology
handa_sanjeev@yahoo.com
Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh
160012, India
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Study name Probiotics in treatment of atopic dermatitis in children
 
Methods Double-blind randomised placebo-controlled parallel-group trial. Computer-generated
randomisation
Method of allocation concealment: sequentially numbered, sealed, opaque envelopes
 
Participants Children with atopic dermatitis of both genders, from 6 months to 18 years of age,
attending JIPMER Paediatrics or Dermatology. Target sample size = 108
Exclusion criteria: children with acute gastrointestinal infection; children with chronic
underlying disease on immunosuppressive therapy; children with known or suspected
immunodeficiency; children on prolonged antibiotic and antituberculous therapy;
children who are included in other studies
 
Interventions Probiotic: Lactobacillus rhamnosus GG. Dose: 10 billion CFUs/capsule or sachet/d for
3 months
Control: placebo: anhydrous glucose powder
Both groups receive also standard treatment
 
Outcomes Primary outcome
Decrease in SCORAD index (weekly assessment after start of treatment)
Secondary outcomes
Changes in skin microflora assessed by skin cultures
Changes in IgE antibody titres measured by IgE ELISA kits
Change in absolute eosinophil counts
Alteration in gut microflora assessed by stool cultures and demonstrated presence
of Lactobacillus
Time point for secondary outcomes: 1 year
 
Starting date 01/11/2017. Registered as not recruiting yet
 
Contact information Dhayalini RK; dhayaliniraj22@gmail.com
Department of Pediatrics (OPD 165) and Department of Dermatology (OPD 72),






Sponsorship: JIPMER Hospital and Research Institution
 
KCT0000914
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Study name IRT5 probiotics atopic dermatitis
 
Methods Phase III 8-week parallel-group randomised double-blind placebo-controlled clinical
trial
 
Participants Children 5 to 12 years of age with atopic dermatitis, SCORAD score between 25 and
50, and continuous or intermittent symptoms of atopic dermatitis over 6 months.
Target sample size = 110 participants; 55 in each group
Other inclusion criterion: signs informed consent form with a legal representative
before participating in the study
Exclusion criteria
Other systemic illnesses or dermatitis history except AD
Receiving immunosuppressants, antibiotics, corticosteroids, antihistamines within 4
weeks
Has taken medicines, Chinese medicine, health functional foods within 4 weeks for
improvement of atopic dermatitis
Systemic phototherapy within 1 month
Probiotics within 2 weeks
Scheduled to participate in another study during this study period or participated in
other study within 4 weeks
Inappropriate for participation as decided by investigator
 
Interventions Probiotic: IRT5 probiotics, 1 × 10¹º CFUs/sachet, to be taken orally 1 sachet per day
for 8 weeks
Placebo group: lactose, to be taken orally 1 sachet per day for 8 weeks
 
Outcomes Primary
SCORAD score at baseline and at 6 and 12 weeks
Secondary
Immunoglobulin A
Skin condition measurement (moisture, skin oil, skin-ph-meter) at baseline and at 6
and 12 weeks
Eosinophil, total IgE, eosinophil cationic protein at baseline and at 12 weeks
 
Starting date Date of first enrolment: 06/11/2013
 
Contact information Professor Kim Beom Jun, CHUNG-ANG University, Korea
 
Notes Registration: KCT0000914. Current status: recruiting. No updates to the registry since
2013




#102 Probiotics for treating eczema
93 / 151
Study name Trial on effectiveness of combined probiotics in atopic dermatitis in children
 
Methods Phase IV randomised parallel-group double-blind placebo-controlled clinical trial
 
Participants Children of both genders older than 6 months up to 19 years of age
Inclusion criteria
Clinical diagnosis of atopic dermatitis
Children over 6 months of age
Teens younger than 19 years
Exclusion criteria
Diagnostic presence or clinical signs suggesting acute or chronic skin disease, as
well as pertinent to the study, which may affect the outcome of the research
Using drugs that can affect systemically the course of the disease, such as
systemic corticosteroids and immunosuppressants, for at least 30 days
Allergy or severe adverse reactions attributable to administration of the probiotic
Non-adherence to treatment (i.e. not regular use, as prescribed) for at least 1
continuous month
Lack of attendance for more than 50% of ratings (clinical and/or laboratory) to be
held during the search
Patient's request (or responsible party's request)
 
Interventions Probiotic: probiotic comprising the mixture of strains: Lactobacillus rhamnosus, 
Lactobacillus acidophilus, Lactobacillus paracasei, and Bifidobacterium lactis, at a
dose of 1 gram sachet, once a day for 6 months (drug: Probiatop)
Control: placebo or maltodextrin in sachet once a day for 6 months
 
Outcomes Primary outcome measures
SCORAD (time frame: 1 year)
Change from baseline in SCORAD every 3 months for 1 year
Secondary outcome measures
Skin prick test (immediate awareness) (time frame: 1 year)
Inflammation composite (time frame: 1 year): γ-IFN, IL-1β, IL-4, IL-6, IL-8, and
tumour necrosis factor
Immune tolerance composite (time frame: 1 year): IL-10, TGF-β, and IL-17
Total serum IgE (time frame: 1 year)
 
Starting date August 2015, with provisional completion date July 2017
 
Contact information Contact: Paula Albuquerque, MD; 5516981329192; paula_albuquerque@usp.br
 
Notes Registration: NCT02519556 (ClinicalTrials.gov)
Country: Brazil. Sponsor: Casa Espirita Terra de Ismael. Estimated primary completion
date: July 2017. Currently enrolling by participant invitation only
 
NCT02945683
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Study name ATOPIA-D3: effects of Lactobacillus reuteri plus vitamin D3 in children with atopic
dermatitis
 
Methods Randomised double-blind placebo-controlled clinical trial
 
Participants Children of both genders, 1 to 4 years of age with diagnosis of atopic dermatitis.
Recruitment target: 88 participants
Inclusion criteria
Diagnosis of atopic dermatitis of mild to moderate grade (SCORAD 25 to 50)
Signature of informed consent from both parents or from a legal representative
Exclusion criteria
Presence of autoimmune disease, immunodeficiency, inflammatory bowel disease,
cystic fibrosis, metabolic disease
Use of immunosuppressive drugs and/or systemic corticosteroids in the previous 2
months
Use of antibiotics in the last 4 weeks
Use of probiotics and/or prebiotics in the last 2 weeks
Use of vitamin D in the last 4 weeks
Participation in other clinical trials
 
Interventions Dietary supplement/active comparator: Reuterin D3 Lactobacillus reuteri DSM
17938 (10E8 CFU in 5 drops), vitamin D3 (400 IU in 5 drops), sunflower oil,
medium-chain triglycerides, silicon dioxide. Participants should take 10 drops once
a day during meals for 3 months
Dietary supplement/placebo comparator: placebo sunflower oil, medium-chain
triglycerides, silicon dioxide. Participants should take 10 drops once a day during
meals for 3 months
 
Outcomes Primary outcome
SCORAD improvement (time frame: 3 months). Improvement in SCORAD
compared to baseline
Secondary outcomes
Vitamin D levels increased (time frame: 3 months). Increase in levels of vitamin D
compared to baseline
LL-37 levels increased (time frame: 3 months). Increase in levels of cathelicidin
compared to baseline
Changes in the faecal microflora (time frame: 3 months). Changes in the faecal
microflora compared to baseline
QoL improvement (time frame: 3 months). Improvement in child's quality of life
 
Starting date February 2015
 








CDLQI: Children's Dermatology Life Quality Index.
CFU: colony-forming unit.
ELISA: enzyme-linked immunosorbent assay.
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QoL: quality of life.
SCORAD: Severity Scoring of Atopic Dermatitis.
TGF: transforming growth factor.
Summary of findings tables
1 Summary of findings
Comparison: probiotics vs no probiotics for treating eczema
Patient or population: male and female patients 0 to 55 years of age with physician-diagnosed eczema
Settings: primary or secondary care. Europe: 22 studies with 1390 participants. Asia: 8 studies with 500 participants.
Australasia: 2 studies with 116 participants
Intervention: probiotics ± prebiotics
Comparison: no probiotics



















(SCORAD part C) at the end of
active treatment 
Visual analogue scale for itch
and sleep disturbance ranging
from 0 to 10 for each symptom
and combined ranging from 0
to 20. The higher the score,
the more severe the symptoms
Duration of follow-up from
baseline until end of active







from 2 to 7.9
Mean SCORAD part
C score in the
intervention groups
was 0.44 points


















probiotic strains for this




global change in eczema
symptoms at the end of active
treatment (binary outcome)
Change in risk for
worsened/unchanged eczema
Duration of follow-up from
baseline until end of active
treatment from 6 weeks to 3
months















300 per 1000 146 per 1000
(57 to 330)
Medium-risk population
400 per 1000 210 per 1000
(85 to 434)
High-risk population
500 per 1000 286 per 1000
(123 to 535)





participant quality of life score
at the end of active treatment
Scales used: DLQI, IDQoL,
Skindex-29, CDLQI. On those
scales, the higher the score,
the more severely the quality
of life is affected
Duration of follow-up from
baseline until end of active



























family quality of life score at
the end of active treatment
Scale used: DFI, FDLQI. On
those scales, the higher the
score, the more severely the
quality of life is affected
Duration of follow-up from
baseline until end of active


























Secondary outcome 4: global
eczema severity score (total
SCORAD) at the end of active
treatment (Investigator-rated
eczema severity)
Scale used: total SCORAD
ranging from 0 to 103. The
higher the score, the more
severe the disease
Duration of follow-up from
baseline until end of active






























Duration of follow-up from
baseline until end of active
treatment from 8 weeks to 3
months








number of events were
included in this analysis
0 per 1000 0 per 1000(0 to 0)
Medium-risk population
100 per 1000 154 per 1000(90 to 263)
High-risk population
200 per 1000 308 per 1000(180 to 526)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The
corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative
effect of the intervention (and its 95% CI).
CDLQI: Children's Dermatology Life Quality Index; CI: confidence interval; DFI: Dermatitis Family Impact; DLQI:
Dermatology Life Quality Index; FDLQI: Family Dermatology Life Quality Index; IDQoL: Infant Dermatitis Quality of Life; OR:
odds ratio; RR: risk ratio; SCORAD: Severity Scoring of Atopic Dermatitis.
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GRADE Working Group grades of evidence.
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may
change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is
likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
Footnotes
aDowngraded by one level due to inconsistency as there was significant heterogeneity among studies (I² = 57%).
bDowngraded by two levels due to small number of studies for this outcome (imprecision) and because of moderate levels of
heterogeneity among studies (I² = 48%).
cDowngraded by two levels due to small number of studies for this outcome (imprecision) and because of significant levels of
heterogeneity among studies (I² = 68%).
dDowngraded by three levels due to inconsistency (one level) as there was significant heterogeneity among studies (I² =
57%) and because of very small number of studies (imprecision) for this outcome (two levels).
eDowngraded by two levels because of extreme levels of heterogeneity among studies (I² = 79%) and because of evidence
of reporting bias.
fDowngraded by two levels because of small number of studies reporting adverse events and small number of events in the
meta-analysis for this outcome (imprecision).
Additional tables 
1 Terms used to categorise trial participants with eczema
Forms of eczema included Forms of eczema excluded
Atopic eczema Seborrhoeic eczema
Atopic dermatitis Contact eczema
Besnier's prurigo Allergic contact eczema
Neurodermatitis atopica (German) Irritant contact eczema
Flexural eczema/dermatitis Discoid/nummular eczema
Periorbital eczema Asteatotic eczema
Childhood eczema Varicose/stasis eczema
Infantile eczema Photo-/light-sensitive eczema
'Eczema' unspecified Chronic actinic dermatitis
Constitutional eczema Dyshidrotic eczema
Endogenous eczema Pompholyx eczema
Chronic eczema Hand eczema
Neurodermatitis Frictional lichenoid dermatitis




2 Non-parametric analyses of SCORAD scores
  Isolauri 2mo LGG Isolauri 2mo Bb12 Isolauri 2mo placebo
N 9 9 9
Median1 0 13.4
IQR 0.1 to 8.7 0 to 3.8 4.5 to 18.2
Footnotes
IQR: interquartile range.
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SCORAD: Severity Scoring of Atopic Dermatitis.
3 Other parameters for quality assessment of included studies
Study Clarity of methods Compliance Dietary management
Brouwer
2006
Clear No compliance measures described Adequate exclusion of other
probiotics during the study
Cukrowska
2008
Total daily dose of intervention clear,
but individual dose, frequency, and
mode of administration not given
No compliance measures reported Not stated
Drago 2012 Clear Dose count (returned sachet packets
counted by clinical investigator).
Compliance measured for the 2 groups:
84.5% and 84.7%. No significant
difference
Clear instructions given: no
change in usual diet but avoid
any type of fermented food
containing live micro-
organisms
Drago 2014 Clear No information provided No information provided
Farid 2011 Aims and Interventions clear.
Outcomes not clear and baseline
severity (SCORAD) not given
No information given Inadequate information
Flinterman
2007
Aims, interventions clear Inadequate information Inadequate information
Folster-Holst
2006
Clear No compliance measures reported Not stated
Gerasimov
2010
Total daily dose of probiotics not
clear. Remaining methods clear
Compliance checked from the parental
report and the weight of remaining
powder. Reported that there were no
differences in compliance between the 2
groups
No information on adequate
exclusion of other probiotics
from the diet. Participants with
challenge proved milk or egg
allergy followed milk or egg
elimination diet, respectively
Goebel 2010 Clear Compliance based on count of remaining
capsules: average 94% for all groups and
93.6%, 95%, and 93.3% for
Bifidobacterium, Lactobacillus, and
placebo groups, respectively. No
significant difference in compliance
between the 3 groups (P = 0.6). No
participating child had compliance lower
than 72%
No information given
Gore 2011 All methods clear
Reporting of adverse events
suggests that these were the result
of the change in formula but the
numbers are totals from intervention
and control groups, and it is not
certain whether the AEs are
associated with the formula or the
probiotics
No compliance measures reported Instructions given that other
fermented or probiotic-




Inadequate information available No information No information
Gruber 2007 Unclear what the placebo was;
otherwise clear
92.5% of doses taken by probiotic group;
94.4% by placebo group
Not stated, other than
encouragement to avoid
allergens
Guo 2015 Dose and exact consistency of
probiotics unclear
No information No information
Han 2012 Preparation of the intervention not
clear. Otherwise clear
No compliance measure described Clear instructions not to
consume fermented food and
products containing live micro-
organisms
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Study Clarity of methods Compliance Dietary management
Hol 2008 Trial designed to study effects of
probiotics in participants with cow's
milk allergy. Effects of probiotics on
eczema - secondary outcome. Aims,
interventions, and outcome
measures clear
Compliance measure not presented. "To
optimise compliance, participants were
supplied with study formula through the
study team and batches were delivered at
home"
No information provided
Iemoli 2012 Clear Method: count of return sachets.
Reported that compliance was similar in
the 2 groups but no measures reported
Instructions given so that
participants do not change
their diet during trial but
should avoid fermented food
products containing live micro-
organisms
Isolauri 2000 Unclear - dose and duration of
probiotic treatment received not
clearly described. Severity of
participant eczema at baseline not
described
No compliance measures reported Not stated
Ivankhnenko
2013
Placebo not described. Otherwise
methods clear
No compliance measures reported Not stated
Kirjavainen
2003
Unclear - intended duration of study
treatment not stated
No compliance measures reported Not stated
Lin 2015 Exact dose of probiotics not given No information provided No information provided
Majamaa
1997
Unclear - precise dose of probiotic
received by participants not stated
No compliance measures described Not stated
Matsumoto
2014
Clear No information provided Clearly stated: "All patients
were asked to avoid probiotic
supplements, fermented milk,






Clear No compliance measures reported Not stated
Passeron
2006
Clear No compliance measures described Not stated
Roessler
2007
Clear No compliance measures described Adequate exclusion of
prebiotics and probiotics 3
weeks before the start and




Clear No compliance measures described Adequate exclusion of other
probiotics during study
Shafiei 2011 Intervention type not clear: synbiotic
mixture of 7 strains of probiotics and
fructo-oligosaccharide. Dose,
frequency of intake, and preparation
clear
Baseline characteristics given only
for participants who completed the
trial
No compliance measures reported Unclear. Stated that
participants did not change
diet before or during the trial




Clear No compliance measures described Not stated
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Study Clarity of methods Compliance Dietary management
Van der Aa
2010
Clear No compliance measures reported.
Participants' parents were keeping diary
for formula intake and adverse events.
Formula with intervention was given on
demand and at the end of intervention.
No significant differences in formula




Method for diagnosing eczema not
described
No compliance measures described Not stated
Wang 2015 All clear. In the publication, not clear
what the placebo was, but this was
clarified by the study author




Weston 2005Clear Sachet counts and parent-completed
sachet administration chart. Good
compliance (94%) - no differences
between the 2 groups
Adequate exclusion of other
probiotics during study
Woo 2010 Clear No measure of compliance was reported,
but it was stated that the 2 groups had no
difference in compliance
No information provided
Wu 2012 Aims, interventions, and outcome
measures clear. Exclusion criteria
not given
Patients and parents were to return to
investigators all unused intervention. No
measure was reported
Instruction given to parents
not to feed their children other
probiotic preparations during
the intervention
Wu 2015 Aims, interventions, and outcome
measures clear. Dose of probiotic
not given in colony-forming units, or
similar measure of bacterial
numbers
Compliance recorded: assessed based
on a count of returned medication
No information provided
Yang 2014 All clear No information given Instructions given to avoid any
commercial probiotic-
containing products 2 weeks
before study initiation. No




All clear No information provided No information provided
Yoshida
2010
Placebo not described. Otherwise
clear
No compliance measures reported No information given
Footnotes
SCORAD: Severity Scoring of Atopic Dermatitis.





































- - - - - - - - - -







































































































































- - - -










































































TCS at end of
intervention















































- - - - - -















































Published and unpublished data [CRSSTD: 3073828]
Brouwer ML, Wolt-Plompen SA, Dubois AE, Van der Heide S, Jansen DF, Hoijer MA, et al. No effects of
probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. Clinical and Experimental Allergy
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a different immunomodulatory potential in vitro versus ex vivo upon oral administration in children with food allergy.
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Data and analyses 
1 Probiotic vs placebo
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
1.1 Participant- or parent-rated
symptoms of eczema (SCORAD part
C) at the end of treatment
13   Mean difference(IV, Random, 95%CI) -0.44 [-1.22, 0.33]
   1.1.1 Parallel-group trials 11   Mean difference(IV, Random, 95%CI) -0.42 [-1.27, 0.43]
   1.1.2 Cross-over trials 2   Mean difference(IV, Random, 95%CI) -0.52 [-3.16, 2.12]
1.2 Participant- or parent-rated
global change in eczema symptoms
at the end of treatment (binary
outcome)
3   Odds ratio(IV, Random, 95% CI) 0.40 [0.14, 1.15]
   1.2.1 Parallel-group trials 2   Odds ratio(IV, Random, 95% CI) 0.70 [0.27, 1.77]
   1.2.2 Cross-over trials 1   Odds ratio(IV, Random, 95% CI) 0.18 [0.05, 0.60]
1.3 Change in participant- or parent-
rated symptoms of eczema
(SCORAD part C) at the end
treatment (continuous outcome)
9   Mean Difference(IV, Random, 95%CI) -0.70 [-1.47, 0.06]
   1.3.1 Parallel-group trials 8   Mean Difference(IV, Random, 95%CI) -0.82 [-1.62, -0.02]
   1.3.2 Cross-over studies 1   Mean Difference(IV, Random, 95%CI) 0.66 [-1.79, 3.11]
1.4 Participant- or patient-related
quality of life score at the end of
treatment
6   Std. Mean Difference(IV, Random,95% CI) 0.03 [-0.36, 0.42]
   1.4.1 Infant's Dermatitis Quality of
Life Index (IDQoL) 2  
Std. Mean Difference(IV, Random,
95% CI) 0.35 [0.08, 0.62]
   1.4.2 Dermatology Life Quality
Index 1  
Std. Mean Difference(IV, Random,
95% CI) -0.33 [-0.95, 0.29]
   1.4.3 Skindex-29 Questionnaire 2   Std. Mean Difference(IV, Random,95% CI) -0.66 [-4.24, 2.92]
   1.4.4 Children's Dermatology
Quality of Life Index 1  
Std. Mean Difference(IV, Random,
95% CI) -0.39 [-0.70, -0.08]
1.5 Participant- or patient-related
quality of life score at the end of
treatment
3   Std. Mean Difference(IV, Random,95% CI) -0.19 [-0.56, 0.18]
   1.5.1 Dermatitis Family Impact
Questionnaire (DFI) 2  
Std. Mean Difference(IV, Random,
95% CI) -0.31 [-0.86, 0.24]
   1.5.2 Family Dermatology
Dermatology Life Quality Index 1  
Std. Mean Difference(IV, Random,
95% CI) -0.01 [-0.32, 0.30]
1.6 Parent- or participant-rated
eczema severity (SCORAD part C)
within 6 months after treatment has
ceased
3 185 Mean Difference(IV, Random, 95%CI) -1.81 [-3.13, -0.49]
1.7 Participant- or parent-related
quality of life within 6 months after
treatment has ceased
2 261 Std. Mean Difference(IV, Random,95% CI) -0.08 [-0.35, 0.20]
   1.7.1 Dermatology Life Quality
Index 1 46
Std. Mean Difference(IV, Random,
95% CI) -0.14 [-0.75, 0.48]
   1.7.2 Child Dermatology Life
Quality Index 1 215
Std. Mean Difference(IV, Random,
95% CI) -0.06 [-0.37, 0.25]
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1.8 Global eczema severity score
(total SCORAD) at the end of
treatment
24   Mean difference(IV, Random, 95%CI) -3.91 [-5.86, -1.96]
   1.8.1 Parallel-group studies 22   Mean difference(IV, Random, 95%CI) -3.84 [-5.95, -1.72]
   1.8.2 Cross-over studies 2   Mean difference(IV, Random, 95%CI) -4.14 [-7.68, -0.59]
1.9 Global eczema severity score
(total SCORAD) at the end of
treatment - sensitivity analysis -
change score
14   Mean difference(IV, Random, 95%CI) -4.46 [-6.49, -2.43]
   1.9.1 Parallel-group trial 13   Mean difference(IV, Random, 95%CI) -4.53 [-6.72, -2.33]
   1.9.2 Cross-over trial 1   Mean difference(IV, Random, 95%CI) -3.93 [-9.25, 1.40]
1.10 Global eczema severity score
(total SCORAD) at the end of
treatment - low risk of bias studies
only
8   Mean difference(IV, Random, 95%CI) No totals
   1.10.1 Parallel-group studies 8   Mean difference(IV, Random, 95%CI) No totals
1.11 Investigator-rated eczema
severity (SCORAD parts A/B) at the
end of treatment - continuous
outcome
10 529 Mean Difference(IV, Random, 95%CI) -2.24 [-4.69, 0.20]
1.12 Global eczema severity score
(total SCORAD) within 6 months
after treatment has ceased
7   Mean difference(IV, Random, 95%CI) -7.72 [-11.85, -3.59]
   1.12.1 Parallel-group studies 6   Mean difference(IV, Random, 95%CI) -9.27 [-13.88, -4.65]
   1.12.2 Cross-over studies 1   Mean difference(IV, Random, 95%CI) 0.20 [-3.86, 4.26]
1.13 Investigator-rated eczema
severity (SCORAD parts A/B) within
6 months after treatment has ceased
2 102 Mean Difference(IV, Random, 95%CI) -8.11 [-13.14, -3.09]
1.14 Adverse events (short term) 7   Risk Ratio(M-H, Random, 95% CI) Subtotals only
   1.14.1 Gastrointestinal symptoms 7 402 Risk Ratio(M-H, Random, 95% CI) 1.54 [0.90, 2.63]
1.15 Participant/parent-rated global
change in symptoms of eczema at
the end of treatment - stratified by
age groups
3   Odds ratio(IV, Random, 95% CI) No totals
   1.15.1 Age under 2 years 1   Odds ratio(IV, Random, 95% CI) No totals
   1.15.2 Age 2 to 12 years 1   Odds ratio(IV, Random, 95% CI) No totals
   1.15.3 Age not categorised 1   Odds ratio(IV, Random, 95% CI) No totals
1.16 Participant/parent-rated
symptoms of eczema (SCORAD part
C) at the end of treatment - stratified
by age groups
12   Mean difference(IV, Random, 95%CI) Subtotals only
   1.16.1 Age under 2 years 5   Mean difference(IV, Random, 95%CI) -0.39 [-2.20, 1.42]
   1.16.2 Age 2 to 12 years 4   Mean difference(IV, Random, 95%CI) -0.63 [-2.04, 0.78]
   1.16.3 Age not categorised 2   Mean difference(IV, Random, 95%CI) -2.23 [-3.71, -0.74]
   1.16.4 Adults only 2   Mean difference(IV, Random, 95%CI) 1.01 [-0.82, 2.84]
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1.17 Global eczema severity score
(total SCORAD) at the end of
treatment - stratified by age groups
24   Mean difference(IV, Random, 95%CI) Subtotals only
   1.17.1 Age under 2 years 10   Mean difference(IV, Random, 95%CI) -0.99 [-3.97, 1.99]
   1.17.2 Age 2 to 12 years 3   Mean difference(IV, Random, 95%CI) -6.08 [-9.68, -2.48]
   1.17.3 Age not categorised 7   Mean difference(IV, Random, 95%CI) -5.25 [-10.43, -0.07]
   1.17.4 Adults only 5   Mean difference(IV, Random, 95%CI) -6.51 [-10.09, -2.93]
1.18 Global eczema severity score
(total SCORAD) at the end of
treatment - stratified by presence of
atopy
23   Mean difference(IV, Random, 95%CI) Subtotals only
   1.18.1 Participants with atopy 4   Mean difference(IV, Random, 95%CI) -3.90 [-15.52, 7.73]
   1.18.2 Participants with unknown
atopic status 19  
Mean difference(IV, Random, 95%
CI) -4.15 [-6.02, -2.27]
1.19 Global eczema severity score
(total SCORAD) at the end of
treatment - stratified by challenge-
proven food allergy
21   Mean difference(IV, Random, 95%CI) Subtotals only
   1.19.1 Food allergy present 3   Mean difference(IV, Random, 95%CI) -1.84 [-6.22, 2.54]
   1.19.2 Unknown food allergic
status 18  
Mean difference(IV, Random, 95%
CI) -3.21 [-5.63, -0.79]
1.20 Global eczema severity score
(total SCORAD) at the end of
treatment - stratified by eczema
severity
6   Mean Difference(IV, Random, 95%CI) Subtotals only
   1.20.1 Severe eczema (SCORAD
over 40) 5 95
Mean Difference(IV, Random, 95%
CI) -3.71 [-10.05, 2.64]
   1.20.2 Moderate eczema
(SCORAD 15 to 40) 6 279
Mean Difference(IV, Random, 95%
CI) -2.95 [-7.65, 1.74]
   1.20.3 Mild eczema (SCORAD
under 15) 1 8
Mean Difference(IV, Random, 95%
CI) -5.53 [-15.29, 4.23]
1.21 Participant- or parent-rated
symptoms of eczema (SCORAD part
C) at the end of treatment - stratified
by probiotic - Lactobacillus species
12   Mean difference(IV, Random, 95%CI) Subtotals only
   1.21.1 Lactobacillus GG alone or
in combination with or without
prebiotic
1   Mean difference(IV, Random, 95%CI) 1.79 [0.29, 3.29]
   1.21.2 Lactobacillus rhamnosus
alone or in combination with or
without prebiotic
5   Mean difference(IV, Random, 95%CI) -0.82 [-2.24, 0.60]
   1.21.3 Lactobacillus salivarius
alone or in combination with or
without prebiotic
1   Mean difference(IV, Random, 95%CI) 0.00 [-0.88, 0.88]
   1.21.4 Lactobacillus
casei/paracasei alone or in
combination with or without
prebiotics
2   Mean difference(IV, Random, 95%CI) 0.56 [-0.29, 1.41]
   1.21.5 Any Lactobacillus species
alone or in combination with or
without prebiotics
12   Mean difference(IV, Random, 95%CI) -0.50 [-1.31, 0.31]
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1.22 Participant- or parent-rated
symptoms of eczema (SCORAD part
C) at the end of treatment - stratified
by probiotic - Bifidobacterium
species
5   Mean difference(IV, Random, 95%CI) Subtotals only
   1.22.1 Bifidobacterium lactis alone
or in combination with or without
prebiotics
4   Mean difference(IV, Random, 95%CI) -0.34 [-1.92, 1.24]
   1.22.2 Bifidobacterium breve alone
or in combination with or without
prebiotics
1   Mean difference(IV, Random, 95%CI) 1.30 [-2.15, 4.75]
   1.22.3 Any Bifidobacteria species
alone or in combination with or
without prebiotic
5   Mean difference(IV, Random, 95%CI) -0.11 [-1.47, 1.25]
1.23 Participant- or parent-rated
symptoms of eczema (SCORAD part
C) at the end of treatment - number
of probiotics
13   Mean difference(IV, Random, 95%CI) Subtotals only
   1.23.1 Studies using single
probiotic with or without prebiotics 8  
Mean difference(IV, Random, 95%
CI) -0.40 [-1.45, 0.66]
   1.23.2 Studies using multiple
probiotics with or without prebiotics 5  
Mean difference(IV, Random, 95%
CI) -0.58 [-1.98, 0.81]
1.24 Participant- or parent-rated
symptoms of eczema (SCORAD part
C) at the end of treatment -
probiotics with no prebiotics
13   Mean difference(IV, Random, 95%CI) -0.44 [-1.22, 0.33]
1.25 Global eczema severity score
(total SCORAD) at the end of
treatment - stratified by probiotic -
Lactobacillus species
21   Mean difference(IV, Random, 95%CI) Subtotals only
   1.25.1 Lactobacillus GG alone or
in combination with or without
prebiotic
3   Mean difference(IV, Random, 95%CI) 3.37 [0.55, 6.20]
   1.25.2 Lactobacillus rhamnosus
alone or in combination with or
without prebiotic
5   Mean difference(IV, Random, 95%CI) -3.49 [-9.81, 2.83]
   1.25.3 Lactobacillus salivarius
alone or in combination with or
without prebiotic
6   Mean difference(IV, Random, 95%CI) -6.86 [-10.08, -3.63]
   1.25.4 Lactobacillus
casei/paracasei alone or in
combination with or without
prebiotics
6   Mean difference(IV, Random, 95%CI) -2.58 [-7.21, 2.05]
   1.25.5 Any Lactobacillus species
alone or in combination with or
without prebiotics
21   Mean difference(IV, Random, 95%CI) -3.80 [-6.06, -1.54]
1.26 Global eczema severity score
(total SCORAD) at the end of
treatment - stratified by probiotic -
Bifidobacterium species
12   Mean difference(IV, Random, 95%CI) Subtotals only
   1.26.1 Bifidobacterium lactis alone
or in combination with or without
prebiotics
7   Mean difference(IV, Random, 95%CI) -1.90 [-5.42, 1.63]
   1.26.2 Bifidobacterium breve alone
or in combination with or without
prebiotics
3   Mean difference(IV, Random, 95%CI) -0.36 [-11.39, 10.67]
   1.26.3 Any Bifidobacteria species
alone or in combination with or
without prebiotic
12   Mean difference(IV, Random, 95%CI) -2.26 [-5.14, 0.63]
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1.27 Global eczema severity score
(total SCORAD) at the end of
treatment - stratified by probiotic -
number of probiotics
24   Mean difference(IV, Random, 95%CI) Subtotals only
   1.27.1 Studies using single
probiotic with or without prebiotics 13  
Mean difference(IV, Random, 95%
CI) -4.90 [-7.66, -2.15]
   1.27.2 Studies using multiple
probiotics with or without prebiotics 12  
Mean difference(IV, Random, 95%
CI) -3.54 [-6.50, -0.58]
1.28 Global eczema severity score
(total SCORAD) at the end of
treatment - stratified by probiotic -
probiotics with no prebiotics
24   Mean difference(IV, Random, 95%CI) -3.83 [-5.81, -1.86]
Figures
Figure 1






Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included
studies.
Figure 3
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Caption
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figure 4
Caption
Trial sequential analysis for a minimum difference of -2 points difference in eczema symptoms (SCORAD part C; range 0 to
20) between probiotic and no probiotics at 90% power. The blue z-curve of the meta-analysis shows that the optimal
heterogeneity-adjusted information size of 258 has been reached. This suggests that future trials of similar interventions are
unlikely to change the findings of no significant difference between probiotic and control for detection of at least a 2-point
difference.
Figure 5
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Caption
Trial sequential analysis for a minimum difference of -1.5 points difference in eczema symptoms (SCORAD part C; range 0 to
20) between probiotics and no probiotics at 90% power. The blue z-curve of the meta-analysis has crossed the red v-shaped
line of futility and has reached the optimal heterogeneity-adjusted information size of 456. This suggests that future trials of
similar interventions are unlikely to change the findings of no significant difference between probiotic and control for detection
of at least a 1.5-point difference.
Figure 6
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Caption
Trial sequential analysis for a minimum difference of -1 point difference in eczema symptoms (SCORAD part C; range 0 to
20) between probiotics and no probiotics at 90% power. The blue z-curve of the meta-analysis has not crossed the red v-
shaped line of futility and has not yet reached the optimal heterogeneity-adjusted information size of 1026. This suggests that
future trials of similar interventions may change the findings of no significant difference between probiotic and control for
detection of at least a 1-point difference.
Figure 7
Caption
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Egger's plot for Analysis 1.1: probiotic vs placebo for participant- or parent-rated symptoms of eczema (SCORAD part C) at
the end of treatment.
Figure 8
Caption
Egger's plot for Analysis 1.8: probiotic vs placebo for global eczema severity score (total SCORAD) at the end of treatment.
Figure 9
#102 Probiotics for treating eczema
133 / 151
Caption
Egger's plot for Analysis 1.9: probiotic vs placebo for global eczema severity score (total SCORAD) at the end of treatment -
sensitivity analysis - change score.
Sources of support 
Internal sources
Murdoch Children's Research Institute, Australia
University of Melbourne, Australia
Royal Children's Hospital, Australia
Department of Paediatrics, Imperial College, London, UK
Western Infirmary, Glasgow, UK
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The NIHR, UK, is the largest single funder of the Cochrane Skin Group.
Feedback 
Appendices 
1 Cochrane Skin Group Specialised Register (CRS) search strategy
(dermatitis or eczema or neurodermatitis or besnier*) AND (probiotic* or lactobacill* or bifidobacter* or lactococc* or
saccharomyc* or microbiome* or microbiotica or "streptococcus thermophilus" or "bacillus subtilis" or "enterococcus faecalis"
or "lactic acid bacteri*" or yoghurt or yoghourt or yogourt or yogurt or (gut or intestin* and (flora or microflora or microbiota)))
2 CENTRAL (the Cochrane Library) search strategy
#1 probiotic*:ti,ab,kw OR lactobacill*:ti,ab,kw OR bifidobacter*:ti,ab,kw OR lactococc*:ti,ab,kw OR saccharomyc*:ti,ab,kw
#2 streptococcus next thermophilus:ti,ab,kw OR bacillus next subtilis:ti,ab,kw OR enterococcus near/6 faec*:ti,ab,kw OR
intestin* near/6 microflora:ti,ab,kw OR intestin* near/6 microbiotica:ti,ab,kw
#3 lactic acid bacteri*
#4 ((gut or intestinal) and (flora or microbiota or microflora))
#5 MeSH descriptor: [Probiotics] explode all trees
#6 microbiome* or microbiotica
#7 MeSH descriptor: [Lactobacillus] explode all trees
#8 MeSH descriptor: [Lactococcus] explode all trees
#9 MeSH descriptor: [Bifidobacterium] explode all trees
#10 MeSH descriptor: [Saccharomyces] explode all trees
#11 MeSH descriptor: [Streptococcus thermophilus] explode all trees
#12 MeSH descriptor: [Bacillus subtilis] explode all trees
#13 MeSH descriptor: [Enterococcus faecalis] explode all trees
#14 (yoghurt or yoghourt or yogourt) .mp.
#15 MeSH descriptor: [Yogurt] explode all trees
#16 {or #1-#15}
#17 MeSH descriptor: [Eczema] explode all trees
#18 MeSH descriptor: [Dermatitis, Atopic] explode all trees
#19 MeSH descriptor: [Neurodermatitis] explode all trees
#20 MeSH descriptor: [Dermatitis] explode all trees
#21 eczema or dermatitis or neurodermatitis or besnier*:ti,ab,kw
#22 #17 or #18 or #19 or #20 or #21
#23 #16 and #22
3 MEDLINE (Ovid) search strategy
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. clinical trials as topic.sh.
6. randomly.ab.
7. trial.ti.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp animals/ not humans.sh.
10. 8 not 9
11. exp Eczema/ or eczema.mp.
12. exp Dermatitis, Atopic/
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13. neurodermatitis.mp. or exp Neurodermatitis/











25. exp Saccharomyces/ or saccharomyces.mp.
26. streptococcus thermophilus.mp. or exp Streptococcus thermophilus/
27. lactic acid bacteri$.mp.
28. bacillus subtilis.mp. or exp Bacillus subtilis/
29. enterococcus faecalis.mp. or exp Enterococcus faecalis/
30. microbiome$.mp.
31. ((gut or intestinal) and (flora or microbiota or microflora)).mp.
32. microbiotica.mp.
33. (yoghurt or yoghourt or yogourt).mp.
34. exp Yogurt/
35. or/17-34
36. 10 and 16 and 35
[Lines 1-10: Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity- and
precision-maximizing version (2008 revision)]




4. (crossover$ or cross over$).tw.
5. placebo$.tw.
6. (doubl$ adj blind$).tw.
7. allocat$.tw.
8. trial.ti.
9. randomized controlled trial.sh.
10. random$.tw.
11. or/1-10
12. exp animal/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
13. human/ or normal human/
14. 12 and 13
15. 12 not 14
16. 11 not 15
17. eczema.mp. or exp ECZEMA/
18. exp DERMATITIS/ or dermatitis.mp.
19. exp atopic dermatitis/
20. neurodermatitis.mp. or exp NEURODERMATITIS/
21. besnier$ prurigo.mp.
22. or/17-21








31. Saccharomyces.mp. or exp Saccharomyces/
32. Streptococcus thermophilus.mp. or exp Streptococcus thermophilus/
33. lactic acid bacteri$.mp.
34. Bacillus subtilis.mp. or exp Bacillus subtilis/
35. Enterococcus faecalis.mp. or exp Enterococcus faecalis/
36. microbiome$.mp.
37. ((gut or intestinal) and (flora or microbiota or microflora)).mp.
38. microbiotica.mp.
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39. exp intestine flora/
40. (yoghurt or yoghourt or yogourt).mp.
41. exp yoghurt/
42. or/23-41
43. 16 and 22 and 42




4. 1 or 2 or 3
5. eczema.ti,ab. or exp Eczema/
6. dermatitis.ti,ab. or exp Dermatitis/
7. neurodermatitis.ti,ab. or exp Neurodermatitis/
8. besnier$ prurigo.mp.
9. 5 or 6 or 7 or 8
10. probiotic$.mp.
11. (lactobacill$ or bifidobacteri$ or lactococc$ or saccharomyces or microbiome$ or microbiotica).mp.
12. ((gut or intestinal) and (flora or microbiota or microflora)).mp.




17. (yoghurt or yoghourt or yogourt).mp.
18. or/10-17
19. 4 and 9 and 18
[Lines 1-3: therapy filter for PsycINFO (Ovid) created by the Health Information Research Unit at McMaster University].
6 AMED (Ovid) search strategy
1. randomized controlled trial$/
2. random allocation/
3. double blind method/
4. single blind method.mp.
5. exp Clinical trials/
6. (clin$ adj25 trial$).mp.
7. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$ or dummy)).mp.
8. (placebo$ or random$).mp.
9. research design/ or clinical trials/ or comparative study/ or double blind method/ or random allocation/
10. prospective studies.mp.
11. cross over studies.mp.
12. Follow up studies/
13. control$.mp.
14. (multicent$ or multi-cent$).mp.
15. ((stud or design$) adj25 (factorial or prospective or intervention or crossver or cross-over or quasi-experiment$)).mp.
16. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
17. exp Eczema/ or eczema.mp.
18. dermatitis.mp. or exp Dermatitis/
19. exp Dermatitis atopic/





25. (lactobacill$ or bifidobacteri$ or lactococc$ or saccharomyces or microbiome$ or microbiotica).mp.
26. ((gut or intestinal) and (flora or microbiota or microflora)).mp.




31. (yoghurt or yoghourt or yogourt).mp.
32. or/23-31
33. 16 and 22 and 32
7 LILACS search strategy
(dermatitis or eczema or neurodermatitis or eccema or besnier$) and (probiotic$ or lactobacill$ or bifidobacter$ or lactococc$
or saccharomyc$ or (streptococcus and thermophilus) or (bacillus and subtilis) or (enterococcus and faecalis) or (lactic and
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acid and bacteri$) or microbiome$ or microbiotica or yoghurt or yoghourt or yogourt)
The above terms were combined with the Controlled clinical trials topic-specific query filter in LILACS.
Graphs
1 - Probiotic vs placebo
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